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Zusammenfassung 
In unserem Labor wurden funktionelle „Yeast-survival-screens“ zur Identifikation 
neuer anti-apoptotischer Onkogene durchgeführt. Als Ausgangsmaterial der 
Identifikation dienten cDNA-Bibliotheken, welche aus Tumorgeweben hergestellt 
worden waren. Das „far upstream element binding protein 1“ (FUBP1) wurde im 
Laufe eines solchen Screens als anti-apoptotisches Onkoprotein detektiert.  
Zu diesem Zeitpunkt war FUBP1 bereits als transkriptioneller Regulator des c-
myc-Onkogens beschrieben. Die Tatsache, dass FUBP1 offensichtlich anti-
apoptotische Eigenschaften aufweist, veranlasste uns dazu, 
immunhistochemische Expressionsanalysen von FUBP1 in verschiedenen 
Tumorgeweben durchzuführen. Anhand dieser Analyse konnte gezeigt werden, 
dass 83% (90 / 109) aller untersuchten hepatozellulären Karzinom (HCC)-Proben 
eine starke nukleäre Färbung für FUBP1 aufwiesen, während das Protein in 
gesunden Lebergeweben nicht nachzuweisen war. Des Weiteren konnte in 
in vitro Experimenten gezeigt werden, dass ein stabiler FUBP1 knock-down in 
der humanen HCC-Zelllinie Hep3B eine deutlich verminderte Proliferation sowie 
die Sensitivierung der Zellen gegenüber apoptotischer Stimuli zur Folge hatte. In 
einem anschließenden Maus-Xenograft Transplantations-Experiment führte der 
stabile FUBP1 knock-down in den verwendeten Hep3B Zellen zu einem deutlich 
verminderten Tumorwachstum im Vergleich zu den kontrollimplantierten Wildtyp-
Zellen. Diese Daten etablierten FUBP1 als wichtiges, im HCC stark 
überexprimiertes Onkoprotein, welches das Tumorwachstum durch direkte und 
indirekte Inhibition von Zellzyklusinhibitoren und anti-apoptotischer Zielgene 
reguliert. 
Auf Grundlage dieser Ergebnisse wurde die Hypothese aufgestellt, dass die 
Inhibition von FUBP1 im hepatozellularem Karzinom zu einem therapeutischen 
Nutzen für die Patienten führen könnte. Daher war die Identifikation und 
Validierung neuer FUBP1-inhibierender Substanzen das Ziel dieser Dissertation. 
Zu diesem Zweck wurde eine rekombinante Expression von FUBP1 in E. coli 
durchgeführt und das Protein über einen 3-stufigen Prozess aufgereinigt.  Um die 
Funktionalität des rekombinanten Proteins nachzuweisen, wurden 
Bindungsstudien mit FUBP1 und dessen Ziel-DNA-Sequenz „FUSEp21“ mit Hilfe 
der sogenannten „surface plasmone resonance (SPR)“ Methode durchgeführt. 
Der durch dieses Experiment durchgeführte Nachweis einer spezifische Bindung 
ermöglichte es, das rekombinante Protein, sowie das FUSEp21 Oligonukleotid 
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für weitere Experimente zu verwenden. Das Screening von 16.000 potentiell 
inhibitorischen Substanzen wurde mit Hilfe des AlphaScreen® Interaktions-
Verdrängungsassays durchgeführt. Nach bioinformatischer Evaluation wurden 
solche Substanzen als „Hit“ bewertet, welche das Interaktionssignal von FUBP1 
und FUSEp21 zu mindestens 70% verminderten.  Eine der gefunden Hit-
Substanzen war Camptothecin (CPT), dessen inhibitorisches Potential in einem 
zweiten, unabhängigen SPR-Test bestätigt wurde, bevor weitere in vitro-Tests 
folgten. Die Behandlung unterschiedlicher HCC-Zelllinien (Hep3B, HuH7 und 
HepG2) mit CPT führte zu einer Sensitivierung gegenüber apoptotischen Stimuli. 
Besonders die Kombination von Camptothecin mit Mitomycin C bewirkte eine 
signifikante, synergistische Steigerung der Apoptoserate in Hep3B Zellen. Des 
Weiteren wurde eine reduzierte Zellexpansion sowie eine verminderte 
mitochondriale Aktivität in CPT-behandelten Hep3B Zellen nachgewiesen. 
Zudem hatte die Behandlung mit CPT in allen drei untersuchten HCC-Zelllinien 
eine signifikante Steigerung des p21-mRNA Levels zur Folge, welches ein 
bekanntes Zielgen von FUBP1 darstellt und dessen Expression von FUBP1 
inhibiert wird.  
Diese Daten legen nahe, dass CPT zusätzlich zu seinem bekannten anti-Tumor 
Wirkungsmechanismus, der Topoisomerase I Inhibition, auch mit der FUBP1 
Funktion in HCC Zellen interferieren könnte. Um diesen Verdacht zu erhärten, 
wurden weitere Topoisomerase-I-Inhibitoren wie NSC 725776, NSC 724998 und 
das Camptothecinderivat 7-Ethyl-10-Hydroxycamptothecin auf eine mögliche 
FUBP1-Inhibition hin untersucht. Durch SPR-Messungen konnte gezeigt werden, 
dass alle getesteten Topoisomerase-I-Inhibitoren auch die Bindung von FUBP1 
an FUSEp21 inhibieren können. Des Weiteren zeigt die Behandlung 
verschiedener HCC Zelllinien die gleichen Effekte, die auch durch die 
Behandlung mit Camptothecin sichtbar wurden.  
Insgesamt zeigen die in vitro-Experimente mit der FUBP1-Inhibition nicht nur 
eine bisher unbekannte Funktion der untersuchten Topoisomeraseinhibitoren, 
sondern auch deren pro-apoptotische Wirkung in verschiedenen HCC-Zelllinien 
nach Kombination mit unterschiedlichen Chemotherapeutika wie Mitomycin C. 
Um die Wirkung von CPT auf einen etablierten Xenograft-Tumor untersuchen zu 
können der nach subkutaner Injektion einer humanen HCC-Zelllinie entstand, 
wurden Maus-Xenograft-Transplantations-Experimente mit dem CPT-Derivat 
Irinotecan durchgeführt. Alle mit Irinotecan und Irinotecan plus Mitomycin C 
behandelten Tiere zeigten eine 100%-ige Tumorremission.   
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Zusammenfassend unterstützen die Daten, die während dieser Dissertation 
erhoben wurden, die Annahme dass FUBP1 ein geeignetes Ziel in der HCC- 
Therapie darstellt. Des Weiteren konnte durch unterschiedliche zelluläre 
Experimente eine neue potentielle HCC-Therapie entwickelt werden, die im 
in vivo Mausmodell zu einer 100%-igen Tumorremission führte. 
Als Weiterführung dieses Projektes wurde eine investigative Pilotstudie in zwei 
Patienten mit intermedian klassifiziertem HCC gestartet, die über eine 
transarterielle Chemoembolisation mit einer Kombination aus CPT und 
Mitomycin C behandelt werden. 
  Summary 
 
 4 
Summary 
In previous studies performed in our laboratory, FUBP1 was isolated in a 
functional yeast survival screen of tumor-derived cDNA libraries for the 
identification of anti-apoptotic oncogenes. Because FUBP1, which had previously 
been described as a transcriptional regulator of the important proto-oncogene 
c‑myc, at the same time protects cells from apoptosis, the expression of FUBP1 
in tumors was analyzed by immunohistochemistry. A strong nuclear staining for 
FUBP1 was found in 83% (90 / 109) of the analysed hepatocelluar carcinoma, 
whereas FUBP1 was not detected in normal liver cells. Furthermore, a stable 
knockdown of FUBP1 in the HCC cell line Hep3B strongly reduced tumor growth 
in a xenograft transplantation mouse model, and we could show decreased 
proliferation and increased sensitivity to apoptosis for these cells in vitro. This 
data established FUBP1 as an important oncoprotein overexpressed in 
hepatocellular carcinoma, which induces tumor propagation by direct or indirect 
regulation of cell cycle inhibitors and pro-apoptotic target genes [1].  
On the basis of these results, we hypothesize that the inhibition of FUBP1 may 
result in a therapeutic benefit for HCC patients. The goal of this thesis was to 
inhibit the function of FUBP1 as a transcriptional regulator by novel identified 
small molecule inhibitors.  
For this purpose, I expressed and purified recombinant FUBP1 in E. coli and 
confirmed its functionality in surface plasmon resonance (SPR) binding studies. 
The protein was used for an AlphaScreen interaction-displacement assay to 
identify small molecules (including FDA-approved drugs) that were able to disrupt 
or prevent the binding of FUBP1 to its single stranded target sequence 
FUSEp21. After bioinformatical evaluation and a subsequent re-evaluation of the 
identified “hit-compounds” in a second binding-interference-assay (SPR), one of 
the identified inhibitors, camptothecin (CPT), was further tested for its therapeutic 
potential in in vitro (HCC cell lines) and in vivo (mouse xenograft transplantation 
experiments) preclinical studies 
Upon treatment of the HCC cell line Hep3B with CPT, reduced cell expansion 
and cell viability were observed. Furthermore, treatment of Hep3B, HuH7 and 
HepG2 cells with CPT resulted in a sensitizing effect towards apoptotic stimuli, 
best seen in the combinatorial treatment of Hep3B cells with CPT and 
mitomycin C, which led to a significant, synergistic increase in cell death rates 
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To confirm the inhibitory effect of CPT on FUBP1 activity, the expression pattern 
of the FUBP1 target gene p21 (repressed by FUBP1) was monitored using qRT-
PCR. When treated with CPT, mRNA expression of the cell cycle inhibitor p21 
increased significantly, whereas FUBP1 protein level remained stable, 
suggesting that CPT in addition to its known function as a topoisiomerase I 
inhibitor indeed interferes with FUBP1 function in Hep3B, HuH7 and HepG2 cells. 
Besides CPT, other topoisomerase I inhibitors like NSC 725776, NSC 724998 
and CPT derivate 7-ethyl-10-hydroxycamptothecin (the active part of the clinically 
used irinotecan) were tested for their potential as FUBP1 inhibitors. In all 
experiments performed these substances showed similar results to CPT 
treatment, consolidating the effects of CPT on FUBP1 in HCC cells. 
Finally, a xenograft transplantation experiment demonstrated that a combinatorial 
treatment of established HCC tumors with irinotecan and mitomycin C led to 
complete tumor remission in 100% of the treated mice.  
Taken together, the data collected in this study does not only strengthen the role 
of FUBP1 as a potential therapeutic target in primary HCC, but also led to the 
evaluation of its novel potent inhibitor camptothecin. Moreover, the results of this 
thesis initiated a pilot study in patients with intermediate stage HCC using 
transarterial chemoembolization with a combination of CPT and mitomycin C. 
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1 Introduction 
1.1 Far Upstream Element Binding Protein 1 
The far upstream element binding protein 1 (FUBP1) was first identified as a 
regulator of the proto-oncogene c-myc. FUBP1 binds to the single stranded, non-
coding DNA strand of the far upstream element (FUSE), which is located 1.5 kb 
upstream of the c-myc promotor. It was shown that the binding of FUBP1 to 
FUSE is required for maximal c-myc transcription upon interaction of FUBP1 with 
the TFIIH subunit of the transcriptional machinery [2]. Duncan et al. analyzed the 
primary FUBP1 amino acid sequence and the predicted secondary structure and 
confirmed that FUBP1 acts as a transcriptional activator of c-myc expression by 
binding to single stranded FUSE [3]. The FUBP1 interacting repressor FIR 
counteracts the binding of FUBP1 to FUSE. FIR can bind to both, FUBP1 and 
TFIIH, which leads to FUBP1 release and subsequent downregulation of TFIIH 
activity [4]. 
 
Figure 1: Generally accepted model of c-myc transcriptional peak activation via FUBP1. 
Upon basal c-myc transcription, torsional stress occurs due to DNA unwinding, leading to 
unwinding and melting of the FUSE double strand. FUBP1 can bind to both the unwinded anti-
sense FUSE strand and the p89 subunit of TFIIH, causing a promoter loop formation and increased 
c-myc transcription. The subsequent FUBP1 inactivation is promoted by FIR, which binds as a 
homodimer to FUBP1, and eventually displaces FUBP1 from FUSE. 
1.1.1 FUBP1 Structure 
The human FUBP1 gene encodes a 644-amino acid long protein, which consists 
of three domains: The N-terminal transcriptional repression domain, the central 
DNA binding domain, and the C-terminal transcriptional activation domain [3, 5].  
The N-terminus is composed of the amino acids 1-106 and it represses the 
activity of the C-terminal domain. Therefore it has been suggested, that FUBP1 
folds into an enclosed conformation in an inactive state and undergoes a 
conformational change upon activation of the protein [5].  
FUBP1 
N
Pol II 
TFIIH 
C
FIR 
c-myc  
expression 
FUSE 
  Introduction 
 
 7 
The central domain, represented by amino acids 107-447, is composed of four K-
homology (KH) motifs, each mediating ssDNA and ssRNA binding [3]. The KH-
domains 1 to 3 are followed by an adjacent amphiphatic helix. KH3 and KH4 are 
sufficient for FUSE binding. To elucidate which bases of the FUSE motif were 
predominantly important for the binding of KH3 and KH4, 10-mer FUSE 
oligonucleotides were used to determine the bases responsible for the interaction 
with FUBP1. It could be shown, that the GXXG motifs in KH3 and KH4 domains 
bound to either the ss 5’-dTTTT (KH3) or 5’-dATTC (KH4) of the FUSE 
oligonucleotides, in vitro [6]. 
The C-terminal domain consists of amino acids 448-644 and inherits three 
tyrosine rich motifs (YM). These motifs were shown to be important for the 
physical interaction between the FUBP1 C-terminus and transcription factor 
TFIIH [4]. FUBP1 binding stimulates the 3’-5’ helicase activity of the 
p89/XBP/ERCC3 subunit of the transcription factor TFIIH, which mediates c-myc 
promoter melting [7]. 
Additionally, FUBP1 itself possesses a 3’-5’ helicase activity and is known as 
helicase V. Its helicase activity is probably mediated by the arginine-glycine-
glycine (RGG) motifs at the C-terminus. These motifs are highly conserved 
among several proteins with helicase activities, e.g. nucleolin and the Ras-GAP 
SH3 binding protein [8]. The helicase activity of FUBP1 might play a role in the 
unwinding of the DNA duplex around FUSE to sustain c-myc activity [9].  
 
Figure 2: Schematic structure of human FUBP1 protein. Adapted from Zhang et al. 2013 [11]. 
FUBP1 consists of three domains: 1. The N-terminal repression domain (aa 1-106), 2. The central 
DNA binding domain (aa 107-447), and 3. The C-terminal activation domain (aa 448 -644). The well 
defined NLS,  localized at the N-terminus, and the central domain are depicted in green. The two 
isoleucins at position 378 and 379 are important for the FUBP1 localization. The caspase cleavage 
site, DPQD [10], is labeled with asterisks. 
63 78 
QKRPLEDGDQPDAKKV **** 
Well defined NLS  
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1.1.2 FUBP1 Family Members 
The FUBP1 gene is highly conserved in eukaryotes, showing over 90% similarity 
among mammals [11]. Two FUBP1 homologs were found, upon screening of a 
human skeletal muscle library: FUBP2 (also known as KHSRP) and FUBP3 [12]. 
The FUBP1 gene is located at chromosome 1p31.1, whereas FUBP2 and 3 are 
located at 19p13.3 and 9q34.11, respectively [13]. 
Sequence homology and the common structural features such as the KH 
domains would suggest an analogous function of the family members. 
Nevertheless, FUBP1 is the only family member with confirmed helicase activity 
[9], and whereas FUBP1 is best known as a DNA binding protein, FUBP2 is 
better known for its RNA binding potential and has mostly been studied for its 
role in mRNA stability regulation (for review see [14]). FUBP3 is less well studied 
than the other two family members. Apart from its initial binding to c-myc FUSE 
before replacement by FUBP1 (for details see 1.1.3) it is assumed to cooperate 
with FUBP2 in RNA binding [15]. 
1.1.3 Transcriptional Regulation by FUBP1-FUSE-FIR 
FUBP1 binds to single stranded FUSE sequence located on the non-coding DNA 
strand. A systematic evolution of binding partners by a SELEX assay indicated 
that FUBP1 interacts with FUSE with a low stringency. In vitro binding of 29-mers 
consisting of partial FUSE sequence to FUBP1-linked KH domains revealed the 
minimal DNA binding sequence required for full length FUBP1: TTGTa(N)4/5 
TYGTa(N)4/5 TYGTa(N)4/5 KTGY (Y=T or C, K= T or G). Every KH-domain 
recognizes the binding sequences with a weak preference for an “A” at the fifth 
position [7]. Binding of FUBP1 to FUSE is not sufficient for c-myc activation, but 
is needed to coordinate additional cis-elements and their corresponding 
transcription factors to promote optimal c-myc transcription [16]. 
FUBP1 binds to FUSE DNA and at the same time to the basal transcription factor 
TFIIH, causing a promoter loop. Furthermore, FUBP1 and TFIIH not only interact 
with each other, but also with the FUBP1 Interacting Repressor (FIR) [16]. FIR is 
a 542 amino-acid long protein, with two RNA recognition motifs in the central 
domain [4, 16] and a U2AF (splicing factor; U2 auxiliary factor) homology motif at 
the c-terminus (UHM) [17]. The UHM mediates protein-protein interactions. FIR 
binds as a homo-dimer to FUSE via its UHM at the C-terminus and its two RNA 
recognition motifs [17]. This interaction might in turn be responsible for the 
interaction between the N-terminal part of FIR and TFIIH, which eventually leads 
to the inhibition of TFIIH activity [4, 16]. 
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In 2008, Levens et al. suggested the following model for the c-myc peak 
transcription involving FUBP1. First, upon basal c-myc expression via RNA 
polymerase II, FUSE becomes exposed due to chromatin remodeling and melts 
because of torsional stress. Afterwards, FUBP1 and FUBP3 recognize the single-
stranded FUSE motif and bind to it. Initially, FUBP3 interacts with FUSE, but is 
replaced by FUBP1 by an unknown mechanism. Subsequently, FUSE-bound 
FUBP1 interacts with TFIIH and stimulates its helicase activity. Due to the 
interactions between FUSE, FUBP1 and TFIIH, the genomic DNA is bending and 
forms a promoter loop, which allows for maximal c-myc transcription. Finally, FIR 
displaces FUBP1 from FUSE, thereby downregulating c-myc expression again 
[18]. 
 
Figure 3: Three-step mechanism of c-myc peak expression. Due to basal transcription and the 
resulting torsional stress, FUSE melts and unwinds. FUBP1 binds simultaneously to both FUSE 
and TFIIH, which leads to a promoter loop formation and maximal c-myc transcription. Afterwards, 
FIR is recruited to the FUBP1/TFIIH/FUSE complex, replaces FUBP1, and stops c-myc 
transcription. 
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1.1.4 FUBP1 as a Cancer Biomarker 
FUBP1 expression is altered in many cancer types (see Table 1, adapted from 
Zhang et al. [11]), and although the transcriptional up-regulation of c-myc is a 
fundamental finding of FUBP1 action in carcinogenesis, the protein also 
facilitates further pro-oncogenic functions independently of c-myc transcription. 
For example, FUBP1 promotes the replication of HCV, a virus, which is one of 
the main causes of hepatocellular carcinoma [19]. 
A study of Weber et al. showed that there is a correlation of elevated FUBP1 and 
c-myc levels in clear cell renal cell carcinoma (ccRCC), but not in bladder or 
prostate cancer, further indicating that FUBP1 facilitates additional oncogenic 
functions [20]. The low expression levels in normal tissue compared to the high 
expression in cancer cells suggest FUBP1 as a potent cancer biomarker.  
Not only the overexpression of FUBP1, but also the loss of FIR plays a role in 
carcinogenesis [21]. In colorectal cancer patients, a splicing variant of FIR, 
lacking exon 2, was found. This truncated variant lacks its N-terminus and is 
therefore unable to inhibit FUBP1 activity. This splicing variant exhibits dominant 
negative effects compared to functional wildtype FIR and is only found in the 
colorectal cancer tissue, but not in the normal neighboring tissue, indicating a 
potential role in colorectal carcinogenesis [21, 22]. 
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Table 1: Role of FUBP1 in different human malignancies; adapted from Zhang et al. 2013 
Malignancy Alterations Downstream Target Reference 
        
Oligodendrioglioma FUBP1 mutation NA [23] 
        
Non-small lung cancer FUBP1é Stathmin 1é [24] 
        
Breast FUBP1é NA  [25, 26] 
        
Clear cell renal cancer FUBP1é c-mycé [20] 
        
Liver FUBP1é p21é, p15é, Cyclin D2é [1, 27] 
        
Liver FUBP1é Stathmin 1é [27, 28] 
        
Colon FIR truncation c-mycé [21, 22] 
        
Bladder FUBP1é NA [20] 
        
Prostate FUBP1é NA [20] 
NA:	  not	  available	  
	   	   	  
	  
	   	   
1.1.5 FUBP1 in Hepatocellular Carcinoma 
As described before, FUBP1 was found overexpressed in many malignancies. In 
our laboratory we could show that FUBP1 is highly overexpressed in 
hepatocellular carcinoma (HCC) compared to normal liver tissue (see Figure 5). 
Furthermore, it was demonstrated that not the transcriptional regulation of c-myc, 
but the inhibition of molecules of the extrinsic and intrinsic apoptosis pathways 
like Noxa and TRAIL, as well as the inhibition of cell cycle regulators like p21 and 
p15, represent the important activities of FUBP1 in HCC (Figure 4) [1]. 
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Figure 4: Model of FUBP1 function in hepatocellular carcinoma [1]. In HCC, FUBP1 inhibits 
important molecules of the extrinsic and intrinsic apoptosis pathway as well as cell cycle inhibitors, 
leading to increased proliferation, decreased apoptosis and cell cycle acceleration. 
Using EMSA and luciferase activity experiments, we could show that p21 is a 
direct target gene of FUBP1 in HCC. Finally, in a murine xenograft 
transplantation model with human Hep3B cells, we demonstrated that the 
knockdown of FUBP1 impairs tumor formation compared to the control cells (see 
Figure 5). 
 
Figure 5: FUBP1 in hepatocellular carcinoma (Rabenhorst et al. 2009). Immunohistochemistry 
of liver carcinoma and normal liver samples with a specific anti-FUBP1 antibody (sc-11098) 
revealed that FUBP1 is highly overexpressed in HCC compared to normal liver tissue. Furthermore, 
a stable FUBP1 knock-down led to impaired tumor growth in a murine xenograft transplantation 
experiment compared to the empty vector transduced Hep3B cells.  
These findings led us to the assumption that FUBP1 might represent a potential 
novel therapeutic target for HCC treatment. 
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1.2 Hepatocellular Carcinoma  
Hepatocellular Carcinoma (HCC) is the fifth most common cancer and the third 
most common cause of cancer-related death worldwide [29]. Conventionally, 
HCC was considered as a disease without curative options, with an overall 
survival of less than 6 month [30]. Improvements of the imaging techniques, in 
early detection and in novel therapies have led to a better patient selection and 
subsequent to improved treatment approaches [31]. Staging of the patients’ 
disease is part of the routine clinical care, using the Barcelona Clinic Liver 
Cancer (BCLC) classification as a prognostic algorithm [30]. The classification 
uses three parameters, the tumor burden, the underlying liver dysfunction and 
the patients’ symptoms, to stage the tumor disease and link this to an appropriate 
treatment approach [32] (see Figure 6, page 14). The treatment options of the 
very early stage (0) and early stage (A) tumors are curative, including resection, 
liver transplantation and local ablations. Unfortunately, the treatment options for 
intermediate stage (B) and advanced stage (C) are only palliative using 
transcatheter arterial chemoembolization (TACE) or the small molecule inhibitor 
sorafenib [33]. In the terminal stage (D) only symptomatic treatment is possible. 
One challenging problem in the treatment of those patients is the occurrence of 
two diseases, the HCC and the underlying cirrhosis (see paragraph 1.2.1). This 
problematic setting became visible in a phase III trial comparing sunitinib against 
sorafenib, which had to be stopped prematurely, because of excessive toxicity in 
the sunitinib arm [34]. The fact that the liver cirrhosis made the patients more 
accessible for toxic reactions and that conventional chemotherapy is ineffective in 
HCC [35], decreases the treatment options and makes the therapy more 
challenging.  
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Figure 6: BCLC staging system and therapeutic strategy according to EALS-EORTC 
guidelines (adapted from Villanueva et al. 2013 [36]): Staging classification inherits 5 stages, 
selecting the best treatment options currently available for each patient. Abbreviations: BCLC: 
Barcelona Clinic Liver Cancer; EALS: European Association for the Study of Liver Disease; 
EORTC: European Organization for Research and Treatment of Cancer; RF: radiofrequency 
ablation; PEI: percutaneous ethanol injection; TACE: transcatheter aterial chemoembolization; OS: 
overall survival, PST: performance status. 
Three well-known HCC risk factors, which lead to the underlying cirrhosis, are 
infections with hepatitis virus B and C (HBV and HCV), alcohol intake and toxins 
like aflatoxin [37]. 
1.2.1 Molecular Mechanisms of HCC Development 
One downstream pathway of HBV- and HCV- infected cells promoting HCC is the 
activation of stem-cell activity through the upregulation of the epithelial cell 
adhesion molecule (EpCAM) and beta-catenin [38, 39].  
Another HCC-promoting mechanism is explained as a secondary effect of liver 
cirrhosis. In the cirrhotic tissue, a decrease of vascular tissue is observed, 
leading to a hypoxic environment. These hypoxic conditions lead to the 
upregulation of the hypoxia inducible factor 1α (HIF1α), which in turn leads to the 
upregulation of the vascular endothelial growth factor (VEGF), cyclo-oxygenase 
2, angiopotein 2, as well as several matrix metalloproteinases [40-42]. This 
massive activation of inflammatory and angiogenic signals results in a 
susceptibility of the parenchyma to damage, inhibition of regeneration and 
subsequent HCC formation [38]. 
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Until today, no oncogenic addiction loop has been identified in hepatocellular 
carcinoma. An identification of such a loop is desirable to be able to define 
patient subgroups with targetable gene alterations [36]. 
1.2.2 Treatment Options in Hepatocellular Carcinoma 
Treatment of HCC is strongly dependent on the progression of the disease, 
which is staged using the BCLC classification. As very early stage (0) and early 
stage (A) patients can be treated with curative options like resection, liver 
transplantation or local ablations, stage (B) and stage (C) patients can only be 
treated with palliative options like sorafenib or TACE.  
1.2.3 Surgical Therapy 
1.2.3.1 Resection 
Surgical resections are first-line options for early stage HCC patients, providing 
five-year survivals of 68% in Child-Plugh class A patients (level of liver cirrhosis) 
with MILAN criteria (single tumor <5 cm, or three nodules <3 cm) and without 
major vascular invasion (MVI) [43]. Shi et al reported even a 100% 5-year 
survival of patients with an initial tumor size of <2 cm [44]. Local ablation has also 
been proposed as a therapy for tumors with a size of <2 cm [45]. Nevertheless, 
the perioperative mortality for HCC resections is 4 – 4.7% higher than for 
resections of benign tumors or colorectal liver metastasis [46].  
1.2.3.2 Liver Transplantation 
Transplantation is the only treatment that offers a cure for both, the HCC and the 
underlying cirrhosis [37]. After individual validation by different groups, it is 
accepted that patients, who fulfill the MILAN criteria and show a good MVI should 
be evaluated for liver transplantation [32, 47]. Despite the fact that 
transplantations seem to be the best treatment for this subset of patients, the lack 
of donor organs leads to a progression of the tumor in 20% of the cases while the 
patients are on the transplantation waiting list which eventually leads to the 
removal of these patients from the list [48, 49]. 
1.2.4 Locoregional Therapy 
Local ablation is the standard care for early stage patients who are not suitable 
for surgery. It is based on the concept that the tumor cells will be directly 
destroyed through percutaneuos, laparoscopic, or open laparotomies using 
chemical toxicity, modifying neoplastic cell temperature, microwaves, 
radiofrequency or cryoablation [37]. Five-year survival rates for this treatment are 
in the range of 50-70% [32, 47]. 
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Intermediate stage patients are treated with TACE with the palliative goal to delay 
the tumor progression and extension of the patients’ survival [32, 47, 50]. 
1.2.4.1 Transcatheter Aterial Chemoembolization (TACE) 
TACE was designed based on the observation that hepatic arteries directly 
supply the HCC. A catheter is inserted into the artery feeding the tumor, and a 
mixture of a chemotherapeutic agent in a lipid emulsion can be injected directly at 
the tumor site. Afterwards, the hepatic artery is embolized to help retaining the 
chemotherapy agent within the tumor, maximizing the exposure of the tumor to 
the drug and minimizing the toxicity for the parenchymal tissue [51, 52].  
The method had been improved by the development of polymeric microsphere 
beads, which ionically bind the chemotherapeutic agents (DEB-TACE), providing 
medium survival rates beyond 30-40 month in referral centers [53]. 
1.2.5 Systemic (Targeted) Therapy 
Until 2007, no systemic therapy had shown beneficial effects for HCC patients. In 
2007, the SHARP (sorafenib HCC assessment randomized protocol) trial was 
performed in Europe, showing a survival benefit of 3 month in patients treated 
with sorafenib [33]. 600 patients with advanced HCC and good liver function 
(Child-Phugh A) were treated with either sorafenib or placebo. The study was 
stopped at the second interim analysis, because of the significant difference 
favouring the sorafenib arm (Medium survival 10.9 vs. 7.9 month). A second trial 
with 200 patients was performed in the Asia Pacific region with similar entry 
criteria and treatment plan. The survival benefit in the sorafenib treated arm was 
2 month (6.5 month vs. 4.2 month) [54]. The FDA did approve sorafenib in 2007 
for patients with late stage HCC and preserved liver function. Furthermore, 
several smaller trials could show that the tolerability and pharmacokinetic profile 
of patients with poorer liver function (Child-Phugh B) is not significantly different 
to those with good liver function [55].  
Nevertheless, several subsequently performed smaller trials could show that 
most patients are not able to pursue the daily dose of 400 mg sorafenib twice, 
because of severe side effects [56]. 
Multiple targeted therapy studies are currently under evaluation. Unfortunately, 
regardless of the initial potential, none of them is showing additional benefit 
compared to the sorafenib treatment. The sunitinib (another multi-kinase 
inhibitor) trial had to be stopped prematurely due to excessive toxicity [34]. 
Brivanib (a potent VEGFR- and FGFR- (fibroblast growth factor receptor) kinase 
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inhibitor) showed an anti-tumor effect that did not significantly improve patient 
survival compared to the placebo group in second line therapies [57]. 
Furthermore, a combinational therapy using erlotinib (EGFR inhibitor) and 
sorafenib failed in comparison to sorafenib single treatment [58]. 
The need of new therapies in HCC treatment is urgent. The understanding of 
potential oncogenic addiction loops and the discovery of new molecular targets in 
HCC would lead to the desired development of new treatments and a subsequent 
better outcome for the patients. 
1.3 Additional Cancer Therapeutics 
1.3.1 Topoisomerase I Inhibitors 
The topoisomerase is a molecule, which is highly conserved among species and 
ubiquitously expressed in eukaryotes, prokaryotes and archea [59]. 
Topoisomerase I regulates the topology of the DNA, facilitating three successive 
reactions in a so-called TopI cleavage complex (TOP1cc) (see Figure 7). First, it 
cleaves the backbone of the DNA, then it allows relaxations of the DNA 
supercoils, and third, it re-ligates the DNA. Under normal conditions, the 
cleavage is transient, whereas the re-ligation is favored over cleavage [60]. 
These processes are needed for the generation of DNA supercoiling due to DNA 
replication, transcription and chromatin remodeling.  
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Figure 7: DNA supercoiling relaxation by TOP1-mediated DNA cleavage complexes. Adapted 
from Pommier et al. 2006 [60]. a) Generation of supercoiled DNA through replication, transcription 
or chromatin remodeling. b) TOP1 introduces single strand breaks to facilitate DNA relaxation. The 
cleavage intermediate is called “cleavage complex”, because TOP1 covalently binds to the 3’ end 
of the DNA. Tyrosine (Y723 for human), which is involved in the covalent binding, is depicted in 
yellow. c) Detailed look into the mechanism of the DNA knicking and relegation within the cleavage 
complex. First step: Transesterification reaction, during which the tyrosin becomes linked to the 3’ 
end of the DNA (Nicking). Second Step (Controlled rotation): The torsional stress caused by DNA 
supercoiling drives the 5’end of the nicked DNA around the intact strand. TOP1 encircles this 
nicked DNA and slows its rotation down. Third step (Religation): The 5’ end is relegated with the 3’ 
end, finally leading to relaxed DNA. 
Drugs like camptothecin trap the topoisomerase I DNA complex by stabilizing it, 
which subsequently leads to apoptosis of the cell. Camptothecin is a 
topoisomerase I inhibitor and belongs to the group of interfacial inhibitors [59] 
(see Figure 8). Interfacial inhibitors selectively bind to interfaces as 
macromolecular machines assemble. In 2002, Staker et al. were able to 
crystallize a TOP1 tertiary complex with topotecan and solved the structure.  The 
drug intercalated in the cleaved DNA and specifically bound to TOP1 [61]. In 
2005 and 2006, two groups could show that not only camptothecin, but also the 
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indenoisoquinolines, the non-camptothecin TOP1 inhibitors, act as interfacial 
inhibitors [62, 63] (see Figure 8).  
Until today, topoisomerase I is the only known target of camptothecin and the 
indenoisoquinolines, but the specific signaling pathways leading to apoptosis 
after topoisomerase I inhibition are not yet fully understood [64]. 
Nevertheless, due to high apoptosis-inducing potential, the camptothecin derivate 
topotecan is approved by the FDA for ovarian and lung cancer treatment and 
irinotecan for colorectal cancer therapy. The indenoisoquinolines NSC 725776 is 
currently tested in a phase II trial with relapsed solid tumors and lymphomas 
(http://clinicaltrials.gov). 
 
Figure 8: Topoisomerase inhibitors: Chemical structures of camptothecin and its derivate 
irinotecan, and of the non-camptothecin derived indenoisoquinoles NSC 724998 and NSC 725776. 
1.3.2 Topoisomerase I Inhibitor Treatment in HCC 
Until today, treatment of HCC with irinotecan failed in different studies as first line 
single therapy [65, 66] as well as in combinational approaches with flavopiridol 
[67] or capeticabine [68]. All of these studies had in common that the substance 
was administered intravenously.  
Nevertheless, in 2009 Koushiro Ohtsubo et al. published a study describing 
hepatic aterial infusion (HAI) of irinotecan followed by proton beam therapy in 
HCC, leading to tumor suppression and long-term survival in a patient [69]. 
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Furthermore, Brandi et al. showed in 2011 that intra-aterial infusion of irinotecan 
(HAI) is feasible in patients with hepatocellular carcinoma, with no major adverse 
drug-related events [70]. These studies led to the assumption, that irinotecan 
might be useful in HCC therapy, if administered directly at the tumor site. 
1.4 Aim of this Project 
The aim of this thesis was to evaluate the efficacy of targeting FUBP1 in 
hepatocellular carcinoma.  
At the beginning of the study it was known that FUBP1 is highly deregulated in 
several cancerous tissues. In our group, we could show that FUBP1 is highly 
overexpressed in hepatocellular carcinoma compared to the normal liver tissue. 
Furthermore, a stable knockdown of FUBP1 in the human HCC cell Hep3B led to 
impaired tumor growth in a xenograft transplantation model [1].  
Based on these findings, FUBP1 might be a potential new target in HCC therapy. 
The goal of this project was to identify novel FUBP1 inhibitors and test their 
efficacy in in vitro and in vivo preclinical studies. For this purpose, the following 
issues were adressed: 
I. The expression and purification of recombinant FUBP1 full length protein 
II. The functional analysis of recombinant FUBP1 
III. The establishment of an inhibitor screening system and the subsequent 
identification of potential inhibitory substances 
IV. The validation of the screening “hits” in an independent binding assay 
V. Studying the effects of the inhibitory substances in vitro 
VI. Studying the anti-cancerous effects of the substances in an in vivo mouse 
model  
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2 Materials and Methods 
2.1 Materials 
2.1.1 Plasmids 
Table 2: Original plasmids 
Name Description Reference 
pET28 b (+) Bacterial Expression vector, 
kanamycin-resistance, optional N- or 
C-terminal Hexahistidine-tag, T7 
promotor 
Novagen, Darmstadt 
coFUBP1/pUC57 Full length, human, codon optimized 
FUBP1 sequence. Commonly used 
plasmid cloning vector in E. coli. The 
pUC57 vector length is 2,710bp and is 
isolated from E. coli strain DH5α by 
standard procedures 
GenScript, Hong Kong 
 
Throughout the whole study, codon optimized FUBP1 sequence (by GenScript), 
is referred to as coFUBP1. 
Table 3: Modified plasmids 
Name Description 
coFUBP1/pET28  Codon optimized FUBP1 sequence in bacterial expression vector, kanamycin-resistance, C-terminal Hexahistidine-tag, T7 promotor 
 
2.1.2 Oligonucleotides 
All oligonucleotides used in this study were synthesized by BioSpring, Frankfurt 
am Main, Germany. 
2.1.2.1 Sequencing Oligonucleotides 
Table 4: Sequencing Oligonucleotides 
Name	   Gene	   Sequence	  (5'-­‐-­‐>3')	   TM	  [°C]	  
coFBP1	  rev	  1	   FUBP1 tacgactaatctgttcacgc	   54	  
coFBP1	  for	  1	   FUBP1 attcagatcgcaccggattc	   52	  
coFBP1	  rev	  1	   FUBP1 atcaccgtgatggaaacccg	   62	  
coFBP1	  for	  2	   FUBP1 tcaccgatctgctgcgtagc	   56	  
coFBP1	  rev	  2	   FUBP1 tacccgtcggcacaatgaag	   62	  
coFBP1	  for	  3	   FUBP1 aagctggtaccgacccgaac	   56	  
coFBP1	  rev	  3	   FUBP1 taatcgacctgaccagccg	   61	  
coFBP1	  for	  A1	   FUBP1 actgaactcgaatgattatgg	   61	  
 
 
  Materials & Methods 
 
 22 
2.1.2.2 Oligonucleotides used for Cloning 
Table 5: Cloning oligonucleotides 
Name Gene Sequence (5'à3') TM [°C] 
coFBP1 NcoI for FUBP1 aaaccatggcagactactcaacggtc 71 
coFBP1 NheI for FUBP1 aaaccatggcagactactcaacggtc 64 
coFBP1 XhoI rev FUBP1 aaactcgagttgaccctgcggagccg 71 
 
2.1.2.3 qRT-PCR Oligonucleotides 
Table 6: qRT-PCR oligonucleotides  
Name Gene Sequence (5'à3') TM [°C] 
qRT PCR huMYC for C-MYC  cgtctccacacatcagcacaa 54 
qRT PCR huMYC rev C-MYC  cactgtccaacttgaccctcttg 57 
118qRT-hGAPDH-for GAPDH aatggaaatcccatcaccatct 41 
119qRT-hGAPDH-rev GAPDH cgccccacttgattttgg 50 
63-qRT-p21-for CDKN1A tggagactctcagggtcgaaa 54 
64-qRT-p21-rev CDKN1A ccggcgtttggagtggta  53 
qRT PCR TRAIL for TNFSF10  gagctgaagcagatgcaggac 56 
qRT PCR TRAIL rev TNFSF10 tgacggagttgccacttgact 54 
qRT PCR BIK for BIK cttgatggagaccctcctgtatg 57 
qRT PCR BIK rev BIK agggtccaggtcctcttcaga 56 
Q21 Pmaip1 for 2 Pmaip1 cagttggaggctgaggttc 58 
Q22 Pmaip1 rev 2 Pmaip1 gttgagtagcacactcgactt 52 
 
2.1.2.4 Oligonucleotides for Binding Studies 
Table 7: Oligonucleotides for binding studies 
Name Gene Sequence (5'à3') TM [°C] 
pGL3-p21-F1/-FUSE p21 FUSE  ctggctttttgttttcattttgtttttttgttttgttttgttttttgagacaa 62 
p21/P3 p21 FUSE  ttttgttttcattttgtttttttgttt 46 
pGL3-p21-F1/-FUSE 
biotinyliert p21 FUSE  ctggctttttgttttcattttgtttttttgttttgttttgttttttgagacaa 62 
p21/P3 biotinyliert p21 FUSE  ttttgttttcattttgtttttttgttt 46 
p21/p31 FUSE p21 FUSE  cagccctggctttttgttttcattt 54 
p21/p31 FUSE 
biotinyliert p21 FUSE  cagccctggctttttgttttcattt 54 
p21/p39 FUSE p21 FUSE  tttgttttgttttttgagacaaggt 48 
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2.1.3 Chemically Competent Bacteria 
Table 8: Chemically competent bacteria 
Host Strain Genotype Manufacturer 
	  BL21(DE3) F– ompT gal dcm lon hsdSB(rB- mB-) λ(DE3 [lacI 
lacUV5-T7 gene 1 ind1 sam7 nin5]) 
Agilent Technologies, 
Santa Clara USA 
	  
One Shot® 
TOP10 
F-mcrAΔ (mrr-hsdRMS-mcrBC) φ80 
lacZΔM15ΔlacX74 recA1 araD139Δ(ara-leu)7697 
Invitrogen GmbH, 
Darmstadt 
	  
 galU galK rpsL(StrR) endA1 nupG 	  
 
2.1.4 Enzymes 
Table 9: Restriction endonucleases 
Enzymes Restriction site [5'-->3'] Concentration [U/ml-1] Manufacturer 
NcoI CCA TTG 20000 NEBiolab, Schwalbach 
XhoI CTC GAG 20000 NEBiolab, Schwalbach 
 
Table 10: Additional Enzymes for molecular biology methods 
Enzyme Concentration [U/ml-1] Manufacturer 
Calf-intestinine Phosphatase (CIP) 10,000 NEBiolab, Schwalbach 
DNAse I 5,000000* Sigma Aldrich Chemie, Taufkirchen 
Platinum® Pfx Polymerase 2,500 Invitrogen GmbH, Darmstadt 
RNAse A 100 mg / ml-1 Roche, Mannheim 
Taq Polymerase 5,000 Invitrogen GmbH, Darmstadt 
T4 DNA Ligase  200,000 NEBiolab, Schwalbach 
Omniscript Reverse Transcriptase 4 Qiagen GmbH, Hilden 
*Was used in lyophilized form, concentration in [U/mg-1] 
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2.1.5 Bacteria Growth Media, Antibiotics and Supplement Stock Solutions 
Table 11: Bacterial growth media 
Media Ingredients for 1 L Preparation 
LB-Medium 5 g yeast extract MQ-water (ddH2O) ad 1L, adjust to pH 7.2, 
autoclave for 30 minutes   10 g peptone 
  10 g NaCl 
    
LB-Agar 5 g yeast extract MQ-water (ddH2O) ad 1L, adjust to pH 7.2, for 
selective LB-agar plates allow media to cool 
down to 50°C before adding selective 
antibiotic(s) 
  10 g peptone 
  10 g NaCl 
  15 g agar-agar 
    
      
Auto-induction 925 ml LB-media Prepare LB- medium as descripted above allow 
media to cool down to room temperature before 
adding remaining reagents immediately before 
inoculation 
Medium 20 ml 5052 
  50 ml NPS 
  1 ml MgSO4 
  4 ml Kanamycin 
 
Table 12: Supplements 
Media Ingredients for 1 L / 
Concentration 
Preparation 
5052 37.5 g glucose MQ-water (ddH2O) ad 1L,stirr at 50°C, filter 
sterilize (0.2 µm)   150 g α-lactose 
  375 g glycerol 
    
NPS 66 g (NH4)SO4 MQ-water (ddH2O) ad 1L, autoclave for 30 minutes 
  136 g KH2PO4 
      
MgSO4 1 M Dissolve in ddH2O, filter sterilize (0.2 µm) 
      
Glucose 20% 
(w/v) 
20% (w/v) Dissolve in ddH2O, filter sterilize (0.2 µm) 
      
IPTG 1 M Dissolve in ddH2O, filter sterilize (0.2 µm), store at 
-20°C (1 ml Aliquots) 
      
Kanamycin 25 mg/ml-1 Dissolve in ddH2O, filter sterilize (0.2 µm), store at 
-20°C (1 ml Aliquots) 
      
Ampicillin 100 mg/ml-1 Dissolve in ddH2O, filter sterilize (0.2 µm), store at 
-20°C (1 ml Aliquots) 
 
  Materials & Methods 
 
 25 
2.1.6 Kits 
Table 13: Kits 
Name Manufacturer 
Plasmid Maxi Kit Qiagen GmbH, Hilden 
Qiaquick® Gel Extraktion Kit Qiagen GmbH,  Hilden 
Omniscript® Reverse Transcription Qiagen GmbH, Hilden 
Amersham ECL Western Blotting Detection GE Healthcare, Munich 
 
2.1.7 Buffers and Solutions 
2.1.7.1 Buffer for Molecular Biological Methods 
Table 14: Buffer for plasmid DNA preparations 
Buffer Ingredients / Concentration Preparation 
GTE buffer 50 mM Glucose filter sterilize (0.2 µm) 
  25 ml Tris-HCl pH 8.0   
  10 mM EDTA   
      
Lysis buffer 200 mM NaOH freshly prepared 
  1% SDS   
      
Neutralization buffer 3 M KoAc, pH 5,2 filter sterilize (0.2 µm) 
 
Table 15: Buffer for agarose gel electrophoresis 
Buffer Ingredients / Concentration 
Running buffer (0.5x TBE) 44.5 mM Tris 
  44.5 mM boric acid 
  1 mM EDTA, pH 8.0 
    
DNA loading buffer 100 mM EDTA 
  1% SDS 
  0.25% (w/v) bromphenol blue 
  0.25% (w/v) xylenecylanol 
  20% (w/v) glycerol 
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2.1.7.2 Buffer for Protein Biochemical Methods 
Table 16: SDS-PAGE gel electrophoresis 
Buffer Ingredients / Concentration 
SDS sample buffer 62.5 mM Tris-HCl, pH 6.8 
  2% (w/v) SDS 
  20% (w/v) glycerol 
  0.1% (w/v) bromphenol blue 
  50 mM DTT 
    
SDS-PAGE runnning buffer 50 mM Tris 
  200 mM glycine 
  0.15% (w/v) SDS 
 
Table 17: Coomassie staining buffer 
Buffer Ingredients / Concentration 
Quick Coomassie staining solution MQ-water (ddH2O) ad 1L 
  0.3% HCl conc. 
  Coomassie blue R-250, 80 mg / 1L solution 
    
Coomassie gel stain MQ-water (ddH2O) ad 1L 
  45% (v/v) methanol 
  1% glacial acetic acid 
  Coomassie blue R-250, 1 g / 1L solution 
    
Coomassie gel destain MQ-water (ddH2O) ad 1L 
  10% methanol 
  10% glacial acetic acid 
 
Table 18: Lysis buffer 
Buffer Ingredients / Concentration 
Bacterial lysis buffer 50 mM MES, pH 6.5 
  50 mM NaCl 
  1 tablet Complete EDTA-free Protease Inhibitor Cocktail ad 50 ml 
solution 
    
RIPA buffer 10 mM Tris-HCl, pH 7.4 
  20 mM KCl 
  1.5 mM MgCl2 
  0.5% SDS 
  1.3 mM PMSF 
  1 tablet Complete EDTA free Protease Inhibitor Cocktail ad 50 ml 
solution 
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Table 19: Western blot analysis buffer 
Buffer Ingredients / Concentration 
Blotting buffer 48 mM Tris, pH 7.5 
  39 mM glycine 
  20% (v/v) methanol 
    
TBS-T 25 mM Tris, pH 8.1 
  150 mM NaCl 
  0.1% Tween20 
    
Blocking buffer 3% non-fat milk powder in TBS-T 
 
2.1.7.3 Buffer for Chromatographic Methods 
Table 20: Immobilized metal ion affinity chromatography (IMAC); HisTrap 
Buffer Ingredients / Concentration 
Bacterial lysis buffer 50 mM MES, pH 6.5 
  50 mM NaCl 
  1 tablet Complete EDTA free Protease Inhibitor Cocktail ad 50 ml 
solution 
    
Wash buffer 50 mM MES, pH 6.5 
  50 mM NaCl 
  4 mM Imidazole 
    
Elution buffer 50 mM MES, pH 6.5 
  50 mM NaCl 
  404 mM Imidazole 
 
Table 21: Affinity chromatography; HeparinTrap 
Buffer Ingredients / Concentration 
Wash buffer (low salt) 50 mM MES, pH 6.5 
  50 mM NaCl 
  3 mM DTT 
    
Elution buffer (high salt) 50 mM MES, pH 6.5 
  2 M NaCl 
  3 mM DTT 
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Table 22: Size exclusion chromatography; Gelfiltration 
Buffer Ingredients / Concentration 
Running buffer 50 mM MES, pH 6.5 
  50 mM NaCl 
  3 mM DTT 
2.1.7.4 Buffer for Interaction Studies 
Table 23: Alpha screen buffer 
Buffer Ingredients / 
Concentration 
Preparation 
Screening buffer 50 mM Tris, pH 7.4   
  100 mM NaCl   
  0.01% Tween20   
  0.1% BSA filter sterilized (0.2 µm), stored at 4°C 
 
Table 24: SPR and MST binding study buffer 
Buffer Ingredients / Concentration Preparation 
SPR buffer 50 mM Tris, pH 7.4 filter sterilized (0.2 µm) 
  100 mM NaCl   
  0.1% BSA   
  1% DMSO freshly added prior to use 
MST buffer 50 mM Tris, pH 7.4 filter sterilized (0.2 µm) 
  100 mM NaCl   
  0.1% BSA   
 
2.1.8 Antibodies 
Table 25: Primary Antibodies 
Name Species Dilution Manufacturer 
Anti-human FUBP1 (N-15) goat 1: 1,000 Santa Cruz Biotechnology, 
Heidelberg 
Anti-human β-Actin   goat 1: 2,000 Santa Cruz Biotechnology, 
Heidelberg 
 
Table 26: Secondary Antibody 
Name Species Dilution Manufacturer 
Anti-goat-HRP rabbit 1: 10,000 Invitrogen GmbH, Darmstadt 
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2.1.9 Size Markers for Gelelectrophoresis  
Table 27: BenchmarkTM Prestainend Protein ladder 
 
 
 
 
 
 
 
 
 
 
2.1.10 Cell Culture Materials 
Table 28: Cell lines 
Name Description Source 
HEK 
293T 
Human embryonic kidney cells, cell line generated by 
adenovirus transformation with SV40 "large T"-antigen, S1 AG Grez, GSH, Frankfurt 
Hep3B Human hepatocellular carcinoma cells, positive for HepB   ATCC (HB-8064™) 
  viral DNA sequences, S1 
HepG2 Human hepatocellular carcinoma cells, S1 ATCC (HB-8065™) 
HuH7 Human hepatocellular carcinoma cell line, S1 AG Piiper, University Hospital Frankfurt 
 
 
 
Band 
No. 
Apparent 
molecular 
weight [kDa] 
1 181.8 
2 115.5 
3 82.2 
4 64.2 
5 48.8 
6 37.1 
7 25.9 
8 19.4 
9 14.8 
10 6.0 
 
Figure 9: Gene RulerTM 1kB Plus DNA ladder, Invitrogen, Darmstadt 
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Table 29: Cell culture media 
Name Description Manufacturer 
DMEM Dulbecco's Modified Eagle Media GIBCO, Eggenstein 
  4.5 g / L-1 glucose 
Advanced DMEM Dulbecco's Modified Eagle Media GIBCO, Eggenstein 
  4.5 g / L-1 glucose 
DMSO Dimethylsulfoxide, highly purified Merck, Darmstadt 
FCS Fetal calf serum PAA Laboratories, Pasching 
L-Glutamine 200 mM solution PAA Laboratories, Pasching 
Pen / Strep 10,000 U / ml-1 Penicillin PAA Laboratories, Pasching 
  10,000 µg / ml-1 Streptomycin 
Trypsin-EDTA 0.05% Trypsin EDTA GIBCO, Eggenstein 
PEI 
 
Polyethylenemine 
 
Sigma-Aldrich Chemie GmbH, 
Steinheim 
 
2.1.11 Chemotherapeutics and Small Molecule Compounds 
Table 30: Chemotherapeutics and small molecules 
Name Concentration Preparation Manufacturer 
mitomycin C  0.4 mg/ml Dissolved in ddH2Osteril / methanol (4:1) Roche, Mannheim 
cisplatin  1 mg/ml Dissolved in ddH2Osteril Teva, Israel 
doxorubicin  10 mg/ml Dissolved in ddH2Osteril 
Sigma-Aldrich, Chemie 
GmbH, Steinheim 
sorafenib 10 mM Dissolved in DMSO, stored at -20°C (1 ml Aliquots) Selleckchem, Boston 
camptothecin 10 mM Dissolved in DMSO, stored at -20°C (1 ml Aliquots) 
Santa Cruz Biotechnology,  
Heidelberg 
7-ethyl- 1000 µM Dissolved in DMSO, stored at -20°C, (1 ml Aliquots)   Selleckchem, Boston 
10-hydroxy     
-camptothecin     
pregnenolone 10 mM Dissolved in DMSO, stored at -20°C, (1 ml Aliquots)   
Santa Cruz Biotechnology,  
Heidelberg 
tosufloxacin 10 mM Dissolved in DMSO, stored at -20°C, (1 ml Aliquots)   
Santa Cruz Biotechnology,  
Heidelberg 
NSC724998 10 mM Dissolved in DMSO, stored at -20°C, (20 µl Aliquots) 
kindly provided by Prof. 
Yves Pommier, NIH 
NSC725776 10 mM Dissolved in DMSO, stored at -20°C, (20 µl Aliquots) 
kindly provided by Prof. 
Yves Pommier, NIH 
 
Table 31: Screening libraries 
Name Manufacturer Source 	  
Prestwick Chemical 
library®  
Prestwick Chemical, Illkirch, 
France 
kindly provided by Ricardo Biondi, Med. 
Klinik1, Uniklinikum Frankfurt 
	  
Maybridge HitFinderTM 
library 
Thermo Fisher Scientific, 
Waltham, USA 
kindly provided by Ricardo Biondi, Med. 
Klinik1, Uniklinikum Frankfurt 
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2.1.12 Laboratory Equipment 
Table 32: Centrifuges 
Name Manufacturer 
Beckman J2-HS Beckman, Munich 
Biocentrifuge, J2-21M/E with JA-10 and JA-20 rotors Beckman, Munich 
Cold-Centrifuge Megafuge 1.0R Heraeus, Hanau 
Cold-Centrifuge Minifuge GL Heraeus, Hanau 
Desk-Centrifuge Biofuge pico Heraeus, Hanau 
 
Table 33: Incubators 
Name Manufacturer 
Bacterial Incubator Function Line  Heraus, Hanau 
Bacterial-Shaker-Incubator Multitron model  Infors AG, Bottmingen (Switzerland) 
Cell Culture Incubator MCO 17 AI Sanyo Component Europe GmbH, Ingolstadt 
 
Table 34: Heat Blocks and Waterbath 
Name Manufacturer 
Cooling-Thermomixer MKR 13 HLC Biotech, Bovenden 
Dri.Block DB-2D Techne Dexford, Cambridge (England) 
Thermomixer Compact for 1.5ml Tubes Eppendorf AG, Hamburg 
Water-Bath  GFL, Burgwedel  
 
Table 35: Electrophoresis 
Name Manufacturer 
BioRad Power Pac 300 BioRad Laboratories, Munich 
DNA Mini-Subcell for Agarose Gels BioRad Laboratories, Munich 
Electrophoresis Power Supply EPS 301 Amersham Pharmacia Biotech 
Gel-Chamber Model Hoefer HE 33 for Mini Gels Amersham Pharmacia Biotech 
Mini-Protean® 3 Cell Gel Chamber BioRad Laboratories, Munich 
Semidry Blotting Unit Semiphor Transphor Unit Hoefer Pharmacia Biotech 
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Table 36: Chromatography material, devices and filters 
Name Manufacturer 
Äkta Purifier GE Healthcare Europe GmbH, Munich 
Amicon Ultrafiltration Membrane MWCO 10 kDa  Millipore GmbH, Schwalbach/Ts.  
Amicon Ultrafiltration Membrane MWCO 30 kDa  Millipore GmbH, Schwalbach/Ts.  
Hi-Load Superdex 16/60 200 GE Healthcare Europe GmbH, Munich 
HiTrap heparin HP 5 ml GE Healthcare Europe GmbH, Munich 
Ni-Sepharose High Performance, 25 ml GE Healthcare Europe GmbH, Munich 
Omnifit® Chromatography Columns Diba Industries Ltd, Cambridge 
Sample loop 5 ml  GE Healthcare Europe GmbH, Munich 
Superloop 50 ml GE Healthcare Europe GmbH, Munich 
 
Table 37: Material and devices for MST and SPR binding studies 
Name Manufacturer 
BioRad ProteOnTM XPR 36  BioRad Laboratories, Munich 
Capillary sealing wax NanoTemper Technologies, Munich  
Monolith NT.115 NanoTemper Technologies, Munich  
ProteOnTM NLC sensor chip BioRad Laboratories, Munich 
Standard capillaries NanoTemper Technologies, Munich  
 
Table 38: Material and devices for Alpha Screen® experiments 
Name Manufacturer 
1000 µl pipette tips Steinbrenner Laborsysteme GmbH 
200 µl pipette tips Steinbrenner Laborsysteme GmbH 
384-well liquidator adapter Steinbrenner Laborsysteme GmbH 
384-well plate Greiner Bio one 
96-well plate Greiner Bio one 
AlphaScreen® General IgG (Protein A) 
Detection Kit Perkin Elmer, Waltham MA 
Envision® multilable plate reader Perkin Elmer, Waltham MA 
Liqudator 96 Steinbrenner Laborsysteme GmbH 
 
Table 39: Others 
Name Manufacturer 
Autoclave Tuttnauer Systec 2540 EL Systec, Wettenberg 
Bunsen Burner Model 1230/1 Carl Friedrich Usbeck KG, Radevormwald  
CryoPure tubes 1.8 ml Sarstedt, Nümbrecht 
Fluorescence Microscope Nikon Eclipse Te300  Nikon, Düsseldorf 
Freezer (-20°C) Liebherr, Ochsenhausen  
Freezer CFC Free (-80°C) Sanyo, Wiesbaden  
Freezing container Qualilab, France 
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Gene Amp® PCR System 9700 PE Applied Biosystems  
Hypercassette Amersham, Buckinghamshire (England) 
Integra Pipetboy Integra Biosciences, Fernwald  
Laminar Air Flow (NSF 49 BS 5726 DIN (1-4))  Clean Air, Woerden (Netherlands)  
Magnetic-Stirrer Model IKA-Combimag RCH IKA Labortechnik, Staufen  
Microscope for Cell Culture Helmut Hund GmbH, Wetzlar  
Mircowave Sharp R-3V10 Sharp Corp.  
NanoDropTM 1000 Spectrophotometer  Thermo Fischer Scientific, Bonn  
Neubauer Improved Hemocytometer Marienfeld Superior, Darmstadt  
pH-Meter Model PHM 83 autocal  Radiometer, Copenhagen (Denmark) 
Refrigerator (4°C)  Bosch 
Roller RM5 Assistant 348 Karl Hechst GmbH&Co.KG, Sondheim  
Rotate roller Gerlinde Kister, Mühlhausen 
UV-Transluminator with video camera and -printer  UVP Inc., San Gabriel (USA) 
vacuum pump KNF Neuberger LABOPORT, Freiburg  
Vortex Genie 2 Scientific Industries, New York (USA) 
Water-Bath  GFL, Burgwedel  
 
2.1.13 Chemicals and Reagents 
Table 40: Reagents 
Name Manufacturer 
Acrylamide Solution (Rotiphorese Gel 30) Carl Roth GmbH&Co.KG, Karlsruhe 
Agarose UltraPure (TM) Agarose Invitrogen GmbH, Darmstadt 
Ampicillin AppliChem GmbH, Darmstadt 
APS (10% in H2O) Sigma-Aldrich Chemie GmbH, Steinheim 
Boric Acid Carl Roth GmbH&Co.KG, Karlsruhe 
Bradford Reagent (Roti®-Quant) Carl Roth GmbH&Co.KG, Karlsruhe 
Bromphenol Blue Carl Roth GmbH&Co.KG, Karlsruhe 
Complete Mini Protease Inihibitor Cocktail Roche, Mannheim 
DTT Sigma-Aldrich Chemie GmbH, Steinheim 
EDTA Sigma-Aldrich Chemie GmbH, Steinheim 
EGTA Sigma-Aldrich Chemie GmbH, Steinheim 
EtBr Carl Roth GmbH&Co.KG, Karlsruhe 
EtOH Carl Roth GmbH&Co.KG, Karlsruhe 
Glucose Carl Roth GmbH&Co.KG, Karlsruhe 
Glycerol Carl Roth GmbH&Co.KG, Karlsruhe 
Glycine Carl Roth GmbH&Co.KG, Karlsruhe 
HEPES Carl Roth GmbH&Co.KG, Karlsruhe 
Illustra™ dNTP Set GE Healthcare Europe GmbH, Munich 
Isopropanol (2-Propanol) Carl Roth GmbH&Co.KG, Karlsruhe 
KCl  Carl Roth GmbH&Co.KG, Karlsruhe 
KH2PO4  Carl Roth GmbH&Co.KG, Karlsruhe 
KoAc Carl Roth GmbH&Co.KG, Karlsruhe 
Kolliphore® EL Sigma-Aldrich Chemie GmbH, Steinheim 
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MeOH Carl Roth GmbH&Co.KG, Karlsruhe 
MES-buffer AppliChem GmbH, Darmstadt 
MgCl2 Sigma-Aldrich Chemie GmbH, Steinheim 
Na-β-glycerophosphate Sigma-Aldrich Chemie GmbH, Steinheim 
Na-pyrophosphate Sigma-Aldrich Chemie GmbH, Steinheim 
Na2HPO4 Carl Roth GmbH&Co.KG, Karlsruhe 
NaAc Carl Roth GmbH&Co.KG, Karlsruhe 
NaCl Carl Roth GmbH&Co.KG, Karlsruhe 
NaF (Natriumfluorid) Sigma-Aldrich Chemie GmbH, Steinheim 
NaOH AppliChem GmbH, Darmstadt 
Nonfat dried milk powder AppliChem GmbH, Darmstadt 
PMSF Carl Roth GmbH&Co.KG, Karlsruhe 
Ponceau S Solution Sigma-Aldrich Chemie GmbH, Steinheim 
Roti®-Quant Carl Roth GmbH&Co.KG, Karlsruhe 
SDS Carl Roth GmbH&Co.KG, Karlsruhe 
Sodium Chlorid Roth, Karlsruhe 
Sucrose Carl Roth GmbH&Co.KG, Karlsruhe 
TEMED Carl Roth GmbH&Co.KG, Karlsruhe 
Tris Carl Roth GmbH&Co.KG, Karlsruhe 
TrisBase Roth, Karlsruhe 
Triton-X-100 Fluka, Buchs (Switzerland) 
Tween-20 Carl Roth GmbH&Co.KG, Karlsruhe 
 
Table 41: Software and databases 
Table 42 
Name Manufacturer 
NTControl (MST data analysis) NanoTemper Technologies, Munich 
NTAnalysis (MST data acquisition) NanoTemper Technologies, Munich 
ProteOn Manager Software BioRad Laboratories, Munich 
Microsoft Excel Microsoft (USA) 
Microsoft Office Microsoft (USA) 
GraphPad® Prism GraphPad Software Inc, La Jolla (USA) 
Lasergen software package DNAstar, Madison (USA) 
UniProt www.uniprot.org 
Expasy www.expasy.org 
ModFit LT Verity Software House 
 
2.2 Methods 
2.2.1 Molecular Biology Methods 
2.2.1.1 Polymerase Chain Reaction (PCR) 
The polymerase Chain reaction is a commonly used method to amplify single and 
double stranded oligonucleotides from template DNA. During this thesis, this 
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method was used to amplify coFUBP1, while deleting the intrinsic stop codon and 
adding the restriction sites for the enzymes NcoI and XhoI. 
Table 43: PCR- Mixture 
Components 
Template DNA (20 ng/µl) 
Pfx buffer solution (10 x) 
Forward and reverse primer (10 µM) 
MgSO4 (50 mM) 
dNTP Mix (2.5 mM) 
Platinum® Pfx DNA Polymerase (2.5 U / ml) 
Add H2O to a final volume of 50 µl 
 
The typical PCR-program consists of three parts: Denaturation, annealing and 
elongation. Denaturation is performed at 94°C, when the double stranded DNA is 
melted into two single strands. Subsequently, the temperature is lowered to 
55°C - 63°C (depending on the melting temperatures of the specific primers). 
Reduction of the temperature leads to hybridization of the oligonucleotides 
(primers), which are present in an excessive amount. Afterwards, the 
temperature is increased to 68°C, resembling the temperature optimum of the 
Platinum® Pfx polymerase, to elongate the primers until double stranded DNA 
strand is produced, which resembles the original DNA template. Since the 
elongation takes place on both strands, the amount of DNA is doubled after every 
cycle. The assembly of the new strands is dependent on the presence of 
desoxynucleotides triphosphates (dATP, dGPT, dTPT, dCTP), serving as 
building elements and MgSO4 as a polymerase cofactor [71].  
The initialization is performed at 94°C for 5 minutes. Afterwards, 25 cycles 
consistent of 94°C for 1 minute, 63°C for 45 seconds and finally 68°C for 
2.5 minute are run. Lastly, a final elongation at 68°C for 10 minutes is followed by 
cooling to 4°C (see Table 44). 
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Table 44: PCR program for coFUBP1 amplification 
PCR step Time Temperature No. of Cycles 
Initialization 5 minutes 94°C 1 
	  	   	  	   	  	     
Denaturation 1 minute 94°C   
Annealing 45 seconds 63°C 25 
Elongation 2.5 minutes 68°C   
        
Final elongation 5 minutes 68°C 1 
  ∞ 4°C   
 
Subsequently, all PCR products were purified using the Qiaquick® PCR 
Purification kit, according to the manufactures manual.  
2.2.1.2 Digestion of DNA by Restriction Endonucleases 
Restriction enzymes are classified according to their recognition and cleavage 
sites. Three types of endonucleases are known (class I, II and III). Class I 
enzymes consist of three subunits; the S- subunit recognizes the DNA sequence, 
the M- subunit methylates and the R- subunits cleaves the DNA. The recognition 
site is specific, whereas the cleavage site is accidental. Class III endonucleases 
consist of several subunits, recognizing specific DNA sequences and cleave 20 -
25 bp up- or downstream of those. Only class II endonucleases are widely used 
in every day laboratory practice. They cleave the DNA at a highly defined site. 
These endonucleases consist of two different proteins, the restriction 
endonuclease and the methylation enzyme. Recognizing the same sequence, the 
endonuclease cleaves the DNA, while the other methylates the hemi-methylated 
DNA, to protect it [71]. 
In this study, the coFUBP1 fragment was ligated into pET28b plasmid, using the 
restriction endonucleases NcoI and XhoI. The digestion of both, the coFUBP1 
fragment and the plasmid, was performed as a “double digestion”, using both 
enzymes at the same time.  
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Table 45: Double digestion of coFUBP1 and pET28b 
Component Plasmid-DNA DNA-fragment 
DNA 20 µl (4 µg) pET28b 30 µl PCR-product 
      
Endonucleases:   
NcoI 1.5 µl 1.5 µl 
XhoI 1.5 µl 1.5 µl 
      
10x buffer 4 4 µl 5 µl 
      
10x BSA 4 µl 5 µl 
      
H2O 9 µl 7 µl 
      
final volume 40 µl 50 µl 
 
The digestion reactions were incubated for 3 hours at 37°C and subsequently 
loaded on an agarose gel. Desired fragments were extracted using the 
Qiaquick® gel extraction kit, according to the manufactures manual. 
2.2.1.3 Ligation Reaction 
To enzymatically link the linearized plasmid and the digested PCR-product, a 
ligation reaction was performed using T4 ligase. The enzyme covalently links the 
DNA fragments via the formation of stable phosphodiester bounds [71]. 
The ligation reaction was performed in a total volume of 10 µl and incubated for 
3 hours at room temperature. 
Table 46: Ligation reaction of coFUBP1 and pET28b 
Component Plasmid-DNA 
pET28b 2 µl 
    
coFUBP1 4 µl 
    
10x buffer  1 µl 
    
T4 ligase 1 µl 
    
H2O 2 µl 
    
final volume 10 µl 
 
Afterwards, the whole ligation reaction was transformed into chemically 
competent bacteria (see page 23, paragraph 2.1.3).  
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2.2.1.4 Transformation of Chemically Competent Bacteria 
The process of non-viral free plasmid DNA transfer into competent bacteria is 
called transformation. In this study, the coFUBP1/pET28b plasmid was 
transformed into two different competent bacteria cell types: One Shot® TOP10 
and BL21(DE3). One Shot® TOP10 bacteria were used for the amplification of 
the plasmids, BL21(DE3) cells for the recombinant expression of the protein (see 
page 23, paragraph 2.1.3).  
Chemically competent cells were thawed on ice for 30 minutes. Afterwards, either 
the whole ligation reaction, or 3 µl of a Mini DNA preparation, was given to the 
bacteria and mixed gently. The mixture was heated at 42°C for 1.5 minutes and 
afterwards, cooled on ice for 1 minute. 1 ml LB-medium was given to the 
reaction, before incubating at 37°C and 200 rpm for 1.5 hours. 
200 µl of the bacterial solution was plated on a LB-Agar plate supplemented with 
kanamycin. The rest of the transformation reaction was centrifuged at 830 x g for 
3 minutes and the supernatant was discarded, leaving 200 µl for re-suspension of 
the bacterial cells. Bacteria plated on a LB-Agar plate supplemented with 
kanamycin and the plates were incubated over night at 37°C. 
The newly formed colonies were analyzed for the presence of the transformed 
plasmid DNA by plasmid Mini DNA preparation with subsequent restriction 
endonuclease digestion (see page 36, paragraph 2.2.1.2). 
2.2.1.5 Plasmid Mini DNA Preparation 
Plasmid Mini preparation was used for a small-scale coFUBP1/pET28b 
preparation from previously transformed One Shot® TOP10 bacteria. After 
successful inoculation, several clones were picked and used to inoculate 5 ml LB 
medium, while shaking at 130 rpm and 37°C on a vertical shaker over night.  
Afterwards, 3 ml of the inoculated culture were centrifuged at 16,000 x g for 
2 minutes. The supernatant was discarded, the bacterial cells were re-suspended 
in 100 µl pre-chilled GTE buffer and subsequently lysed by the addition of 200 µl 
lysis buffer. 150 µl of ice-cold neutralization buffer was used to precipitate 
undesired bacterial DNA, proteins and detergents. The cell suspension was 
incubated on ice for 5 minutes, followed by a centrifugation at 16,000 x g for 
5 minutes. The supernatant containing the desired plasmid DNA was transferred 
to a new reaction tube, and the DNA was precipitated by the addition of 1 ml 
100% ethanol and thorough vortexing. The suspension was centrifuged at 
16,000 x g for 10 minutes, afterwards the supernatant was discarded and the 
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DNA pellet was re-suspended in 500 µl 70% ethanol and washed via 
centrifugation at 16,000 x g for 10 minutes. Subsequently, the DNA pellet was 
air-dried for 10 minutes and later on dissolved in 30 µl HPLC purified water 
containing 200 µg/ml RNAse A. 
To analyze the plasmid DNA, an analytical digestion with the same enzymes 
used for the previous cloning was performed. The generated fragments were 
analyzed by agarose gel electrophoresis (see page 40, paragraph 2.2.1.10). 
Furthermore, all clones used for protein expression were sequenced and stored 
as glycerol stocks at -80°C.  
2.2.1.6 Glycerol Stock Preparation 
To keep competent bacteria containing the desired plasmid alive, the culture is 
mixed with 100% sterile glycerol for long term storage at -80°C. Accordingly, 1 ml 
of sterile glycerol were added to 1 ml bacteria culture and mixed thoroughly by 
vortexing.  
2.2.1.7  Plasmid Maxi DNA Preparation 
Large scale preparations of plasmid DNA were performed according to the 
manufacturers manual of the Maxi Kit® by Qiagen. The precipitated DNA was 
diluted in 100 µl ddH2Osteril, and to verify the successful preparation, an analytical 
restriction enzyme digestion and sequencing was performed (see page 40, 
paragraph 2.2.1.9). The concentration of the plasmid DNA was determined by the 
use of a NanoDrop100 device from Thermo Fisher.  
2.2.1.8 Quantification of DNA Concentration and Purity 
Spectrophotometric analysis was used to determine the quantity and purity of 
plasmid DNA and RNA samples. As nucleotides absorb ultraviolet light at 
260 nm, the concentration can be calculated using the following equation. 
Equation 1: 
! µμ!µμ! = !"260nm ∗ ! ∗ !! ∗ !  c=  Concentration  D=  Dilution  factor  F=  Multiplication  factor  (e.g.  50  for  dsDNA)  M=  Molecular  weight  of  each  base  pair  (660  g  /mol)  L=  Length  in  bp  
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2.2.1.9 Sequencing 
The sequencing reactions were performed either by an in-house sequencing 
service (AG Dietrich; Georg-Speyer-Haus), or by GATC Biotech AG (Cologne). 
According to the companies guidelines, 1 µmol sequencing primer was added to 
100 ng DNA for each sequencing reaction. The sequences were analyzed using 
Lasergene® software. 
2.2.1.10 Agarose Gel Electrophoresis 
To separate different DNA fragments according to their length, agarose gel 
electrophoresis was performed. All samples were diluted in 6x DNA sample 
buffer and loaded on a 0.8% - 2% agarose gel, containing 10 µg ethidium 
bromide (EtBr) ad 100 ml gel for visualization of the DNA.  
Due to the negative charge of the DNA, the fragments migrate to the positive 
charge, when a direct current of 120 V to 150 V is applied. As the migration of the 
fragments is negatively correlated to their length, larger oligonucleotides migrate 
slower than the shorter ones. To define the length of the fragments, a so-called 
DNA-marker, with defined fragment sizes, was also applied to the gel to serve as 
a size standard. 
The Gel Doc XR System from BioRad (Munich) was used to document the 
agarose gels. For subsequent analysis of the DNA fragments, the Qiagen Gel 
Extraction® Kit was used according to the manufacturer’s manual. 
2.2.1.11  RNA Isolation and Analysis 
2.2.1.11.1  RNA Isolation 
To isolate RNA from mammalian cells, 1 x 106 cells were first washed with PBS 
and afterwards collected by the use of a cell scraper in 1 ml PBS and transferred 
to a reaction tube. After centrifugation at 1,000 x g (3,000 rpm) for 3 minutes, 
cells were immediately used for RNA isolation. RNA was isolated using the 
RNeasy® Mini Kit by Qiagen according to the manufacturers manual. The lysis of 
the cells was performed using QIAshredder® columns by Qiagen. The RNA was 
immobilized on silica-membrane columns, where an on-column DNAse I 
digestion was performed to remove contaminating DNA. 
2.2.1.11.2  Reverse Transcription 
To convert RNA into cDNA,’s manual. 1.5 µg RNA was transcribed in a 20 µl 
reaction mix containing RT reaction buffer, oligonucleotide (poly dT) and random 
hexamer primer (Fermentas), dNTPs, RNAse inhibitor (RiboLock®, Fermentas) 
and reverse transcriptase. 
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2.2.1.11.3  Quantitative Real Time PCR 
To determine the copy number of a given RNA molecule in a sample (e.g. 
cultivated cells), quantitative real time PCR (qPCR) was performed. The RNA 
has to be transcribed into cDNA before the analysis (see page 40 paragraph 
2.2.1.11.2). 
The principle of qPCRs is based on the same principle as normal qualitative 
PCRs (see page 34 paragraph 2.2.1.1). The difference to a conventional PCR is 
the use of a fluorescent dye as a quantitative indicator for the amplified target 
sequence, whose emitted light signal is measured during the process. 
Throughout all PCR cycles, quantification of the fluorescent signal allows to 
monitor the target amplification.  
The fluorescent dye SYBR Green is a DNA intercalator and acts as a non-
specific dye. To ensure the specificity of a reaction performed with SYBR Green, 
a combinational analysis of melting peaks, agarose gel analysis and sequencing 
of the PCR product has been used. 
The acquired fluorescence signal is plotted against the number of cycles to 
quantify the target sequence. Defining of a fluorescence background threshold is 
used to determine the cycle at which the measured signal crosses this threshold 
(cycle threshold (CT) value) for each sample. 
The target copy number differences are calculated by the following equation: 
Equation 2:     ! = !0   ∗ !n N=  Number  of  amplified  copies  N0=  Number  of  targeted  copies  at  the  beginning  of  the  reaction  E=  PCR  efficacy  n=  Number  of  cycles  
Measurement of the Ct value occurs at the exponential phase of the reaction, and 
therefore the PCR efficacy can be assumed as equal 2 (see Equation 3). 
Equation 3:     ! = !0 ∗ !n N=  Number  of  amplified  copies  N0=  Number  of  targeted  copies  at  the  beginning  of  the  reaction  
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n=  Number  of  cycles  
A relative quantification was performed using a housekeeping gene for 
normalization. Housekeeping genes should be stably expressed in all samples 
and are used to normalize possible variations in the amount and quality of the 
RNA samples used in every reaction. Ct values are determined from both the 
target and the housekeeping gene, to calculate the ΔCt value (see Equation 4). 
Equation 4: !!t = !t   !"#$%!  !"#$"%&" − !t  (!"#$%&%%'()*  !"#") 
To further compare the relative amount of a target sequence in different samples, 
the ΔCt value can be used to calculate the ΔΔCt value (see Equation 5). 
Equation 5: ∆!!t = !!t   !"#$%&  ! − !!t(!"#$%&  !) 
 
Assuming a PCR efficacy of 2, the relative target sequence abundance can then 
be calculated by the following equation: 
Equation 6: !"#$%&'"  !"#$%!  !"#$"%&"  !"#$%!$&' = !-­‐ΔΔCt 
 
2.2.1.11.3.1 qPCR	  using	  SYBR	  Green	  –based	  Assays	  
The mRNA expression levels of all mammalian cells used in this study were 
analyzed by SYBR Green qPCRs. RNA was isolated and transcripted to cDNA 
as described before (see page 40, paragraph 2.2.1.11.1 and page 40, paragraph 
2.2.1.11.2). For each sample, qPCR reactions were performed in technical 
duplicates and biological triplicates in a reaction volume of 24 µl. To ensure the 
absence of DNA contaminations, reactions were performed using nuclease-free 
water. Furthermore, a reaction where the cDNA was replaced by nuclease-free 
water was set up as a negative control. Assays were performed on a 
LightCycler®480 (Roche) with 4-titude 96-well plates.  
The PCR-protocol was performed as followes:  
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Table 47: qPCR protocol 
PCR step Time Temperature No. of Cycles 
        
Denaturation 15 minutes 95°C 1 
	  	   	  	   	  	     
Amplification 20 seconds 95°C   
  30 seconds 58°C 40 
  30 seconds 72°C   
        
Melting Curve 10 seconds 50°C 1 
  10 seconds +2.2°C   
  … 95°C   
 
2.2.2 Mammalian Cell Culture 
2.2.2.1 Freezing and Thawing of Mammalian Cells 
To be able to store cells for long-term, cells were frozen in FCS containing 10% 
dimethyl sulfoxide (DMSO). The solvent prevents excessive formation of ice 
crystals during the freezing process, thereby protecting the cell membrane. 
To freeze mammalian cells, 80%-90% confluent cells were washed with PBS, 
trypsinized at 37°C for 5 minutes and finally re-suspended in fresh media before 
passaging into a 15 ml reaction tube. Cells were centrifuged (5 minutes, 4°C, 
400 x g) before decantation of the supernatant. The cell pellet was diluted in FCS 
containing 10% DMSO and transferred to a cryo tube (Nunc, Wiesbaden). Tubes 
were stored in a freezing container (Cryo1°C, Nalgene, Roskilde, Denmark) and 
kept at -80°C in a refrigerator over night. Afterwards, cryo tubes were removed 
from the freezing container and kept at -80°C for long-term storage. 
Thawing of the cells was performed in a 37°C water bath. The cells were 
immediately diluted in 10 ml cell culture media and harvested by centrifugation 
(5 minutes, 4°C, 400 x g). The supernatant was decanted, and the cells were 
seeded in fresh medium into a new cell culture dish. 
2.2.2.2 Culture of Mammalian Cells 
All cells were cultured in a MCO 17 AI incubator at 37°C with 5% CO2 in a 
humidified atmosphere. Hep3B and HuH7 cells were cultured in AdvancedMEM 
and HepG2 in RPMI medium, both containing 10% FCS, 1% P/S (10 µg/ml) and 
1% L-Glutamin (100 mM). FCS was inactivated by incubation at 56°C for 
30 minutes prior to use. 
Cells were usually passaged twice a week (Hep3B 1:5, HuH7 1:7, HepG2 1:5). 
The medium was removed via aspiration, before washing the cells carefully with 
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PBS. 0.05% Trypsin-EDTA was given to the cells and incubated for 3 to 
5 minutes in an incubator. Afterwards, detached cells were diluted in fresh media 
and transferred to new cell culture plates. 
2.2.2.3 Determination of Cell Numbers using a Neubauer Improved 
Hemocytometer 
To quantify cell numbers in a given solution, a Neubauer improved 
Hemocytometer was used. 10 µl cell suspension was applied to the counting 
chamber. The number of cells was counted in four large squares (each 
containing 16 small squares) under a microscope at 100 x magnification. The cell 
number was calculated according to the following equation: 
Equation 7: !"#$%&  !" !"##$ !" = !"#$%&'  !"##$! ∗ !"4 
 
2.2.2.4 Cell Lysis of Mammalian Cells With RIPA Lysis Buffer 
1 x 106 cells were washed with PBS and then, by use of a cell scraper, collected 
in 1 ml PBS and transferred to a reaction tube. After centrifugation at 1,000 x g 
(3,000 rpm) for 3 minutes, cells were immediately used for cell lysis. Depending 
on the size of the cell pellet, the cells were diluted in 100 µl – 200 µl RIPA buffer 
(including protease inhibitor cocktail) and subsequently incubated on ice for 
40 minutes. Afterwards, the lysis suspension was centrifuged at 4°C and 
20,800 x g for 10 minutes. The supernatant was transferred into a new reaction 
tube, and the protein concentration was measured by a Bradford assay (see 
page 51, paragraph 2.2.4.1.1) before storage at -20°C. 
2.2.2.5 Treatments of Cells 
2.2.2.5.1 Treatment of Cells with Chemotherapeutic Substances and 
subsequent Analysis of Target Gene Expression (qRT-PCR) and 
Protein Expression (Western Blot) 
1 x 106 cells were seeded in 10 cm plates. Compounds were pre-diluted in 100% 
DMSO to a concentration of 1,000 µM. Medium was removed via aspiration and 
replaced by fresh medium ad 10 ml. Cells were treated for 6 hours according to 
the following table. qPCR experiments were performed in biological triplicates 
and technical duplicates, WT and a DMSO-treated control cells were included for 
each experiment.  
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Table 48: Treatment schedule for target gene expression studies (qPCR) 
Compound Initial 
Concentration 
[µM] 
Final 
Concentration 
[µM] 
Quantity of 
Compound 
[µl] 
Final Volume 
[ml] 
untreated       10 
          
DMSO (ctrl.)     100 10 
          
camptothecin 1,000 1 10 10 
    5 50 10 
    10 100 10 
          
7-ethyl-10 hydroxy 
camptothecin 
1,000 1 10 10 
  5 50 10 
    10 100 10 
          
NSC 724998 1,000 1 10 10 
    5 50 10 
    10 100 10 
          
NSC 725776 1,000 1 10 10 
    5 50 10 
    10 100 10 
 
After 6 hours of treatment, cells were harvested, and either RNA preparation (see 
page 40, paragraph 2.2.1.11), or cell lysis (see page 44, paragraph 2.2.2.4) was 
performed as described before. 
2.2.2.5.2 Cell Treatment  
To determine the effect of different compounds on cell death and cell cycle 
alterations in HCC cell lines, 5 x 105 cells were seeded in 6 cm plates. Medium 
was removed via aspiration and replaced by fresh media ad 4 ml. Compounds 
were pre-diluted in 100% DMSO to a concentration of 1,000 µM. Cells were 
treated for 24 hours and 72 hours in single treatments, or for 24 hours in double 
treatments combined with doxorubicin, mitomycin C, cisplatin or sorafenib 
(Treatment schedule see below). 
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Table 49: Nicoletti assay single treatment schedule 
Compound Initial 
Concentration 
Final 
Concentration  
Quantity of 
Compound 
[µl] 
Final Volume 
[ml] 
untreated     4 
          
DMSO ctrl.     200 4 
          
MeOH ctrl.     400   
          
DMSO/MeOH ctrl.   200 + 400   
          
          
camptothecin 1,000µM 1 µM 4 4 
   5 µM 20 4 
  
 
10 µM 40 4 
        
tosufloxacin 1,000µM 1 µM 4 4 
   10 µM 20 4 
   50 µM 200 4 
         
pregnenolone 1,000µM 1 µM 4 4 
   10 µM 20 4 
   50 µM 200 4 
         
mitomycin C 400µg/ml 5 µg/ml 50 4 
   10 µg/ml 100 4 
   20 µg/ml 200 4 
   40 µg/ml 400 4 
         
sorafenib 1,000µM 2.5 µM 10 4 
    5 µM 20 4 
    10 µM 40 4 
 
Single treatment was performed in technical duplicates, as was the double 
treatment with pregnenonlone, tosufloxacin or 7-ethyl-10-hydroxycamptothecin 
(see page 30). Double treatments with camptothecin were performed in biological 
triplicates and technical duplicates. 
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Table 50: Camptothecin double treatment  
  WT 1.25 µM CPT 2.5 µM CPT 5 µM CPT 
WT x x x x 
  	  	         
DMSO x	         
  	  	         
MeOH  x	         
  	  	         
DMSO/MeOH x	         
  	  	         
4 µg/ml mitomycin C x x x x 
  	  	         
1.25 µg/ml doxorubicin x x x x 
  	  	         
2.5 µg/ml cisplatin x x x x 
	  	   	  	         
2.5 µM sorafenib x x x x 
 
 
Table 51: Tosufloxacin double treatment  
  WT 1 µM tosu 10 µM tosu 30 µM tosu 
WT x x x x 
  	  	         
DMSO x	         
  	  	         
MeOH  x	         
  	  	         
DMSO/MeOH x	         
  	  	         
4 µg/ml mitomycin C x x x x 
  	  	         
1.25 µg/ml doxorubicin x x x x 
  	  	         
2.5 µg/ml cisplatin x x x x 
	  	   	  	         
2.5 µM sorafenib x x x x 
 
  Materials & Methods 
 
 48 
Table 52: Pregnenolone double treatment 
  WT 1 µM pregno 10 µM pregno 50 µM pregno 
WT x x x x 
  	  	         
DMSO x	         
  	  	         
MeOH  x	         
  	  	         
DMSO/MeOH x	         
  	  	         
4 µg/ml mitomycin C x x x x 
  	  	         
1.25 µg/ml doxorubicin x x x x 
  	  	         
2.5 µg/ml cisplatin x x x x 
	  	   	  	         
2.5 µM sorafenib x x x x 
 
Table 53: 7-ethyl-10-hydroxycamptothecin double treatment 
  WT 1.25 µM HC 2.5 µM HC 5 µM HC 
WT x x x x 
  	  	         
DMSO x	         
  	  	         
MeOH  x	         
  	  	         
DMSO/MeOH x	         
  	  	         
4 µg/ml mitomycin C x x x x 
  	  	         
1.25 µg/ml doxorubicin x x x x 
  	  	         
2.5 µg/ml cisplatin x x x x 
	  	   	  	         
2.5 µM sorafenib x x x x 
 
2.2.2.6 Nicoletti Assay 
During apoptotic cell death, genomic DNA is hydrolyzed by specific nucleases, a 
process which can be measured by different techniques, to discriminate between 
apoptotic and normal cells. Propidium Iodid (PI), a dye that specifically 
intercalates into nucleic acids, is used in to determine the quantity of dead cells 
via flow cytometry. For this purpose, cells were fixed in 70% ethanol and 
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subsequently stained with PI, in the presence of RNAse. After RNA digestion, the 
intensity of the PI signal is directly proportional to the DNA amount. Not only the 
amount of apoptotic cells, but also the cell cycle distribution of living cells can be 
determined using this assay. Fixation with ethanol leads to permeabilisation of 
the nuclear membrane, and DNA fragments leak out of the dead cells, which then 
appear in a subG1 peak during the flow cytometry analysis [72] 
Cells were harvested with trypsin and transferred to FACS tubes. After 
centrifugation (5 minutes, 4°C, 400 x g), the supernatant was discarded, cells 
were washed with 1 ml PBS and again pelleted by centrifugation. Afterwards, 
cells were fixated by adding 1 ml ice-cold 70% ethanol with thorough mixing, and 
subsequently stored at 4°C for at least 24 hours up to 14 days.  
Cells were then washed with 38 mM Na-Citrate (pH 7.4), centrifuged and stained 
with 200 – 500 µl PI staining solution, depending on the amount of cells. For the 
staining reaction, cells were kept 20 minutes at room temperature in the dark. 
Flow cytometry measurement was performed on a Becton Dickinson Biosciences 
FACS Calibur. The PI fluorescence was measured in FL2 at 585 nm, separated 
into FL-A/FL-W channel (DDM module) and analyzed using Cell Quest-Pro 
software (Becton Dickinson Biosciences). For each sample, at least 
20,000 events were collected to ensure significance of the statistics. Cell cycle 
profile analysis was performed using ModFit LT (Verity Software House). 
 
Staining solution: 38 mM Na-Citrate (pH7.4), 50 µg/ml propidium iodide, 5 µg/ml 
RNAseA. 
2.2.2.7 WST Assay 
WST assays are used to quantify living cells by determination of the metabolic 
activity of the cells. The underlying principle is the enzymatic conversion of a dye 
into a cleavage product, whose absorption spectrum is different from the one of 
the uncleaved dye. If cells expand, it results in an increase in the overall 
mitochondrial dehydrogenases, leading to increased enzyme activity and 
subsequently to an increased amount of cleavage product. The amount of 
cleavage product directly correlates with the amount of active enzymes. Its 
quantification can be achieved by spectrophotometric measurements. 
WST assays were performed according to the user manual of the Cell 
Proliferation Reagent WST-1® by Roche Diagnostics, Mannheim. Hep3B cells 
were seeded with a density of 3,000 cells per well in a 96-well plate. Cells were 
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treated for 48 hours with compound or vehicle in the presence of 10% FCS. 
Afterwards, the WST-1 reagent was incubated for 4 hours, before cell viability 
was assessed using a microplate reader (infinite M200, Tecan Group Ltd, 
Crailsheim, Germany). Values were calculated as a ratio of the absorbance 
between treated samples and solvent control. 
Experiments were performed in the laboratory of Prof. Dr. Eugen Proschak, 
University of Frankfurt. 
 
2.2.3 Recombinant Protein Expression Methods 
2.2.3.1 Protein Expression in an E. coli Auto-Induction System 
2.2.3.1.1 Principles of protein expression using lac promoter-driven genes 
Originally in bacterial cells, lac gene products were required for the 
metabolization of lactose to glucose and galactose in the absence of glucose in 
the surrounding media, to provide a secure carbon source. The lac operon is 
composed of four genes: lac I, lac Z, lac Y and lac A. Whereas the last three 
genes are under the control of the lac promotor, lac I is under the control of its 
own weak promotor, transcribing the lac repressor. In a tetraedic conformation, 
the lac repressor can bind to the lac promotor and thus prevent the transcription 
of downstream targets. In the presence of glucose in the bacterial medium, cAMP 
(cyclic adenoside-monophosphate) levels are reduced, leading to diminished 
amounts of CRP (cAMP response protein), which results in less activation of lac 
gene transcription. Furthermore, glucose inhibits the function of lactose 
permease, which is needed for the transport of lactose into the bacteria cell, 
leading to low intracellular lactose amounts. Depletion of glucose in the media 
leads to diminished amounts of lac repressor, followed by an increase of lactose 
import into the cell via lactose permease activity. β-Galactosidase, the product of 
the lacZ gene transforms lactose into allolactose. Allolactose in turn, is able to 
bind to the lac repressor, inhibits its binding to the lac promotor and thus leads to 
the transcription of lac Z, lac Y and lac A.  
Elevation of cAMP, serving as a starvation signal in bacteria, leads to the binding 
of CRP and enhanced transcription levels of lac [73]. 
BL21(DE3) bacterial cells contain a T7 RNA polymerase, which is provided via 
the chromosomal DNA of the D3 prophage. This polymerase is under the control 
of a lac promotor, therefore its transcription can be induced via allolactose. 
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Consequently, target gene expression, which is under the control of T7 promotor, 
can occur. 
2.2.3.1.2 Auto–Induction of coFUBP1 protein expression 
Auto-induction was performed according to the protocol established by Studier et 
al. (2005) [74] in a 10 L fermenter. A freshly prepared 100 ml overnight culture 
was used to inoculate the 10 L main culture. Cells were grown to an optical 
density of OD600= 1.4 at 37°C. Afterwards, the temperature was reduced to 22°C, 
and cells were grown for 35 hours before harvesting. To prevent excessive 
amounts of foam formation, 2 ml anti-foam was added daily. The ventilation of 
the system was ensured by a constant airflow between 4 and 12 l/min. The 
bacterial pellet was distributed into 6 parts and stored at -20°C. 
2.2.3.2 Cell Lysis of Bacterial Cells using a Constant Cell Disruption System 
Different types of pressures and stresses are applied to the cells via a cell 
disruption system by Constant System Limited (Northhants, United Kingdom) to 
disrupt bacterial cells. 
2.2.3.2.1 Large Scale Cell Lysis of BL21(DE3) bacteria 
To purify the expressed coFUBP1 from BL21(DE3) bacteria, 3 out of 6 cell pellets 
obtained from 10 L auto-inducted cell suspension were used. The pellets were 
thawed on ice and re-suspended in bacterial lysis buffer, containing DNAse and 
complete EDTA-free pills®. Subsequently, the cell suspension was processed in a 
constant cell disruption system using a three-step protocol. Beforehand, the 
system was washed with 100 ml lysis buffer, while applying a pressure of 
0.5 kbar. Afterwards, the cell suspension was applied with a pressure of 1 kbar, 
followed by two runs at 2 kbar pressure. All steps were performed at 4°C. After 
cell disruption, the system was cleaned with 200 ml ddH2O and 2 N 200 ml 
NaOH. 
2.2.4 Protein Biochemistry Methods 
2.2.4.1 Protein Concentration Quantifications 
2.2.4.1.1 Bradford Assay 
During the binding of Coomassie brilliant blue G-250 to proteins, the absorption 
maxima of the dye shifts from 465 nm (without protein) to 595 nm (with protein). 
The absorption increase at 595 nm provides the signal for the quantification of 
the protein concentration in the tested solution [75]. 
5 µl protein solution were diluted in 800 µl ddH2O and mixed thoroughly. 
Afterwards, 200 µl RotiQuant Bradford (5 x) from Carl Roth GmbH&CoKG 
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(Karlsruhe) were given to the dilution, mixed and incubated at room temperature 
for 5 minutes. Subsequently, absorbance at 595 nm was measured in a 
spectrometer, and the protein concentration was determined via a standard 
calibration curve. 
2.2.4.1.2 NanoDrop 1000  
To determine protein concentrations between 0.1 and 100 mg/ml of purified 
protein solutions, the absorption spectra at 280 nm were measured. At 280 nm, 
the aromatic ring systems of tryptophan and tyrosin, as well as cysteine disulfide 
bonds absorb UV radiation. The quantification with the NanoDrop 1000 is only 
reliable, if the mass extinction coefficient and the molar mass of the tested 
protein sample are included. In this study, these parameters were generated 
using the ExPASy ProtParam tool (Bioinformatics Resource Portal). 
Table 54: Mass extinction coefficient of FUBP1 
Protein Molar mass  
(kDA) 
Molar extinction 
coefficient  
(M-1cm-1) 
Mass extinction 
coefficient  
(L gm-1 cm-1) 
coFUBP1 68.6 67,270 0.996 
 
2.2.4.2 Sodium Dodecyl Sulfate Polyacrylamide Gel Electrophoresis (SDS-
PAGE) 
Gel electrophoresis serves as an analytic tool to determine the apparent 
molecular weights of proteins in a solution. The proteins bind to the detergent 
SDS, which leads to a negatively charged SDS-protein complex with a constant 
charge-mass ratio (1.4 g SDS / g protein in 1% SDS-solutions). Furthermore, 
SDS denatures disulfide bridges, and thereby prevents protein-protein 
interactions, leading to protein-SDS complexes of various proteins, which only 
differ in mass. Upon loading on a polyacrylamide gel in a continuous electric field, 
these complexes migrate to the positive pole [75].  
In this study, 10% and 12% SDS-gels with a thickness of 100 or 150 mm were 
used. 
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Table 55: SDS-PAGE composition 
Ingredient 2.5% 
stacking gel 
10% 
running gel 
12% 
running gel 
ddH2O 5.52 ml 6.25 ml 5.25 ml 
        
Acrylamid/Bisacrylamid (37.5 : 1) 1.25 ml 5 ml 6 ml 
        
SDS 20% (w/v) 37.5 µl 75 µl 75 µl 
        
1.5M Tris-HCl pH 6.8 - 3.75 ml 3.75 ml 
        
1M Tris-HCl pH 8.8 925 µl  - -  
        
APS 10% (w/v) 100 µl 100 µl 100 µl 
        
TEMED 5 µl 10 µl 10 µl 
 
Protein samples were diluted in 5 x SDS-loading buffer and heated to 95°C for 
5 minutes, before loading on a SDS-PAGE gel. The electrophoresis was 
performed using a Mini-Protean II System from BioRAD (Munich), filled with 
1 x SDS-running buffer, and with a current voltage of 80 V for the stacking gel 
and 150 V for the running gel. Additionally, 18 µl BenchMark® Prestained Protein 
Ladder (Invitrogen, Karlsruhe) were applied to the gel as a size standard. 
2.2.4.3 Coomassie Staining of SDS-Gels 
To fixate and visualize proteins in a SDS-PAGE gel, Coomassie staining was 
performed. Gels with a thickness of 150 mm were stained in Coomassie staining 
Solution for one hour on a vertical shaker. De-staining was performed in water 
over night.  
Gels with a thickness of 100 mm were stained with Quick Coomassie. For this 
purpose, gels were first boiled in water (30 seconds, microwave), afterwards in 
Quick Coomassie (30 seconds, microwave), in which they were finally incubated 
on a vertical shaker for 10 minutes. De-staining was performed with MiliQ-H2O for 
1 hour on a vertical shaker. 
2.2.4.4 Protein Transfer onto Nitrocellulose Membranes 
Semi-dry blotting was used to transfer proteins from SDS-PAGE gels onto a 
nitrocellulose membrane. First, the nitrocellulose membrane has to be activated 
by a short incubation in blotting buffer with 20% methanol. The activated 
membranes are able to bind protein migrating along an applied voltage due to 
their hydrophobic surface property [75]. 
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Blotting was performed according to the following set up: 3 pieces of pre-wetted 
whatman paper, nitrocellulose membrane, SDS-gel and 3 pieces of pre-wetted 
whatman paper. Proteins were transferred for 2 hours with 45 mA current per 
membrane, in a blotting chamber (Keutz, Reiskirchen). 
 
Figure 10: Semi-dry-blot construction 
To verify successful blotting of the proteins, the membrane was incubated with 
Ponceau S (Fluka, Buchs, Switzerland) for 10 minutes on a vertical shaker, to 
stain proteins. Removal of background staining was achieved by pouring ddH2O 
onto the membrane.  
2.2.4.5 Immunodetection of Blotted Proteins 
Prior to immune blotting, membranes were incubated with 3% skimmed-milk 
powder in TBS-T for 1 hour at room temperature on a vertical shaker. This 
procedure is required to saturate unspecific protein binding sites on the 
nitrocellulose membrane, leading to decreased background signals. After 
blocking, membranes were incubated with primary antibodies diluted in blocking 
buffer and incubated at 4°C and mild shaking over night. Afterwards, membranes 
were washed 3 times with TBS-T for 10 minutes, each time at room temperature. 
Incubation with the secondary antibody diluted in blocking buffer was performed 
at room temperature for 1 hour with mild shaking. Subsequently, membranes 
were again washed 3 times, before the proteins were visualized using Amersham 
ECL Prime Western Blotting Detection Reagent from GE Healthcare (Munich). 
Horseradish peroxidase (HRP), which is coupled to the secondary antibody, 
catalyzes the oxidation of luminol, which results in a to a chemiluminescent signal 
[75].  
3 ml freshly prepared ECL-reagent was poured onto the membrane for 1 minute, 
and residual liquid was removed carefully, before the signals were detected with 
a photosensitive film. 
Whatman-paper 
Whatman-paper 
SDS-PAGE-gel 
Nitrocellulose membrane 
Cathode (-) 
Anode (+) 
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2.2.4.6 Immobilized Metal Ion Affinity Chromatography (IMAC) 
To purify recombinant proteins containing hexa-histidin tags, 25 ml 
Ni Sepharose High Performance affinity media for high-resolution 
(GE Healthcare, Munich) was packed onto an Omnifit® Chromatography Column 
(Diba Industries, USA). Ni Sepharose High Performance consists of highly cross-
linked agarose beads to which a chelating group has been coupled. This 
chelating group is pre-charged with Ni2+ that selectively retains proteins with 
exposed histidine groups. The purification was performed at 4°C using an Äkta 
purifier® system. 
Cell lysate, prepared from the Constant Cell Disruption System, was centrifuged 
at 20,000 x g for 1 hour at 4°C. The supernatant was applied to the Ni- 
Sepharose column via a peristaltic pump system with flow rate of 2.5 ml / minute 
at 4°C.  
After absorption of the his-tagged proteins to the column, it was equilibrated with 
4 column volumes of washing buffer with a flow rate of 4 ml / minute. Afterwards, 
the loaded column was washed with a gradient of up to 55% elution buffer (final 
imidazole concentration 222 mM) for 6.25 column volumes, wile fractionating 
13 ml volume samples using a flow rate of 2 ml / minute. Elution of protein was 
achieved using a flow of 1 ml / minutes of a continually increasing IMAC elution 
buffer gradient up to 95% for 18.75 column volumes, while fractionating 12 ml 
volume samples. The final elution step was performed with 100% elution buffer 
and a flow rate of 2 ml / minute for 2 column volumes, while fractionating 13 ml 
volume samples. Upon analysis of the chromatogram, fractions showing an 
elution peak at A280 absorption were analyzed by SDS-PAGE electrophoresis. 
Fractions containing coFUBP1 were pooled and applied to a heparin affinity 
column. 
2.2.4.7 Heparin Affinity Chromatography 
Heparin is a negatively charged, polydispersed linear polysaccharide, which 
selectively interacts with many enzymes and, among others, with DNA-binding 
proteins [76].  
Following the IMAC purification protocol, this absorption chromatography was 
used as a second purification step for recombinantly expressed coFUBP1. The 
purification was performed at 4°C using an Äkta Purifier® system. Pooled 
fractions of the IMAC purification were applied to 5 x 5ml HiTrap heparin HP 
columns (GE Healthcare, Munich) via a peristaltic pump system with a flow rate 
of 2.5 ml / minute at 4°C.  
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After absorption of the protein to the column, it was washed with 10 column 
volumes 10% (0.2 M NaCl) heparin elution buffer with a flow rate of 2 ml / minute 
and fractionation of 13 ml volume samples. The elution of proteins was achieved 
in 3 steps with a flow rate of 2 ml / minute each. First, a continually increasing 
elution buffer gradient from 0% to 17% for 51 column volumes and a fractionation 
in 13 ml volume samples were performed. Secondly, a gradient from 17% to 21% 
elution buffer was performed for 15 column volumes, fractionating 5 ml volume 
samples. In the third step, a gradient from 21% to 28% elution buffer was used, 
fractionated in 13 ml volume samples for 18 column volumes. The final elution 
was performed with 100% elution buffer for 1 column volume with a flow rate of 
2 ml / minute without fractionation. Upon analysis of the chromatogram, fractions 
showing an elution peak at A280 absorption were analyzed by SDS-PAGE 
electrophoresis. Fractions containing coFUBP1 were pooled, concentrated and 
applied to a HiLoad 16/60 Superdex 200 column (GE Healthcare, Munich) for 
size exclusion chromatography. 
2.2.4.8 Size Exclusion Chromatography (SEC) 
Size exclusion chromatography was performed using a HiLoad 16/60 Superdex 
200 column (GE Healthcare, Munich). Pooled fractions from the heparin column 
purification were concentrated to an end volume of 4 ml. The initial volume of 
36 ml was first concentrated in an Amicon stirr cell system to a volume of 20 ml, 
using a 10 kDa membrane. The remaining volume of 16 ml was reduced to an 
end volume of 4 ml using a 30 kDa membrane with an input concentration of 
0,378 µg/µl. 
The protein solution was applied via an Äkta Purifier® system in a volume of 4 ml 
with an initial flow rate of 0.5 ml / minute. Afterwards, the flow rate was increased 
to 1 ml / minute and fractionation was performed in 2 ml volume samples.  
2.2.5 Binding Studies 
2.2.5.1 Surface Plasmone Resonance 
Surface plasmone resonance (SPR) is a method used to determine binding 
events on a surface, enabling the determination of kinetic and thermodynamic 
binding constants.  
To calculate binding constants, one partner, the ligand, is bound to a metal 
surface (mostly gold), whereas the other partner, the analyte, is applied in a fluid 
phase.  
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At the interface between the metal and the di-electrium (air, water, etc.) an 
electronic cloud is formed, which can be set into oscillation via a light wave with a 
matching frequency. Based on the conservation law of energy, the light energy 
will be included in the electronic cloud, which leads to the stimulation of the 
surface plasmone. A plasmone is described as a light wave, which travels along 
the metal surface, containing an electromagnetic pulse, which is decreasing 
exponentially to the distance from the surface. A helium-neon-laser is used as 
the light source and the gold surface as well as an adjacent glass prism are 
located at a rotatable platform, leading to a modifiable incidence of light. The 
light, reflected by the gold surface, is measured with a photocell. For incidence 
angles higher than the critical angle of total reflection, the light intensity 
decreases with higher angles reaching a minimum, which describes the maximal 
excitation of the plasmone, before rising again to its original intensity. If 
molecules bind to the surface, its refractive index changes, leading to a change in 
the critical light angle for total reflection, which can be detected by the photocell. 
In SPR studies, the modification of the optical layer thickness, described as the 
modification of the refractive index, is measured [77]. The results are displayed in 
a SPR sensogram where movement of the measured signal (shown as 
Response Units [RU]) are measured over time. 
  Materials & Methods 
 
 58 
 
Figure 11: Schematic illustration of the SPR mechanism: On the gold sensor surface, a 
ligand is bound. Monochromatic, polarized light is used to determine the angle needed for 
the excitation of the surface plasmone. At this time point, a dip in the reflected light intensity 
is measureable. If an analyte is binding to the ligand, the refractive index of the surface 
changes, leading to a shift of the reflected light intensity dip to higher angles. The change of 
the SPR-dip is the measured signal and its movement over time generates the SPR 
sensorgram. 
2.2.5.1.1 The Equilibrium Mode Analysis 
The analysis of the equilibrium is used to determine the strength of the binding. 
The analyte is given to the ligand until the signals level out, meaning that the net 
association is equal to the net dissociation. This process is repeated with several 
analyte concentrations. The response rates are afterwards plotted versus the 
analyte concentration, and a fit is used to determine the binding affinity constant 
(KD). 
2.2.5.1.2 Determination of the Binding Constant for coFUBP1 and FUSEp21 
To determine the binding constant for the interaction between coFUBP1 and 
FUSEp21, two different approaches were chosen with the ProteOnTM XPR36 
system.  
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In one approach, a ProteOnTM GLM Sensor Chip to covalently bind the 
recombinant protein, and in a second approach, a ProteOnTM NLC Sensor Chip 
to bind the biotinylated FUSEp21 oligonucleotide were used. With both chips, 6 
parallel channels could be used simultaneously to immobilize one of the binding 
partners. Both approaches were tested to ensure that the immobilization of either 
partner does not interfere with the binding of coFUBP1 and FUSEp21. 
The GLM Chip is used to covalently bind proteins via general amine coupling. 
The surface of the chip was activated with 0.1 x and 0.5 x NHS/EDC, before 
loading of the protein. coFUBP1 was loaded with 3,800 response units (RU). 
Furthermore, MBP (maltose-binding-protein, approximately 45 kDa), used as a 
negative control protein, was loaded with 1,800 response units. Two negative 
control oligonucleotides 31 and 39 of the FUSEp21 locus were used in addition to 
FUSEp21, to prove the specificity of the binding. Oligonucleotides were chosen 
from the EMSA assays performed by Rabenhorst et al. 2009 [1]. 
To determine the thermodynamic binding capacity of coFUBP1 and FUSEp21, 
the oligonucleotide was used in a dilution series of 0 nm, 10 nM, 50 nM and 
100 nM. Analysis was performed in the equilibrium mode using a Langmuir fit. 
The NLC Chip was used to immobilize the 5’-end biotinylated FUSEp21 
oligonucleotide via the streptavidin-coated chip surface. 50 nM FUSEp21 was 
immobilized with a final RU of 120. 
2.2.5.1.3 Hit-Confirmation by SPR Measurements 
To ensure that all inhibitors can be tested in the SPR system (independently of 
their potential, individually used FUBP1 binding motif), the oligonucleotide was 
used as ligand leading to a high degree of freedom for the unbound, recombinant 
protein, used as the analyte. 
FUSEp21 was used as a ligand immobilized with 120 RU, bound to a ProteOnTM 
NLC Sensor Chip via its biotinylated 5’-end. coFUBP1 was used as the analyte 
(50 nM). Differences in the response units after 300 seconds dissociation time 
were used to determine inhibitory effects of the tested hit compounds. A dilution 
series of each compound (0 µM (DMSO control), 1 µM, 10 µM and 50 µM) was 
used to determine the inhibitory effect. The analyte and the compounds were 
mixed immediately prior to measurement. 
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2.2.5.2 Microscale Thermophoresis 
Microscale thermophoresis (MST) is used to determine molecular interactions via 
the measurement of changes in the hydration shell, charge or size of the 
molecules due to their interaction. It can be performed under close-to-nature 
conditions, as molecules can be measured label-free and/or immobilization-free 
in any buffer or complex bioliquid. Any change of the hydration shell of the 
analyzed biomolecules due to changes in their structure affects the movement 
along a temperature gradient and can be used to determine binding affinities via 
an altered thermal movement (Nano Temper Technologies). 
To generate a precise temperature gradient within thin glass capillaries filled with 
the examined samples, an infrared laser is used. To monitor the movement of the 
molecules along the temperature gradient, the fluorescence of the molecules is 
detected at the heated spot of the capillary. This fluorescence can either be 
intrinsic (e.g. tryptophane) or extrinsic through the use of a dye or a coupled 
fluorescence protein (e.g. GFP) (Nano Temper Technologies). 
The thermophoretic movement takes place in different steps. First, the laser is 
switched on, resulting in a fast heating of the capillary and a temperature jump, 
which leads to a decrease of the fluorescence signal. Afterwards, the 
thermophoresis occurs until the molecular movement reaches steady state. 
Finally, the laser is turned off again, and the back diffusion is measured.  
If one molecule is used in different dilutions, the normalized fluorescence 
(Fhot / Fcold) of each measurement can be plotted against the concentration of the 
diluted binding partner, allowing the determination of a KD value. 
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Figure 12: Schematic Illustration of MST measurements (http://www.nanotemper-
technologies.com): In the initial state, the molecules are equally distributed in the capillary. 
If the laser is switched on, thermophoresis of the molecules take place, which leads to a 
rapid drop of the normalized fluorescence signal. After 30 seconds, a steady state of the 
molecule movement is reached, before the laser is turned off, followed by the backdiffusion 
of the molecules. 
2.2.5.2.1 Binding Constant Determination for coFUBP1 and FUSEp21 by MST 
The recombinant coFUBP1 protein was labeled through the help of a NT.115 
Protein labeling kit RED-NHS, performed according to the manufacturer’s 
manual. The single stranded oligonucleotide remained unlabeled. The FUSEp21 
oligonucleotide was titrated to a stable concentration of 1 µM recombinant 
coFUBP1. 
The measurement was performed in a Monolith NT.115TM device from Nano 
Temper Technologies (Munich). MonolithTM Standard Treated Capillaries were 
used. Fluorescence was excited using red LED light (100%) with an intensity of 
15%. 
2.2.5.3 AlphaScreen® Technology 
The Amplified luminescent proximity homogenous assay (Alpha) screen is used 
to determine inter-molecular interactions of various molecules including DNA, 
RNA and proteins. It represents a bead-based assay system, which is performed 
in a 96-, 384- or 1536- well plate format. If the molecules, captured on the 
surface of different beads, are binding to each other, illumination of the donor 
bead leads to a signal transfer to the acceptor bead, resulting in the production of 
luminescence, which can be detected. The donor beads contain a 
photosensitizer, phtalocyanine, which converts ambient oxygen to singlet oxygen, 
when excited with a light signal at 680 nm. The singlet oxygen can travel up to 
200 nm in solution within its 4 µsec half-life. If an acceptor bead is located within 
this proximity, the singlet oxygen transfers its energy to thioxene derivatives on 
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the bead, resulting in a light production at 520-620 nm. In absence of the 
acceptor bead, the singlet oxygen falls back into its ground state, and no signal is 
produced (Perkin Elmer).  
2.2.5.3.1 Inhibitor Screening to Interfere with the Binding of FUBP1 and 
FUSEp21 
Recombinant coFUBP1 was bound to a protein-A acceptor bead via the specific 
anti-FUBP1 antibody N-15 (Santa Cruz biotechnology, Heidelberg), whereas 
FUSEp21 was biotinylated at its 5’-end and bound to a streptavidin donor bead. 
To perform the screening, a two-step protocol was established. First, potential 
inhibitors were diluted to a final concentration of 50 µM. 10 µl of each potential 
inhibitor was given into one well of a 384-well plate. Afterwards, two mixtures 
were prepared, according to the schedule below (Table 56). Mixture I (10 µl) was 
given into each well, centrifuged for 12 seconds in a quick run mode and 
afterwards incubated for 1 hour at room temperature in a dark room. Mixture II 
(5 µl) was added, the plate was centrifuged again and afterwards incubated for 
20 hours at room temperature in a dark room, before evaluating the results with 
the Envision® multilable plate reader SN 1040002, Perkin Elmer. Hits were 
defined as molecules that diminished the signal intensity down to 30% or less. 
Table 56: AlphaScreen® experimental setup 
  final concentration Mix1 Mix 2 
coFUBP1 3 nM x  
      
FUSEp21 1.6 nM x  
      
poly dIdC 3 µM x  
      
N-15 antibody 10 pM x  
      
Acceptor beads 1: 100 x  
      
      
Donor beads 1: 50  x 
 
2.2.6 Xenograft Experiments 
Hep3B cells (passage 16 after thawing) were harvested by trypsinization and 
collected in a sterile reaction tube. Cells were separated by carefully pipetting 
them through a 100 µm cell strainer. This procedure was repeated a second time, 
before using a 40 µm cell strainer for the last separation step. For each mouse, 
5 x 106 Hep3B cells were diluted in a total volume of 75 µl PBS and distributed in 
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individual reaction tubes. Shortly before injection of the cells into the flank of 
immune compromised NOD/SCID mice, 25 µl matrigel was mixed to each vial. 
Tumors were allowed to grow to an average size of 100 mm3. Mice were grouped 
(6 – 8 mice per group) and treated according to the schedule below (Table 57). 
During the treatment period, mice were weighed daily for 21 days, and tumor 
volumes were measured every third day. After the treatment period, tumor size 
and mouse weights were measured twice a week. Mice were sacrificed, when 
tumors reached a volume of 1000 mm3. The effects of six different treatments on 
tumor growth were evaluated: irinotecan, mitomycin C, irinotecan + mitomycin C, 
sorafenib, i.p. control, and oral control. 
Table 57: First xenograft experimental grouping and experimental setup 
Groups Concentration Solvent Application Application schedule 
i.p. control    0.9% NaCl i.p 5 days / week, 3 weeks 
         
oral control   Kolliphore® EL / 
Ethanol (50/50) 
oral 7 days / week, 3 weeks  
         
sorafenib 30 mg/kg Kolliphore® EL / 
Ethanol (50/50) 
oral 7 days / week, 3 weeks 
      
 
  
irinotecan 20 mg/kg 0.9% NaCl i.p. 5 days / week, 3 weeks 
         
mitomycin C 3.25 mg/kg 0.9% NaCl i.p. 1 day / week, 3 weeks 
      
 
  
irinotecan +  
mitomycin C 
10 mg/kg 
0.8125 mg/kg 
0.9% NaCl i.p. 5 days / week, 3 weeks 
i.p.: intra peritoneal 
For the second treatment experiment, concentrations were reduced according to 
Table 58. 
Table 58: Second xenograft experimental grouping and experimental setup  
Groups Concentration Solvent Application Application schedule 
i.p. control    0.9% NaCl i.p 5 days / week, 3 weeks 
irinotecan 10 mg/kg 0.9% NaCl i.p. 5 days / week, 3 weeks 
        
mitomycin C 0.8125 mg/kg 0.9% NaCl i.p. 1 day / week, 3 weeks 
        
irinotecan +  
mitomycin C 
see single treatment 
concentrations 0.9% NaCl i.p. 5 days / week, 3 weeks 
i.p.: intra peritoneal 
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3 Results 
3.1 Recombinant Protein Expression and Purification of Codon-Optimized 
Human FUBP1 in E. coli 
3.1.1 Cloning Strategy for C-terminally His6-tagged Codon-Optimized 
FUBP1 (coFUBP1) in pET28b 
Bacterial codon-optimized human FUBP1, synthesized by GenScipt®, was 
delivered in a pUC57 plasmid. For subsequent cloning of FUBP1 into the pET28b 
vector, the restriction sites NcoI and XhoI were introduced by PCR amplification 
at the 5’- and 3’- ends. Furthermore, this amplification led to the desired deletion 
of the intrinsic STOP codon TGA.  
Subsequently, the construct was purified and ligated into a pET28b expression 
vector, harboring a c-terminal His6-tag (Figure 13).  
 
Figure 13: Cloning strategy for c-terminal His6-tagged codon-optimized FUBP1 in pET28b. 
coFUBP1 was cloned into the multiple cloning site (MCS) of the pET28b plasmid using the unique 
cloning sites NcoI and XhoI. The FUBP1 coding sequence is under the control of a T7 promotor, 
suitable for protein expression in bacterial cells via IPTG or lactose induction. The TGA Stop codon 
of the coding sequence was deleted, leading to a c-terminal His6-tag delivered by the pET28b 
vector.  
After ligation into the MCS of pET28b, using the unique restriction sites NcoI and 
XhoI, the plasmid was transformed into BL21-DE3 expression bacteria. Four of 
the resulting clones were used to inoculate twelve different liquid cultures, 
3 each. Plasmid preparations were used to verify the presence of coFUBP1 by 
test cleavage and sequencing of different constructs.  
The analysis of the test cleavage with a 0.8% agarose gel revealed that all clones 
showed the expected fragment sizes for coFUBP1 (1944bp) and the pET28b 
backbone (5326bp) (see Figure 14). Furthermore, sequencing analysis of the 
clones 1A, 2A, 3A and 4A demonstrated that all of them inherited the correct 
sequence of coFUBP1.  
For the subsequent protein expression, clone 2A was used.  
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Figure 14: Test cleavage of coFUBP1/pET28b plasmid preparations. DNA Plasmid 
preparations were performed. Beforehand, each clone was subdivided into two to three liquid 
cultures (A, B, C). The DNA was cleaved by NcoI and XhoI and subsequently analyzed using a 
0.8% agarose gel. All clones show the expected cleavage products, resembling the size of 
coFUBP1 and the pET28b vector backbone.    
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3.1.2 Expression of coFUBP1 using an Auto-Induction System 
3.1.2.1 Cell Growth and Harvesting 
The frozen glycerol stock of clone 2A was used to inoculate a 200 ml overnight 
culture of LB-medium containing 1% glucose and 10 mg kanamycin. 100 ml of 
the aforesaid overnight culture were used to inoculate a 10 l fermenter. Cells 
were grown to an optical density of OD600= 1.4 at 37°C. Afterwards, the 
temperature was reduced to 22°C, and cells were grown for 35 hours before 
harvesting. The growth of cells was monitored every few hours by optical density 
measurements (see Figure 15). After harvesting of the cells, the cell sediment 
was stored at -20°C. 
 
Figure 15: Growth curve of BL21DE3 [coFUBP1/pET28b]. E. coli were grown in a 10 l fermenter 
using an auto-induction medium. After inoculation at 37°C, the optical density was measured every 
few hours. When the culture reached a density of OD600= 1.4, the temperature was reduced to 
22°C. After 35 hours, cells were harvested, the cell sediment was stored at -20°C. 
3.1.3  Recombinant coFUBP1 Protein Purification using a 3-step Protocol  
Purification of recombinant human coFUBP1 was performed using a three - step 
protocol. All purification steps were performed with the Äkta Purifier. Fractions 
obtained during each purification step were analyzed by SDS-PAGE and 
Coomassie staining in order to evaluate the expression level and purity of the 
recombinant protein. Eventually, the purified protein was aliquotated and shock-
frozen with liquid nitrogen before storing at -80°C. 
The first step of the purification procedure was an immobilized metal-ion affinity 
chromatography (IMAC) using a Ni-NTA resin (25 ml volume, GE Healthcare, 
Munich), followed by a heparin column (5 x 5 ml, GE Healthcare, Munich) and 
finally a size exclusion chromatography using gelfiltration (GE Healthcare, 
Munich) 
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3.1.3.1 Purification of His6-tagged coFUBP1 via a His-Trap Column 
The cell sediment, harvested from a total amount of 5 l bacterial culture, was 
thawed on ice and diluted in 200 ml lysis buffer. The lysate was processed in a 
Constant Cell Disruption System (Constant Systems Ltd., England) and 
subsequently centrifuged. Afterwards, the supernatant was loaded on a Ni-NTA 
column and purified using a “Äkta Purifier”.  
 
Figure 16: First purification step of recombinant coFUBP1 using a Ni-NTA column. (A) 
Chromatogram of the Ni-NTA purification. (B) Fraction analysis of the Ni-NTA purification. Fraction 
2 and 3 resemble the input, fractions 9-25 the wash fractions. The elution of a protein resembling 
the expected size of coFUBP1 (68 kDa) is shown in fraction 32-48, indicated by the black arrow. 
The chromatogram showed a high UV-absorbance in the input fractions 1-6, as 
well as in the washing fractions 9-25. Elution of a protein with the expected size 
of approximately 68 kDa was predominantly seen in fractions 32-48. The amount 
of other, undesired proteins in these fractions was reduced compared to those 
seen in the input and wash fractions (see Figure 16). Aforesaid fractions were 
immediately pooled and loaded on a HeparinTrap. 
3.1.3.2 Further Purification of His6-tagged coFUBP1 via a Heparin Column 
The pooled fractions 32-48 were loaded on a 25 ml HeparinTrap (5 serially 
connected 5 ml heparin columns) through an electric peristaltic pump with a flow 
rate of approximately 2.5 ml / min, resulting in a loading time of 1 ½ hours at 4°C. 
Afterwards, the HeparinTrap was connected to an Äkta Purifier system.  
The chromatogram of the heparin purification showed two different UV absorbtion 
peaks at 14,6% - 17% NaCl and 23,9% - 25,9% NaCl (Figure 17 A). SDS-PAGE 
analysis showed that both resemble the elution of an approximately 68 kDa 
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protein with no detectable amount of undesired impurities. Fractions 28 to 30 
were pooled for further purification using gel filtration (Figure 17 B). 
 
Figure 17: Second purification step for recombinant coFUBP1 using a heparin column. (A) 
Chromatogram of the heparin purification. (B) Fraction analysis of coFUBP1 after heparin 
purification. Elution of protein was seen in two different elution steps. Both peaks resemble the 
elution of an approximately 68 kDA protein (indicated with black arrow) without any undesired 
impurities visible. 
 
3.1.3.3 Final purification of His6-tagged coFUBP1 via preparative size exclusion 
chromatography 
The pooled fractions 28-30 of the heparin column were concentrated to an end 
volume of 4 ml: The initial volume of 36 ml was first concentrated in an Amicon 
stirr cell system to a volume of 20 ml, using a 10 kDa membrane. The remaining 
volume of 16 ml was reduced to an end volume of 4 ml using a 30 kDa 
membrane with an input concentration of 0,378 µg/µl. After size exclusion 
chromatography, one sharp UV absorption peak was visible in the chromatogram 
(Figure 18 A). Fractions B5-B8 (Figure 18 B) were pooled and concentrated 
using a 30 kDa membrane to a final concentration of 0,388 µg/µl, leading to the 
overall yield of 0.27 mg recombinant protein (obtained from 5 l bacterial culture).  
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Figure 18: Third purification step of recombinant coFUBP1 using size exclusion. (A) 
Chromatogram of the gel filtration. (B) Fraction analysis of coFUBP1 after size exclusion 
chromatography. Elution of an approximately 68 kDa protein was seen in one elution peak 
(indicated with black arrow) without any undesired impurities visible. Fractions B5 to B8 were 
pooled and aliquotated with a final concentration of 0.388 µg/µl before shock freezing in liquid 
nitrogen and storage at -80°C. 
 
3.1.4 Verification of the Identity of the Purified Recombinant Protein 
coFUBP1 using Western Blot and MS-Analysis  
To confirm the identity of the purified, recombinant protein, two different analyses 
were performed. Following SDS-PAGE, purified protein samples were stained 
with Coomassie followed by a subsequent analysis of those bands via MS-
analysis. Alternatively, the protein samples were hybridized with a specific anti-
FUBP1 antibody and detected via Western blot technique. Both analyses could 
verify that the purified recombinant protein was indeed human FUBP1 (Figure 
19). The analysis of different fractions via Coomassie staining and Western blot 
analysis after size exclusion chromatography showed a protein with a size of 
approximately 68 kDA, without any undesired impurities, which is specifically 
recognized by the anti-FUBP1 antibody (Figure 19 A).  
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Figure 19: Verification of human FUBP1 using Western blot- and MS-analysis. (A) Fraction 
analysis of coFUBP1 after size exclusion purification using Coomassie staining and Western blot 
analysis. A protein of approximately 68 kDa without any undesired impurities could be seen upon 
Coomassie staining and Western blot analysis using an anti-FUBP1 antibody (N-15, SantaCruz). 
(B) Mass spectrometry analysis of the protein samples also proved that the purified recombinant 
protein was human FUBP1. 
 
3.2 Functional Analyses of Recombinant coFUBP1 
Recombinant coFUBP1 was tested for its ability to specifically bind to its single 
stranded target DNA FUSE sequence. The FUSE oligonucleotide FUSEp21, 
used in the following assays, is part of the FUSE upstream of the p21 promoter.  
The oligonucleotide, a 53- mer, was earlier used in EMSA assays by Rabenhorst 
et al. 2009 and is a confirmed binding partner of FUBP1 [1]. During this study, it 
was used in surface plasmone resonance (SPR), as well as in microscale 
thermophoresis (MST) measurements.  
3.2.1 Surface Plasmone Resonance Measurements Revealed Specific 
Binding of coFUBP1 to its Single Stranded Target DNA FUSEp21 
To determine the binding constant of coFUBP1 and FUSEp21, surface plasmone 
resonance studies were performed. Negative controls, the FUBP1 non-binding 
oligos p31 and p39 [1], were included to evaluate the specificity of the binding. 
Recombinant protein was used as ligand, covalently bound to the surface of a 
ProteOn™ GLM sensor chip. FUSEp21 oligonucleotide served as the analyte in 
the liquid phase. 
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3.2.1.1 Negative Controls using Non-Binding FUSE Oligonucleotides and 
Dummy Proteins Confirmed Specificity of coFUBP1 Binding to FUSEp21 
The FUBP1 non-binding oligonucleotides p31 and p39 as well as an unrelated 
protein, “maltose-binding-protein (MBP)”, were used to confirm the binding 
specificity between recombinant coFUBP1 and FUSEp21. Increasing 
concentrations of the analyte FUSEp21 resulted in increasing response units 
when titrated to covalently bound coFUBP1 ligand. Covalently bound MBP on the 
other hand showed no response to any concentration of the FUSEp21 analyte 
(Figure 20). 
 
Figure 20: Specificity control of coFUBP1 binding to FUSEp21 using MBP as unrelated 
protein. FUSE p21 was titrated (light pink: 0 nM, dark blue: 10 nM, light blue: 25 nM, green: 50 nM, 
dark pink: 100 nM) to either coFUBP1 (A) or MBP (B). Increasing concentrations of FUSEp21 led to 
increasing response units in the coFUBP1 channel (A) whereas no response was visible in the 
MBP channel (B). The response unit (RU) is defined as 1 RU= 1 pg/mm2, it is an arbitrary value 
displaying the actual measured value (wavelight and angle). 
Titration of the non-binding oligonucleotides p31 and p39 showed almost no 
response in the coFUBP1 channel (maximum 20 RU) compared to the response 
units when using FUSEp21 as an analyte. In this case, a dose-dependent 
increase in response units (RU) with a maximum of 60 RU was seen (Figure 21). 
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Figure 21: Specificity control of coFUBP1 binding to FUSEp21 using the non-binding 
oligonucleotides p31 and p39. FUSE p21 (A), p31 (B) or p39 (C) were titrated to coFUBP1 (light 
pink: 0 nM, dark blue: 10 nM, light blue: 25 nM, green: 50 nM, dark pink: 100 nM). Increasing 
concentrations of FUSEp21 led to a dose-dependent increase in response units in the coFUBP1 
channel (A). Increasing concentrations of p31 and p39 showed only minor or no response ((B) and 
(C)). 
3.2.1.2 Quantification of the Dissociation Constant of FUBP1 and FUSEp21 
using SPR Measurements Revealed a Tight Binding between both 
Molecules 
To determine the thermodynamic binding capacity of coFUBP1 and FUSEp21, 
the oligonucleotide was used as the analyte in a dilution series of 0 nM, 10 nM, 
50 nM and 100 nM. The increasing amounts of FUSEp21 led to a subsequent 
increase of the measured response units [RU]. Plotting of the response units 
[RU] measured in the saturation phase (equilibrium mode, see page 58, 
paragraph 2.2.5.1.1) against the FUSEp21 concentration, revealed a dissociation 
constant (KD) of 12.9 nM between recombinant FUBP1 and FUSEp21 (Figure 
22).  
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Figure 22: Surface Plasmone Resonance measurement of the interaction between coFUBP1 
and the FUSEp21 oligonucleotide. coFUBP1 served as the ligand, covalently bound to the 
surface of a GLM sensor chip. The FUSEp21 oligonucleotide was used in a dilution series (0 nM, 
10 nM, 25 nM, 50 nM and 100 nM) as the analyte in the liquid phase. A dissociation constant of 
approximately 12.9 nM between recombinant FUBP1 and FUSEp21 could be determined under 
steady state conditions. 
3.2.2 Microscale Thermophoresis Measurements of Recombinant 
coFUBP1 and the FUSEp21 Oligonucleotide Confirmed the Tight 
Binding between both Molecules 
The recombinant protein was labeled using a NT.115 Protein labeling kit RED-
NHS according to the manufacturers manual. The single stranded FUSEp21 
oligonucleotide remained unlabeled. The fluorescence of FUBP1 is used to 
monitor the motion of the molecules along a temperature gradient. LED power 
was set to 100%, infra-red laser (IR) power to 15%. The on-off cycle of the laser 
was set to the following schedule: Initial laser off: 5 seconds, laser on: 
30 seconds, final laser off: 5 seconds. Standard capillaries were used during the 
measurements. Lower temperature limit was set to 20°C, upper temperature limit 
to 40°C. When titrating the FUSEp21 oligonucleotide to a stable concentration of 
1 µM recombinant coFUBP1, a dissociation constant of 12.31 nM could be 
determined by the change of the fluorescence signal in the hot and cold areas 
through thermophoretic movement of the molecules (Figure 23).   
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Figure 23: Quantification of the binding constant between recombinant FUBP1 and FUSEp21 
by microscale thermophoresis. FUSEp21 oligonucleotide (5,000 nM, 2,500 nM, 1,250 nM, 
625 nM, 312.5 nM, 78.125 nM, 39.06 nM, 19.5 nM, 9.7 nM, 4.88 nM) was titrated to a stable 
concentration of 1 µM recombinant coFUBP1. The thermophoresis is defined as the change of the 
fluorescence signal in the hot and cold capillary areas at steady state conditions. Plotting of those 
values against the FUSEp21 oligonucleotide concentration led to the determination of a 
dissociation constant of 12.31 nM between recombinant FUBP1 and FUSEp21. 
3.3 AlphaScreen® Interaction Studies for the Identification of FUBP1 
Inhibitors 
The AlphaScreen® technology was used to identify potential inhibitors of FUBP1. 
This bead dependent assay system is used to determine inter-molecular 
interactions of various molecules including DNA, RNA and proteins (see page 61, 
paragraph 2.2.5.3). The inhibition of binding between coFUBP1 and FUSEp21 by 
different compounds was determined by the reduction of light emission at 520 -
620 nm. Recombinant coFUBP1 was bound to a protein-A acceptor bead via its 
specific antibody N-15 (santa cruz biotechnology), whereas FUSEp21 was 
biotinylated at its 5’-end and bound to a streptavidin donor bead. 
3.3.1 Determination of Optimal Binding Conditions via Cross Titrations 
Increasing concentrations of recombinant coFUBP1 and FUSEp21 were used to 
determine optimal binding conditions for the subsequent screening of FUBP1 
inhibitors. Light emission at 520 – 620 nm (referred to as counts) was depicted 
against the concentrations used for coFUBP1 and FUSEp21. Increasing 
concentrations led to increasing counts with a maximum of 230,000 counts 
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(Figure 24). After evaluation, concentrations of 3 nM coFUBP1 and 1.6 nM 
FUSEp21 (resulting in approximately 100,000 counts) were chosen for further 
experiments, as those values displayed the highest possible signals in the 
exponential phase. 
 
Figure 24: Cross titrations of coFUBP1 and FUSEp21 to determine optimal binding 
conditions. To define optimal concentrations for the subsequent FUBP1 inhibitor screen, 
increasing concentrations of recombinant coFUBP1 and FUSEp21 were tested in the Alpha Screen 
setup. Dilution series of both, FUBP1 and FUSEp21, were prepared and subsequently mixed in 
every possible variation. Concentrations of 3 nM coFUBP1 and 1.6 nM FUSEp21 resulted in a 
signal of approximately 100,000 counts and were chosen for further experiments. 
3.3.2 Competitive Assay using Unbound FUSEp21 Confirmed 
Functionality of the AlphaScreen® Experimental Setup as an 
Inhibitor Screening System 
To test whether it is possible to interfere with the interaction between FUBP1 and 
FUSEp21, a proof-of-principle experiment was performed. Increasing 
concentrations of free FUSEp21 were titrated to the AlphaScreen setup 
described before to compete with coFUBP1 binding to the bead-coupled 
FUSEp21 and to mimic a potential inhibitor. Administration of free FUSEp21 led 
to a dose-dependent decrease of the signal counts down to 7,500 counts at a 
concentration of 100 nM unbound FUSEp21, compared to 100,000 counts, when 
no competitor was given to the reaction (Figure 25). 
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Figure 25: Increasing concentrations of free FUSEp21 led to a dose-depended decrease of 
signals in a competitive assay setup. Free FUSEp21 oligonucleotides mimicking potential 
FUBP1 inhibitors demonstrated that interference with the binding of coFUBP1 and FUSEp21 is 
possible in the established Alpha Screen setup. 
3.3.3 Minimizing the Effects of DNA-Intercalators by the Use of Poly dIdC 
Poly (2′-deoxyinosinic-2′-deoxycytidylic acid) sodium salt (poly dIdC) is used as a 
DNA mimic, to intercept DNA intercalators and thereby minimize the false 
positive hits in the experimental setup. To ensure that poly dIdC does not 
influence the binding of coFUBP1 to FUSEp21 itself, increasing concentrations 
were added to the mixture and the resulting light signals were compared to the 
signal occurring without addition of poly dIdC. To furthermore evaluate the effect 
of a real DNA intercalator, 50 µM ethidiumbromide were added to each mixture. 
The addition of poly dIdC did not show an influence on the binding of coFUBP1 to 
FUSEp21, even at high doses of 100 µM. The addition of ethidiumbromide, on 
the other hand, led to a huge signal decrease of almost 3/4 of the original value, 
independently of the amount of poly dIdC used (Figure 26). After evaluation, a 
concentration of 3 µM poly dIdC was chosen for further experiments. 
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Figure 26: Unspecific inhibition of coFUBP1/FUSEp21 binding facilitated by the DNA 
intercalator ethidiumbromide. The addition of poly dIdC did not influence the binding of coFUBP1 
to FUSEp21 at concentrations up to 25 µM. The addition of 50 µM ethidiumbromide reduced the 
signal to 1/4 of the original value, independently of the poly dIdC concentration. 
3.3.4 FUBP1 Inhibitor Screening Resulted in a Total of 158 Hit Compounds 
To find potential small molecule FUBP1 inhibitors, two different libraries were 
screened, the Prestwick Chemical library and the Maybridge Hit FinderTM library, 
both together containing approximately 16,000 compounds. Molecules, whose 
addition to the coFUBP1/FUSEp21-coupled beads led to a signal decrease of 
70% or more in the Alpha Screen®, were defined as positive hits. All hits were re-
screened in the AlphaScreen® system and subsequently bioinformatically 
evaluated, using a self-organizing map (SOM), designed by Janosch Achenbach, 
AG Proschak, University of Frankfurt. 103 hit compounds were found in the 
Maybridge Hit FinderTM library (displaying ≤1% of the total compound amount in 
this library), whereas the Prestwick Chemical library yielded a total of 55 hits 
(displaying ~3.43% total compound amount in this library) (Figure 27). 
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Figure 27: Screening results after bioinformatical evaluation. Two libraries, the Prestwick 
Chemical and the Maybridge Hit FinderTM library with a total of approximately 16,000 compounds, 
were screened to find potential new FUBP1 small molecule inhibitors. Molecules were defined as 
hits, whose addition led to a signal decrease of ≥ 70% in the AlphaScreen®. All hits were re-
screened in the same setting and subsequently bioinformatically evaluated, using a self-organizing 
map (SOM) (Janosch Achenbach, AG Proschak, University of Frankfurt). The hit evaluation 
resulted in 103 hit compounds in the maybridge Hit FinderTM library, and 55 hits in the Prestwick 
Chemical library.  
3.4 SPR Measurements Confirmed Potential FUBP1 Inhibitor Hit 
Compounds  
To confirm that the molecules identified in the AlphaScreen® indeed interfered 
with FUBP1 binding to FUSEp21, they were re-tested in a SPR setup (see page 
59, paragraph 2.2.5.1.3). FUSEp21 was used as the ligand, immobilized with 
120 RU, bound to a neutravidin chip via its biotinylated 5’-end. coFUBP1 was 
used as the analyte in increasing concentrations (2.5 nM, 5 nM, 10 nM 15 nM 
and 20 nM). All compounds were diluted with DMSO and used in a concentration 
of 100 µM each. If a compound showed the expected FUBP1/FUSEp21 binding 
inhibition, it was tested with a stable coFUBP1 concentration of 50 nM in a 
dilution series (0,1 µM, 1 µM, 10 µM, 50 µM and 100 µM). Analyte and compound 
were added immediately prior to SPR measurements. 
Molecules of the Prestwick library, positively tested for their ability to prevent or 
inhibit the binding between FUBP1 and FUSEp21 in AlphaScreen® and SPR 
setups, were subsequently tested in cell culture experiments.  
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3.4.1 SPR-Measurements Confirmed Four Compounds of the Maybridge 
Hit FinderTM Library as Potential FUBP1 Inhibitors 
17 hit substances were re-tested in SPR measurements to confirm the Alpha 
Screen® results. Only four substances showed the expected dose-dependent 
decrease in response units (RU). The molecule HTS 06795 showed the strongest 
dose-dependent inhibitions with a signal decrease of 75% at a compound 
concentration of 10 µM (Figure 28). 
 
Figure 28: Alpha Screen hit confirmation by SPR measurements. FUSEp21 was immobilized 
with 120 RU, coFUBP1 was used as the analyte (20 nM). Dilution series of four different 
compounds showed a dose-dependent inhibitory effect on FUBP1 / FUSEp21 binding (yellow: 
DMSO control 0 µM, pink: 0.1 µM, green: 1 µM, dark blue: 10 µM, light blue: 50 µM, red: 100 µM). 
(D) The best inhibitory effect was achieved using compound HTS 06795. A concentration of 10 µM 
decreased FUBP1 / FUSEp21 association to 25% residual binding, compared to the DMSO control. 
3.4.2 SPR-Measurements Confirmed Three Compounds of the Prestwick 
Chemical Library as Potential FUBP1 Inhibitor: Camptothecin, 
Pregnenolone and Tosufloxacin 
13 hit substances were re-tested in SPR measurements to confirm the Alpha 
Screen results. Three substances showed the expected dose-dependent 
decrease in FUBP1 / FUSEp21 binding measured in response units [RU]. The 
best inhibitory effects were seen when camptothecin and pregnenolone were 
given to FUBP1 / FUSEp21. At 10 µM, both compounds decreased the response 
units to 30% of the original signal. The addition of tosufloxacin to FUBP1 / 
FUSEp21 led to 50% signal reduction, when used at 10 µM concentration. 
Furthermore, all three substances were able to diminish the signal to almost zero, 
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when used at concentrations of 50 µM to 100 µM (Figure 29). This experiment 
was done in collaboration with Stefanie Hauck, AG Zörnig [78]. 
 
Figure 29: Dose-dependent decrease of the SPR signal upon addition of three identified 
FUBP1 inhibitors. FUSEp21 was used as ligand immobilized with 120 RU, bound to a neutravidin 
chip via its biotinylated 5’-end. coFUBP1 was used as the analyte (50 nM). The analyte was mixed 
immediately prior to measurement to the dilution series of camptothecin, pregnenolone and 
tosufloxacin, respectively. camptothecin (A), pregnenolone (B) and tosufloxacin (C) were used at 
four different concentrations (dark blue: 100 µM, ligth blue: 50 µM, grey: 10 µM, orange: 1 µM and 
yellow: DMSO control with 50 nM FUBP1). All three compounds showed the capacity to diminish 
the binding of FUBP1 / FUSEp21, depicted as response units [RU], to almost zero, when treated 
with concentrations of 50 µM and 100 µM.  
3.4.2.1 SPR Measurements of Camptothecin Structurally Related Compounds 
Revealed a Potent FUBP1/FUSEp21 Binding Interference by Different 
Topoisomerase I Inhibitors 
Since camptothecin behaved in both experimental setups (Alpha Screen® and 
SPR measurements) as a potential FUBP1 inhibitor, further topoisomerase I 
inhibitors were tested. NSC 724998 and NSC 725776 were kindly provided by 
Professor Yves Pommier (NIH, USA) and were tested as additional, potential 
FUBP1 inhibitors. Furthermore, the active group of irinotecan, 7-ethyl-10-
hydroxycamptothecin, was also tested in a dilution series (0 µM: DMSO control, 
1 µM, 10 µM and 50 µM). Comparison of the response units after 300 seconds 
dissociation time revealed that all topoisomerase I inhibitor were able to interfere 
with the binding between coFUBP1 and FUSEp21. Camptothecin and 
NSC 725776 decreased the response signal at 10 µM down to 30% of the 
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original response. At 50 µM, the response signal diminishes to almost zero when 
treated with NSC 725776 (Figure 30). These measurements were done in 
collaboration with Stefanie Hauck, AG Zörnig [78]. 
 
 
Figure 30: All tested Topoisomerase I inhibitors were able to interfere with the binding of 
FUBP1 and FUSEp21. This experiment was performed in the same manner as the one depicted in 
Figure 29. Comparison of the response units after 300 seconds dissociation time revealed that all 
tested topoisomerase I inhibitors were able to interfere with the binding between FUBP1 and 
FUSEp21. The response units after 300 seconds dissociation time were normalized to values 
representing the interaction between coFUBP1 and FUSEp21 diluted with DMSO. Three 
independent binding tests were used to calculate the error bars (10 RUs, 12.5 RUs and 50 RUs of 
immobilized FUSEp21).  
3.5 Evaluation of the FUBP1 Inhibition Effect on Human HCC Cell Lines 
Tosufloxacin, pregnenolone, camptothecin and all topoisomerase I inhibitors 
positively tested for their interference of the binding between FUBP1/FUSEp21 
were subsequently tested in different cell culture experiments to evaluate their 
effects on cancers cell lines with regard to proliferation, apoptosis and expression 
of the FUBP1 target gene p21. All compounds were diluted in DMSO and stored 
at -20°C.  
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3.5.1 Camptothecin-Treated HCC Cells Showed Reduced Cell Expansion 
Similar to Those Treated with Sorafenib, the Current HCC “Gold 
Standard Therapy”  
1 x 105 Hep3B cells were seeded into 6-well plates and treated with 
camptothecin, tosufloxacin or pregnenolone in increasing concentrations for 
72 hours. Control cells were either untreated or treated with DMSO. The medium 
was changed every 24 hours. For each time point, an individual plate was 
collected, cells were stained with crystal blue and counted in a “Neubauer 
improved counting chamber”. Treatment of HCC cells with sorafenib cells 
currently serves as a “gold standard” for HCC therapy. Cells treated with 
pregnenolone and tosufloxacin showed only minor changes in their cell 
expansion. Only high concentrations of 10 µM to 100 µM showed an effect on the 
number of expanding cells. On the other hand, cells treated with camptothecin or 
sorafenib showed an inhibition of cell expansion after 24 hours even at low drug 
concentrations (1 µM). After 72 hours, all cells, apart from those treated with 
1 µM sorafenib, were killed by the treatment (Figure 31). 
 
Figure 31: Cell expansion assays showed almost no cellular response to tosufloxacin and 
pregnenolone treatment, whereas camptothecin efficiently interfered with cell growth. 
1 x 105 Hep3B cells were seeded into 6-well plates and treated with DMSO (as a control), 
camptothecin, tosufloxacin or pregnenolone in increasing concentrations up to 72 hours. After 
24 hours, 48 hours and 72 hours, cells were collected, stained with crystal blue and counted in a 
“Neubauer improved counting chamber”. Only cells treated with camptothecin showed a dramatic 
cell number decrease in cell numbers, comparable to the one seen sorafenib-treated cells. 
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3.5.2 Monitoring the Effect of Potential FUBP1 Inhibitors on Cell Viability 
using WST Assays 
To identify the percentage of viable cells after treatment with camptothecin, 
tosufloxacin and pregnenolone, WST assays were performed. Hep3B cells were 
treated for 24 hours, before the cell viability was measured.  
3.5.2.1 Camptothecin Single-Treated Hep3B Cells showed a Dose-Dependent 
Cell Viability Decrease  
Pregnenolone and tosufloxacin showed no specific effect on cell viability 
measured in the WST assay. The pregnenonlone- and tosufloxacin-treated cells 
lost their metabolic activity only at high concentrations of 100 µM. Cells treated 
with camptothecin showed a loss of 50% cell activity even with the lowest 
camptothecin concentrations of 100 nM. The IC50 value of sorafenib-treated cells 
was 1 µM (Figure 32). The WST assays were performed in the laboratory of 
Eugen Proschak, University of Frankfurt.  
 
Figure 32: Hep3B WST Assay after 24 hours of single treatment with different hit 
compounds from the inhibitor screen. Cells were treated for 24 hours, with single treatments of 
camptothecin tosufloxacin, pregnenolone or sorafenib in increasing concentrations. Afterwards, the 
cell proliferation reagent WST-1 (La Roche) was administered to the cells for 4 hours, before 
evaluating the cell activity via a spectrophotometric quantification. Results were normalized to 
DMSO-treated cells. Experiments were performed in biological triplicates, the mean ± SD was 
calculated. Camptothecin- and sorafenib-treated cells show a sigmoidal, dose-dependent cell 
activity decrease, wheras pregenolone- and tosufloxacin-treated cells only responded to the highest 
concentration of 100 µM compound with a loss of cell activity. 
3.5.2.2 Double Treatment of Hep3B Cells with a Combination of 7-Ethyl-10-
Hydroxycamptothecin and Mitomycin C Showed a High Synergistic 
Effect 
To identify possible synergistic effects, WST assays were performed with cells 
receiving double treatment of chemotherapeutics and inhibitors. To Hep3B cells, 
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both 7-ethyl-10-hydroxycamptothecin and mitomycin C (Figure 33 A), or 7-ethyl-
10-hydroxycamptothecin and sorafenib (Figure 33 B) were given. The amount of 
viable cells was measured in % of DMSO-treated cells. The combination of 
0.3 µM 7-ethyl-10-hydroxycamptothecin and 3 µM mitomycin C showed a high 
synergy and led to an amount of 15.6% viable cells compared to the amount of 
the single-treated cells of 88% and 115%, respectively. 
 
 
Figure 33: Hep3B WST Assays after 24 hours double treatment with 7-ethyl-10-
hydroxycamptothecin and mitomycin C or 7-ethyl-10-hydroxycamptothecin and sorafenib 
showed synergistic effects. Cells were treated for 48 hours, with single- and double-treatments of 
7-ethyl-10-hydroxycamptothecin and mitomycin C, or 7-ethyl-10-hydroxycamptothecin and 
sorafenib in increasing concentrations. Afterwards, the cell proliferation reagent WST-1 was 
administered to the cells for 4 hours, before evaluating the cell activity via a spectrophotometric 
quantification. Results were normalized to DMSO-treated cells. Experiments were performed in 
biological triplicates, the mean ± SD was calculated and depicted in a red (100% cell activity) and 
green (0% cell activity) color code. 
3.5.3 Determination of Apoptosis Induction via Potential FUBP1 Inhibitors 
in Human HCC Cell Lines 
3.5.3.1 Single Treatment of Hep3B Cells With Camptothecin led to a Dose-
Dependent Killing of Cells after 72 Hours of Treatment 
To identify the amount of apoptotic cells after treatment with camptothecin, 
tosufloxacin or pregnenolone, Nicoletti assays were performed. 2 x 105 Hep3B 
cells were seeded in 6-well plates to measure the amount of apoptotic cells after 
24 hours of treatment. To evaluate the effect after 72 hours, 1 x 105 Hep3B cells 
were seeded in 6-well plates. Media substituted with the potential inhibitors were 
changed every 24 hours, to maintain stable concentrations of the given 
substances. Cells were fixed, stained with propidium iodide (PI) and analyzed via 
flow cytometry.  
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Regardless of the kind of treatment, after 24 hours, the cell cycle profile of all 
living cells was not altered compared to those of the DMSO-treated control cells. 
mitomycin C- and sorafenib-treated cells showed a dose-dependent increase in 
the number of dead cells. Cells treated with either tosufloxacin or pregnenolone 
did not exhibit increased amounts of cell death, as the rate of dead cells was 
equivalent to those treated with the DMSO solvent. Treatment with 5 µM 
camptothecin led to 17% dead cells. All three tested compounds showed a lower 
amount of induced cell death compared to those treated with mitomycin C or 
sorafenib (Figure 34). 
 
Figure 34: Cell cycle distribution and cell death rates of pregnenolone, tosufloxacin and 
camptothecin single-treated Hep3B cells after 24 hours. Cell cycle profiles and cell death rates 
were obtained by cell fixation and subsequent staining via propidium iodide using the Nicoletti 
protocol. Mitomycin C- and sorafenib-treated cells served as controls. None of the tested potential 
FUBP1 inhibitors was able to increase cell death rates as potent as the controls mitomycin C and 
sorafenib, when administered as single agents. Experiments were performed once in technical 
duplicates. Mean values were calculated. 
The absolute number of cells in the subG1 peak increased significantly after 
72 hours treatment (Figure 35). With all concentrations used (5, 10, 20 and 
40 µg/ml) treatment with mitomycin C led to 58% to 85% dead cells after 
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72 hours. Furthermore, the cell cycle profile of the living cells was altered 
compared to the DMSO-treated and -untreated WT cells. Furthermore, incubation 
with 5 µg/ml and 10 µg/ml mitomycin C led to an increased cell population in the 
G0/G1- and S-phases, however, this effect reversed upon treatment with higher 
concentrations of this chemotherapeutic. The cell cycle profile of the living 
sorafenib-treated cells was comparable to those of the DMSO-treated and -
untreated WT cells. Interestingly, the amount of cells in SubG1 was decreased 
compared to the 24 hours treatment. A maximum cell death rate was seen at a 
concentration of 10 µM, where approximately 50% of the fixed cells were visible 
in the apoptotic subG1 peak. Cells treated with pregneneolone or tosufloxacin 
alone showed no specific killing, as the rate of dead cells was almost equivalent 
to those treated with the DMSO solvent. Treatment with camptothecin led to two 
different consequences. First, the cell cycle of the living cells was significantly 
altered to those of the DMSO-treated cells. The G0/G1 phase was almost 
completely abolished, while the G2/M cell cycle phases were increased. Second, 
cell death rates were dose-dependently increased with a final proportion of 
approximately 60% at the 10 µM camptothecin concentration.  
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Figure 35: Cell death distribution and cell death rates of pregnenolone, tosufloxacin and 
camptothecin single-treated Hep3B cells after 72 hours. Cells were treated with different 
compounds for 72 hours before fixation and staining with propidium iodide (Nicoletti protocol). 
Mitomycin C- and sorafenib-treated cells served as chemotherapeutic control-treated cells. 
Camptothecin-treated cells did not only show a dose-dependent increase in cell death rates, but 
also an alteration of the cell cycle distribution, with an increased G2/M Phase and a decreased 
G1/G0 Phase in all given concentrations. Experiments were performed once in technical duplicates. 
Mean values were calculated. 
3.5.3.2 Double Treatment of Hep3B Cells with Different Hit Compounds from 
the Inhibitor Screen and Known Chemotherapeutics Exposed 
Synergistic Effects on Cell Death Rates 
To increase the impact of the compounds camptothecin, pregnenonlone and 
tosufloxacin on cell death, their application was combined with known 
chemotherapeutics like mitomycin C, cisplatin and doxorubicin. Hep3B cells were 
treated for 24 hours. Afterwards, the percentage of cells in the subG1 peak was 
measured using PI-staining of fixed cells via flow cytrometry. 
3.5.3.2.1 Double Treatment with Pregnenolone and other Chemotherapeutics 
Showed No Synergy in Cell Killing Efficacy 
Cells were treated with all substances in single and combined applications. None 
of the single pregnenolone concentrations (1, 10, 50 µM) was sufficient to induce 
cell death in Hep3B cells. Furthermore, no additional or synergistic effect was 
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seen when pregnenolone was combined with doxorubicin, cisplatin or 
mitomycin C (Figure 36). 
 
Figure 36: Cell cycle distribution and cell death rates of pregnenolone double-treated Hep3B 
cells with different chemotherapeutics after 24 hours. Hep3B cells were treated for 24 hours 
with pregnenolone or pregnenolone in combination with chemotherapeutics to evaluate possible 
synergistic effects of the double treatment. The cell cycle distributions of the living cells were not 
altered to those seen in solvent-treated or untreated wildtype cells. No synergistic effect of 
pregnenolone with either doxorubicin, mitomycin C or cisplatin could be determined in any given 
concentration. Experiments were performed once in technical duplicates. Mean values were 
calculated. 
3.5.3.2.2 Double Treatment with Tosufloxacin and Doxorubicin Showed Minor 
Additional Effects on Cell Death Rates 
Hep3B cells were treated with tosufloxacinin, doxorubicin, mitomycin C and 
cisplatin in single and combined applications (Figure 37). None of the single 
tosufloxacin concentrations used (1, 10, 30 µM) was sufficient to induce cell 
death by itself. Furthermore, no additional or synergistic effect was observed 
when tosufloxacin was combined with cisplatin or mitomycin C. A minor 
additional effect was seen upon combinational treatment with both 10 µM or 
30 µM tosufloxacin and doxorubicin. Cell numbers in the subG1 fraction rose from 
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25% in single treated cells to 30% and 40% in tosufloxacin / doxorubicin–treated 
cells, respectively. 
 
Figure 37: Cell cycle distribution and cell death rates of tosufloxacin double-treated Hep3B 
cells with different chemotherapeutics after 24 hours. Hep3B cells were treated for 24 hours 
with tosufloxacin or tosufloxacin in combination with different chemotherapeutics to evaluate 
possible synergistic effects of the double treatment. Combination of 10 µM and 30 µM tosufloxacin 
with doxorubicin led to a small synergistic increase in cell death rates, compared to the single 
treatments. Experiments were performed once in technical duplicates. Mean values were 
calculated. 
3.5.3.2.3 Double Treatment with Camptothecin and Mitomycin C Resulted in 
Major Synergistic Effects on Cell Death Rates 
Cells were treated with camptothecin, doxorubicin, mitomycin C and cisplatin in 
single and combined applications (Figure 38). A dose-dependent synergistic 
effect was seen in all combinations apart from treatment of cells with 
camptothecin and doxorubicin, where a minor additional effect was seen. The 
highest synergistic effect was seen upon combination of camptothecin and 
mitomycin C, leading to a significant cell death increase in all tested 
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concentrations. Up to 40% of the double-treated cells were in the apoptotic subG1 
cell fraction, compared to only 3 to 6% of the cells treated with camptothecin or 
mitomycin C alone.  
 
Figure 38: Cell cycle distribution and cell death rates of camptothecin double-treated Hep3B 
cells with different chemotherapeutics after 24 hours. The effects on cell death rates and cell 
cycle distribution of camptothecin (CPT)-treated cells, in single or double administration with either 
doxorubicin, mitomycin C, cisplatin or sorafenib, was monitored via Nicoletti staining. Solvent-
treated and wildtype cells served as control. The cell cycle distribution was not altered significantly 
in any given treatment. Nevertheless, all double treatments led to a synergistic cell death rate 
increase, with a significant increase seen in all combinations of camptothecin with mitomycin C (p-
values between <0.0001 and 0.0088). Experiments were performed in biological triplicates, each 
consisting of technical duplicates. Mean values ± SD, as well as p-values (two-tailed t-test), were 
calculated. 
3.5.3.2.4 Double Treatment of 7-ethyl-10-hydroxycamptothecin and Mitomycin C 
Resulted in Synergistically Increased HCC Cell Death  
Cells were treated with 7-ethyl-10-hydroxycamptothecin, doxorubicin, 
mitomycin C and cisplatin in single and combined applications (Figure 39). 7-
ethyl-10-hydroxycamptothecin is the active part of Irinotecan, the clinically used 
camptothecin derivate. Almost no additive effect was seen, when 7-ethyl-10-
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hydroxycamptothecin was combined with any concentration of cisplatin, leading 
to a cell death rate of approximately 11%. Combination of 7-ethyl-10-
hydroxycamptothecin with doxorubicin led to a minor increase in the apoptotic 
subG1 fraction of cells from 23% (single doxorubicin treatment) to 32% (double 
treatment). The combination of 7-ethyl-10-hydroxycamptothecin with mitomycin C 
led to a major synergistic effect, increasing cell death rates from 2-5% in 
mitomycin C single-treated cells to 23% when combined with 1.25 µM 7-ethyl-10-
hydroxycamptothecin. 
 
Figure 39: Cell cycle distribution and cell death rates of 7-ethyl-10-hydroxycamptothecin 
double-treated Hep3B cells with different chemotherapeutics after 24 hours. After treatment 
with 7-ethyl-10-hydroxycamptothecin without or with the addition of doxorubicin, mitomycin C or 
cisplatin, the cell cycle distribution was not altered significantly compared to those of the wildtype 
and solvent-treated cells. Nevertheless, a cell death rate increase was seen in combinations of 7-
ethyl-10-hydroxycamptothecin with doxorubicin and with mitomycin C. Experiments were performed 
once in technical duplicates. Mean values were calculated. 
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3.5.3.3 Further Evaluation of the Effects on Cell Death from the Combinatorial 
Application of Camptothecin and other Chemotherapeutics in the HCC 
Cell Lines HepG2 and HuH7  
To further investigate the effect of camptothecin and cisplatin, mitomycin C or 
doxorubicin double treatment on further HCC cells lines, HuH7 and HepG2 cells, 
were treated and subsequently analyzed as described before.  
3.5.3.3.1 HepG2 Camptothecin Single- and Double-Treatment with 
Chemotherapeutics Excessively Induced Apoptosis 
Cells were treated with camptothecin, doxorubicin, mitomycin C and cisplatin in 
single and combinatorial applications (Figure 40). HepG2 cells reacted sensitive 
to all substances. The solvent control (DMSO / MeOH) led to 17% dead cells. 
Furthermore, the cells showed a dose-dependent increase in cell death rates up 
to 50% upon camptothecin single treatment. Double treatment with camptothecin 
and either cisplatin or sorafenib also showed a dose-dependent increase in 
apoptotic cells, but was not significantly different from death rates seen upon 
camptothecin single treatment. The combination of camptothecin and 
mitomycin C resulted in a small additive effect with a total of approximately 72% 
dead cells.  
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Figure 40: Cell cycle distribution and cell death rates of camptothecin double-treated HepG2 
cells with different chemotherapeutics after 24 hours. HepG2 cells are sensitive to all treatment 
possibilities, leading to increased amounts of cells in the subG1 peak. Increased cell death is seen 
in cells treated with 2.5 µM camptothecin and either doxorubicin, mitomycin C or cisplatin. 
Experiments were performed in biological triplicates, each consisting of technical duplicates. Mean 
values ± SD were calculated. 
3.5.3.3.2 Treatment of HuH7 Cells with all Camptothecin-Combinational 
Applications Resulted in an Additive Increase in Cell Death Rates 
Cells were treated with camptothecin, doxorubicin, mitomycin C and cisplatin in 
single and combinatorial applications (Figure 41). An additive effect was seen in 
all combinations. camptothecin single treatment led to a maximum amount of 
15% dead cells. In combination with 5 µM sorafenib, a total of 21% dead cells 
were measured. The camptothecin double treatment with cisplatin and 
doxorubicin lead to a total of 21% and 41% respectively. The highest amount of 
apoptotic cells were measured upon mitomycin C double treatment with a 
maximum of 57% dead cells compared to mitomycin C single treatment with an 
amount of 46% cells in the subG1 fractions. 
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Figure 41: Cell cycle distribution and cell death rates of camptothecin double-treated HuH7 
cells with different chemotherapeutics after 24 hours. The cell cycle distribution was not altered 
significantly under any given treatment. Furthermore, beside camptothecin / sorafenib double- 
treatment, all combinational treated cells showed an additive cell death effect, leading to increased 
numbers of cells in the subG1 peak in any given concentration. Experiments were performed in 
biological triplicates, each consisting of technical duplicates. Mean values ± SD were calculated. 
3.5.4 Influence of Camptothecin and other Topoisomerase I Inhibitors on 
FUBP1 Target Gene Expression  
p21 is a well known direct target gene of FUBP1 [1]. To examine the effect of 
camptothecin, its derivate 7-ethyl-10-hydroxycamptothecin and other 
topoisomerase I inhibitors like NSC 725776 and NSC 724998 on FUBP1 activity 
in cells, target gene expression of p21 and c-myc were investigated after 6 hours 
of treatment via qRT-PCR. Furthermore, the amount of FUBP1 protein was 
validated via western blot analysis.  
3.5.4.1 All tested Topoisomerase I Inhibitors Induced a Dose-Dependent mRNA 
Expression Increase of the FUBP1 Target Gene p21 while FUBP1 
Protein Level Remained Stable 
All treated cells showed a significant, dose-dependent increase in p21 levels after 
treatment with any of the topoisomerase I inhibitors used in this study 
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(camptothecin, 7-ethyl-10-hydroxycamptothecin, NSC 725776 and NSC724998) 
(Figure 42). Furthermore, the application of these inhibitors did not change the 
expression level of c-myc significantly. Cells treated either with camptothecin, 
NSC 724998 or NSC 725776 showed a dose-dependent increase in p21 mRNA 
levels, with the highest alteration induced by a 10 µM compound concentration 
(12,9-fold, 5.4-fold and 8.5-fold p21 mRNA expression compared to DMSO-
treated control cells). Treatment with 7-ethyl-10-hydroxycamptothecin also 
increased the amount of p21 mRNA, but not in a dose-dependent manner (4.2-
fold compared to DMSO-treated cells). Western blot analysis showed that the 
protein levels of FUBP1 were not altered upon application of the inhibitors. 
 
Figure 42: FUBP1 target gene expression in Hep3B cells after topoisomerase I inhibitor 
treatment. Cells were incubated with the inhibitors for 6 hours. Target gene expression was 
investigated via qRT-PCR and normalized to GAPDH mRNA. Protein expression was verified via 
western blot analysis. (A), (C), (D) Cells treated either with camptothecin, NSC 724998 or 
NSC 725776 showed a significant, dose-dependent increase in p21 mRNA with a maximum of 
12,9-fold, 5.4-fold and 8.5-fold expression compared to DMSO-treated control cells. (B) Treatment 
with 7-ethyl-10-hydroxycamptothecin increased the amount of p21 mRNA significantly (4.2-fold), 
compared to DMSO-treated cells, independently of the concentration used. Western blot analysis 
showed that the amount of FUBP1 protein was not altered by any of the treatments. Experiments 
were performed in biological triplicates, each consisting of technical duplicates. Mean values ± SD 
as well as p-values (two-tailed t-test) were calculated. 
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3.5.4.2 Treatment of HepG2 and HuH7 Cells Led to an Increase in FUBP1 
Target Gene p21 mRNA Expression Levels, while FUBP1 Protein 
Levels Remained Stable 
HepG2 cells showed an inverted significant, dose-dependent effect of p21 mRNA 
expression levels upon camptothecin treatment (Figure 43). While incubation with 
1 µM camptothecin led to a 9.2-fold increase, 5 µM evoked a 4.2-fold and 10 µM 
only to a 2.4-fold increase compared to the DMSO-treated cells. Furthermore, c-
myc mRNA levels were significantly decreased to a 0.3-fold expression 
compared to the DMSO-treated cells. FUBP1 protein levels were not altered by 
camptothecin application. HuH7 cells showed a significant, dose-dependent 
increase of p21 mRNA levels after camptothecin treatment. The p21 mRNA 
expression level rose from 5-fold (1 µM), to 10.2-fold (5 µM) and finally 12.4-fold 
(10 µM). During camptothecin application, expression levels of c-myc mRNA 
were slightly, but significantly decreased to 68% (5 µM) and 75% (10 µM), 
respectively. FUBP1 protein expression was not altered in the presence of 
camptothecin. 
 
Figure 43: FUBP1 Target gene expression in HepG2 and HuH7 cells after camptothecin 
treatment. Cells were treated for 6 hours. Target gene expression was investigated via qPCR and 
normalized to GAPDH mRNA levels. Protein expression was verified via western blot analysis. (A) 
HepG2 cells showed a significant, inverted dose-dependent effect on p21 mRNA expression levels. 
Furthermore, c-myc mRNA levels decreased significantly to 0.3-fold of the DMSO-treated control 
cells. (B) HuH7 cells showed a significant, dose-dependent increase in p21 mRNA expression level 
following camptothecin treatment, c-myc mRNA levels decreased significantly to 0.5- and 0.7-fold 
of the DMSO-treated control cells. The amount of FUBP1 protein, confirmed by westerblot analysis, 
was not altered under any of the tested conditions. Experiments were performed in biological 
triplicates, each consisting of technical duplicates. Mean values ± SD, as well as p-values (two-
tailed t-test) were calculated. 
3.6 Therapeutic Treatment of Hep3B Xenograft Tumors using Irinotecan 
Induced Total Tumor Remission 
To investigate the effect of irinotecan on established HCCs in an in vivo mouse 
model, 5 x 106 Hep3B cells were injected into the flank of NOD/SCID mice. 
Tumors were allowed to grow to a volume of 100 mm3, before treatment with 
irinotecan started. Mice were grouped (6-8 mice per group) and treated according 
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to the schedule presented earlier (see page 62, paragraph 2.2.6). During the 
treatment period, mice were weighed daily for 21 days, and tumor volumes were 
measured every third day. After the treatment period, tumors and body weight 
were measured twice a week. Mice were sacrificed, when tumors reached a 
volume of 1,000 mm3. The effects of six different treatments on tumor growth 
were evaluated: irinotecan, mitomycin C, irinotecan plus mitomycin C, sorafenib, 
i.p. control with solvent, and oral control with solvent. 
3.6.1 Irinotecan Single-Treatment led to Total Tumor Remission and 
Significantly Increased Overall Survival in a Xenograft Mouse Model 
but Displayed Side Effects  
Due to an unexpected rapid weight loss of more than 20%, all mice of the 
irinotecan / mitomycin C double treatment group were sacrificed after 7 days of 
treatment. Apart from the irinotecan-treated group, all others showed an increase 
in tumor volume during the treatment period, with no significant differences 
compared to the control-treated groups (Figure 44). After 3 days of treatment, 
tumors of the irinotecan-treated group stopped progression, and after six days, 
the first shrinkage of tumors was measureable. After 18 days of treatment 
(day 34), in all 8 mice of the irinotecan group a total tumor remission was seen. 
Up to day 87, these mice showed no sign of tumor recurrence. Eventually, all 
mice developed tumors again and were sacrificed. The life span of the irinotecan-
treated mice was significantly increased compared to those of the other groups. 
 
Figure 44: First Xenograft Mouse Model with Irinotecan Treatment 5 x 106 Hep3B cells were 
injected into the flank of NOD/SCID mice. The tumors were allowed to grow to a volume of 
100 mm3 before treatment started. Mice were treated with either 20 mg/kg irinotecan, 3.25 mg/kg 
mitomycin C, 30 mg/kg sorafenib, 20 mg/kg irinotecan plus 3.25 mg/kg mitomycin C or 0.9% NaCl- 
treated solvent control (i.p.- and oral-control). Due to an unexpected rapid weight loss of more than 
20% in all mice of the irinotecan / mitomycin C double treatment group, the animals were sacrificed 
after 7 days of treatment. (A) Treatment with irinotecan led to a total tumor remission after 18 days 
of treatment in 100% of mice. The animals were kept remission-free for 53 days, before tumors 
relapsed. (B) The life span of irinotecan-treated mice was significantly increased compared to those 
of all other treated groups. Mean values ± SD were calculated with a size of 6 to 8 mice per group. 
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Minor side effects were seen in the irinotecan-treated group. All mice lost weight 
during the consecutive 5 days of treatment, but regained most of it in the 2 days 
between treatments. Mice regained their starting weight, when the treatment was 
stopped after 21 days (Figure 45).  
 
Figure 45: Body weight loss during irinotecan treatment. Mice were treated for 5 consecutive 
days followed by a treatment pause of two consecutive days. The cycle was repeated three times. 
Minor body weight losses (≤ 20%) were seen in all mice during the time of the treatment. 
3.6.2 Irinotecan Single- and Double-Treatment resulted in Total Tumor 
Remission and Significantly Increased Overall Survival in a 
Xenograft Mouse Model With no Measureable Side Effects  
In the second xenograft transplantation experiment, the concentrations of drugs 
given to the mice were reduced, based on the experience of the first experiment. 
Half of the dose of irinotecan (10 mg/kg) and a quarter of the mitomycin C 
(0.8125 mg/kg) dose were used. No unexpected side effects occurred this time. 
The treatment started at day 14, after injection of the Hep3B cells, when the 
tumors had reached an average size of 100 mm3 (Figure 46). During the 
treatment period, tumors of mitomycin C single-treated mice showed almost no 
difference in growth compared to the control-treated group. Both groups were 
sacrificed after 35 days, when the xenograft tumors had reached a volume of 
approximately 1,000 mm3. After 14 days of treatment, all 6 mice of the irinotecan 
single-treated group showed total tumor remission. The mice of the 
irinotecan / mitomycin C double-treated group showed a total remission already 
after 10 days of treatment. The single-treated animals remained tumor-
recurrence free for a total of 43 days until day 71, the irinotecan / mitomycin C 
double-treated mice for a total of 63 days until day 91. Mice of both groups were 
again treated with the irinotecan / mitomycin C double treatment, when the 
relapsed tumors reached again a volume of 100 mm3 (Figure 46). 100% (6/6) of 
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the irinotecan single-treated mouse group showed a tumor relapse (the latest 
after 120 days in total), which went into total remission after the second round of 
irinotecan / mitomycin C double treatment. Until day 120, only 50% (3/6) of the 
irinotecan / mitomycin C double-treated mice showed a relapse, and after the 
second chemotherapy with irinotecan and mitomycin C, two tumors went into 
total remission, while one remained stable in size. One mouse of the double-
treated group had to be sacrificed after 94 days due to non-tumor related injuries. 
 
Figure 46: Second xenograft mouse model with irinotecan treatment. 5 x 106 Hep3B cells 
were injected into the flank of NOD/SCID mice. The tumors were allowed to grow to a volume of 
100 mm3 before the treatment started. Mean values ± SD were calculated with a size of 6 mice per 
group. Mice were treated with either 10 mg/kg irinotecan, 0.8125 mg/kg mitomycin C, 10 mg/kg 
irinotecan plus 0.8125 mg/kg mitomycin C or 0.9% NaCl solvent oral-control. (A) Irinotecan-treated 
animals showed a total tumor remission after 14 days of treatment and remained recurrence-free 
for a total of 43 days. The double-treated mice showed a total tumor remission after 10 days of 
treatment and remained relapse-free for a total of 63 days. (B) Mitomycin C single-treated mice had 
no survival benefit compared to the control-treated mice. The life span of irinotecan and irinotecan 
plus mitomycin C treated mice was significantly increased during the period of this experiment 
compared to those of the control mice. (C) After 120 days, 100% (6 / 6) of the irinotecan single-
treated mice showed a tumor relapse. Nevertheless, only 50% (3 / 6) mice of the irinotecan / 
mitomycin C double-treated group relapsed. The earliest relapse in this group occurred 20 days 
after the earliest relapse in the single-treated group.  
No side effects were seen in the group of irinotecan-treated animals. None of the 
mice dropped weight during the consecutive 5 days of treatment. The 
irinotecan / mitomycin C double-treated mice showed only minor effects of 
approximately 7% maximum weight loss (Figure 47). 
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Figure 47: Body weight loss during the second irinotecan treatment xenograft experiment. 
Mice were treated for 5 consecutive days, followed by a treatment pause of two days. The cycle 
was repeated three times. (A) 10 mg/kg Irinotecan single treatment had no effect on the body 
weight of the mice. (B) 10 mg/kg irinotecan/ 0.8125 mg/kg mitomycin C double treatment had only 
minor effects on the body weight of the treated mice. 
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4 Discussion 
The aim of this project was the identification of novel FUBP1 inhibitors to target 
FUBP1 activity in hepatocellular carcinoma (HCC). Until today, treatment options 
for late stage HCC (stage B and C) are restricted to TACE (transcatheter aterial 
chemoembolization) or the application of the multi-kinase inhibitor sorafenib, and 
both are only used as palliative treatments [79].  
In our laboratory, the transcriptional regulator FUBP1 was found to be highly 
overexpressed in HCC compared to normal liver tissue [80]. In the same study, 
target genes of FUBP1 in HCC could be identified, which play important roles in 
the intrinsic and extrinsic apoptosis pathway as well as in the regulation of the 
cell cycle. The cyclin-dependent inhibitor p21 (WAF1/CIP1), an important cell 
cycle inhibitor [81], was identified as a direct target of FUBP1 in HCC. 
Furthermore, we could show that the constitutive knockdown of FUBP1 in a HCC 
xenograft transplantation experiment resulted in a significantly decreased tumor 
formation compared to the injected control tumor cells (see page 12, Figure 5). 
These finding led us to the assumption that FUBP1 might serve as a novel target 
in HCC therapy. 
4.1 Expression and Purification of Codon-Optimized FUBP1 
4.1.1 Expression of coFUBP1 
Expression of human FUBP1 was performed using the pET28b vector in BL21 
E. coli. To efficiently express functional protein in the heterologous host, the 
codon sequence was optimized for bacterial cells. It was shown that redesigning 
the entire gene sequence dramatically improved the likelihood of high protein 
expression in general [82]. Furthermore, the protein was expressed using an 
auto-induction system in a 10 l fermenter at 22°C. Auto-induction was developed 
for proteins whose expression might be harmful to the host cells. In addition, the 
high-density cultures obtained by auto-induction produce more target protein per 
volume unit, than IPTG-induced expression systems [74]. We were able to 
express the full-length human FUBP1 protein in BL21 bacteria and purify it using 
a three-step protocol. However, only minor amounts of full-length protein were 
obtained, in total 0.27 mg of purified coFUBP1 from 5 l culture media. The low 
amounts of protein could be due to significant protein degradation. In her diploma 
thesis, Stefanie Hauck could show that degradation of recombinantly expressed 
full-length FUBP1 occurs at defined sequences, and the degradation pattern 
suggested that proteolysis takes place at the C-terminal region of FUBP1 [78]. 
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Until today, the structure of FUBP1 remains unsolved. In 1994, Duncan et al. 
could show that the carboxy-terminal domain of FUBP1 is separated from the 
central domain by a highly flexible proline/glycine rich linker. Furthermore, this 
domain is glutamine- as well as tyrosine-rich and is described as mostly 
unstructured [3]. Unstructured domains, as for example, glycin-rich-regions 
(GRR), are prone to be degraded by proteases [83]. Furthermore, in a proteome 
analysis of S. cerevisiae, Gsponer et al. could show that mRNA encoding highly 
unstructured proteins are less abundant and exhibit a shorter half-life than 
structured proteins. Additionally, highly unstructured proteins are less abundant, 
the rate of synthesis is significantly lower and their half-life is shorter compared to 
the structured proteins. According to their grouping, highly unstructured proteins 
contain between 30-100% of unstructured regions [84]. If the amount of 
unstructured regions can negatively influence the protein synthesis rate as well 
as the protein half-life, these effects could contribute to the low amount of 
recombinantly expressed FUBP1, which inherits 32.5% of unstructured regions, if 
the C-terminus is accepted as such one. Ms. Hauck could furthermore 
demonstrate the influence of the unstructured C-terminus on the protein 
expression and degradation. The expression of a truncated FUBP1 missing the 
c-terminal region (FUBP1ΔC) led to the isolation of significantly higher protein 
amounts, as well as significantly lowers protein degradation products [78]. 
To further enhance the amount of full-length protein, different strategies could be 
pursued, e.g. the use of different host strains, as well as the co-production of 
chaperones [85]. In the engineered E. coli host strain “Artic Express” (Agilent 
Technologies) the mRNA is stabilized by attenuation of RNase activity. The co-
production of chaperones supports the initial protein folding, leading to less 
protein aggregation. Additionally, the change of the expression system could also 
lead to superior results. We therefore expressed full-length FUBP1 in 
mammalian, as well as in insect cells. Both systems were suitable for FUBP1 
expression, but nevertheless, the protein yield was comparable to the one 
achieved by the bacterial expression system (data not shown). 
4.1.2 Recombinant Protein Purification 
To purify recombinant FUBP1, a three-step protocol was established. First, IMAC 
purification using Ni-NTA columns was performed. Afterwards, a heparin column 
was used, exploiting the FUBP1 DNA-binding capacity. Finally, size exclusion 
using a Superdex 16/60 200 column was used. In contrast to the experience from 
Hsiao et al. 2010, no nonspecific interaction of the protein with the superdex 
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column was observed [17]. To analyze the protein fractions, samples for SDS-
PAGE electrophoresis were collected, before protein sample fractions were 
pooled and subsequently stored at -80°C. Although only low total protein 
amounts of coFUBP1 were obtained, the samples were pure and, according to 
the size exclusion chromatogram, monomeric. 
To verify the identity of the recombinant protein, Western blot analysis and mass 
spectrometry were performed, and confirmed the identity of human FUBP1.  
4.2 Functional Analyses of recombinant FUBP1 
To ensure the functionality of the recombinant protein, binding studies with a 53-
mer p21-FUSE oligonucleotide were performed. The binding affinity between 
FUSEp21 and FUBP1 could be determined in a nanomolar range in SPR as well 
as in MST measurements. 
To guarantee the specificity of the binding between FUBP1 and FUSEp21, the 
oligonucleotides p31 and p39 were used as negative controls. These 
oligonucleotides were previously found not to bind to FUBP1 in electro mobility 
shift (EMSA) assays [80]. Furthermore, MBP (maltose binding protein) protein 
was used as a protein not binding to FUSE DNA, to show the specificity of the 
p21 oligonucleotide. In two independent experiments, a binding constant of 
12.9 nM for the interaction of FUBP1 and FUSEp21 could be determined. 
During MST measurements with the same FUSEp21 oligonucleotide and 
recombinant FUBP1, a binding constant of 12.31 nM was measured. In an 
additional, independent MST experiment, a binding constant of 8.8 nM could be 
calculated (data not shown). 
In summary, the KD values of all experiments suggest a specific, high affinity 
binding between recombinant FUBP1 and FUSEp21.  
In 2010, Hsiao et al. purified a FUBP1 full-length variant, which inherited cloning 
artifacts of 69 additionally included amino acids at the N-terminus, expressed in a 
baculovirus expression system. Furthermore, the cysteines 132, 148 and 332 
were replaced with alanines in this FUBP1 variant. To determine a binding 
constant between FUBP1 and FUSE, a synthetic 53-mer oligo of the non-coding 
c-myc-FUSE was used as the binding partner [17]. FUBP1 FUSE binding was 
quantified using fluorescence anisotropy measurement and fluorescence 
correlation spectroscopy measurements. Fluorescence anisotropy measurement 
resulted in a KD determination of 415.8 ± 137.78 nM, in the fluorescence 
correlation spectroscopy measurements a KD of 168.6 ± 36.6 nM could be 
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calculated. In 2002, Braddock et al. measured a KD of 10 nM between a FUBP1 
variant (consisting of only KH3 and KH4) and a 29-mer c-myc FUSE [86]. 
The independent experiments performed by different groups show that FUBP1 
and FUSE form a high-affinity complex. Differences in KD values can be 
explained by multiple factors. As described before, the full-length protein used by 
Hsiao et al. 2010 inherited several cloning artifacts, which could have affected 
the binding capacity of the protein. Furthermore, the FUSE oligonucleotide used 
by this group was derived from the c-myc, not the p21 FUSE element. FUBP1 
can bind to different FUSE motifs with varying affinities; therefore it is likely that 
the binding affinities of FUBP1 towards c-myc and p21 FUSE differ from each 
other. Although Braddock et al. in 2002 also used the c-myc FUSE motif, the 
measured KD is almost similar to the one we measured [86]. However, in contrast 
to our study, they used only the DNA binding-domains KH3 and KH4 of FUBP1, 
not the full-length protein, which could explain the similar high affinity binding, 
despite the different FUSE motifs. 
4.3 AlphaScreen® Interaction Studies 
To identify small molecule inhibitors of the FUBP1 and FUSEp21 interaction, an 
AlphaScreen® assay procedure was established. The assay system was used to 
subsequently screen two different libraries, one small molecule library with 
14,400 substances (Maybridge Hit FinderTM library) and one FDA-approved drug 
library with 1,600 substances (Prestwick Chemical library). Hits were defined as 
substances, which diminished the signal intensity to 30% or less and were 
subsequently re-screened using the same assay. After the second screen, all hits 
were bioinformatically evaluated by the use of a SOM (self-organizing-map), 
established and performed by Janosch Achenbach (AG Proschak, University of 
Frankfurt). A total of 103 compounds of the Maybridge Hit FinderTM library (<1%) 
and 55 compounds of the Prestwick Chemical library (3.43%) were defined as 
hits. 
In 2004, Huth et al. already screened for FUBP1 inhibitors using three 
approaches: HTS-NMR, Virtual Ligand Binding (VLB) and affinity selection/mass 
spectrometry (ASMS) [87]. In contrast to the project pursued during this thesis, 
they only used the KH3/KH4 DNA-binding domain as described in 2002 [86]. 
Nevertheless, they only found four compounds, which bound with rather low 
affinities between 0.35 mM and >4 mM to the recombinant FUBP1 DNA-binding 
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domain. None of these compounds have been further investigated as FUBP1 
inhibitors. 
To estimate the quality of the established AlphaScreen® assay, the statistical 
effect size (z-factor) was calculated. The z-factor is a dimensionless, simple 
statistical characteristic for high throughput screenings (HTS). A value of 1 
defines an ideal assay, a factor between 0.5 and 1 defines an excellent assay, 
values between 0 and 0.5 a marginal assay [88]. The values of the competitive 
assay (see page 75, paragraph 3.3.2) are used to determine the statistical effect 
size. 0 nM unbound free FUSEp21 were used as the negative control, 100 nM 
unbound FUSEp21 as the positive control. The AlphaScreen® assay established 
in this study was classified as an excellent assay with a z-factor of 0.74. 
 
Equation 8: ! − !"#$%&: 1 − 3(!p − !n)µμp − µμn  σp:  standard  deviation  positive  control  σn:  standard  deviation  negative  control  µμp:  mean  positive  control  µμn:  mean  negative  control    
To identify further FUBP1 inhibitors in the future, an additional, already 
established screening approach could be used. In 2014, Mahapatra et al. 
described a HTS fluorescence anisotropy screen for the oncogenic mRNA 
binding protein IMP-I [89]. They used purified protein and a 93-nucleotide 
fluorescently labeled c-myc mRNA binding site. The advantage of this assay 
system compared to the Alpha® technology is the cost efficacy, because no 
additional dye or bead system need to be purchased. Furthermore, the assay 
functions as a real time assay measuring the steady state binding conditions, 
thereby decreasing the amount of incubation time to the time needed to for the 
binding between both partners until the equilibrium phase is reached.   
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4.4 Re-Screening of Potential FUBP1 Inhibitors using SPR Technology 
Re-screening of potential FUBP1 inhibitors, which I found in the AlphaScreen® 
assay, was performed using SPR measurements. The FUSEp21 oligonucleotide 
was used as the ligand, whereas recombinant coFUBP1 protein served as the 
analyte. Immediately prior to measurement, a dilution series of each compound 
(0 µM, 0.1 µM, 1 µM, 10 µM, 50 µM and 100 µM) was added to the analyte 
samples. The decrease of the association of both components was measured, 
thereby evaluating the potential of the compound as a FUBP1 inhibitor. 
17 hit compounds of the Maybridge Hit FinderTM library, representing at least one 
compound from every group organized by the SOM, were tested, and four 
promising candidates were identified. The molecule HTS 06795 showed the best 
dose-dependent inhibition with a decrease in signal intensity of 75% at 10 µM 
concentration (Figure 28). 
13 hit compounds isolated from the Prestwick Chemical library were re-tested, 
leading to the validation of 3 hit compounds: tosufloxacin, pregnenolone and 
camptothecin. 
As camptothecin is known as a potent inhibitor of the topoisomerase I (TOP1) 
[60], the additional TOP1 inhibitors NSC 725776, NSC 724998 as well as 7-ethyl-
10-hydroxy-camptothecin (active part of the clinically used irinotecan) were also 
tested in SPR measurements. All tested TOP1 inhibitors provoked a dose-
dependent decrease of the FUBP1-FUSEp21 interaction (see page 80, 
paragraph 3.4.2.1). Furthermore, they all act as interfacial inhibitors, targeting 
protein/ssDNA complexes [59]. This suggested, that the mechanism responsible 
for the FUBP1 inhibition might be identical: As the topoisomerase also binds to 
single stranded DNA, the compounds might also function as interfacial inhibitors, 
when inhibiting the FUBP1/FUSE interaction. Nevertheless, the SPR results 
would argue against this hypothesis, as pre-mixed protein/compound samples 
show a dose-dependent reduction of FUBP1/FUSEp21 binding, and not a 
trapping of the binding complex. Of note, no experiment was performed, during 
which preformed FUBP1/FUSEp21 complexes where incubated with the 
inhibitors, showing the effect of the inhibitors on the already formed DNA/protein 
complex. The crystallization of the FUBP1/FUSEp21 complex together with the 
identified inhibitors might reveal the molecular mechanism how the inhibitors 
interfere with the FUBP1 function.  
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Interestingly, tosufloxacin, another hit compound, is also known as an interfacial 
topoisomerase inhibitor. In contrast to camptothecin, tosufloxacin selectively 
targets the bacterial topoisomerase type IIA enzyme (gyrase) [90].  
As two out of three of the inhibitors isolated in the AlphaScreen® work with a 
comparable inhibitory mechanism, these findings would support the hypothesis 
that the FUBP1/FUSEp21 complex inhibition by camptothecin and tosufloxacin 
could also be mediated by an interfacial mechanism. 
4.5 Functional Analyses of FUBP1 Inhibitors 
To monitor the effects of the inhibitory substances camptothecin, pregnenolone 
and tosufloxacin on hepatocellular carcinoma cell lines, cell expansion and cell 
activity as well as cell death assays were performed. Interestingly, in all of these 
tests, only camptothecin induced significant cellular effects. To further monitor 
the extent of FUBP1 inhbition by camptothecin, expression of the FUBP1 direct 
target gene (p21) was monitored in treated and untreated cells. 
4.5.1 Tosufloxacin and Pregnenolone Treatment Showed no Effect on Cell 
Expansion or Cell Death in Hep3B Cells 
Cell expansion assays were performed over a period of 72 hours (see page 82, 
paragraph 3.5.1). Cells treated with tosufloxacin or pregnenolone showed almost 
no alteration in cell expansion. Furthermore, WST assays performed with 
tosufloxacin- and pregnenolone-treated cells displayed no specific effect on cell 
activity (see page 83, paragraph 3.5.2.1). In Nicoletti experiments, no cell death 
induction could be observed after single treatment with tosufloxacin or 
pregnenolone, regardless whether the cells were treated for 24 or 72 hours. To 
apply an additional apoptotic trigger, double treatments with the known 
chemotherapeutics doxorubicin, mitomycin C and cisplatin were performed for 
24 hours. Although double treatments with pregnenolone and chemotherapeutics 
had no additional effect on cell death rates, a minor additional effect was seen 
when combining tosufloxacin and mitomycin C (see page 88, paragraph 
3.5.3.2.2). 
The fact that tosufloxacin and pregnenolone interacted with recombinant FUBP1 
protein in biochemical binding studies, but showed no effects in cellular assays, 
needs to be further elucidated. To address this problem, it is necessary to map 
the binding-sites of these substances to FUBP1 (see page 106, paragraph 4.4). If 
the binding concept is elucidated in vitro, it is important to verify this process in 
the cell. Throughout the binding of FUBP1 to FUSE, FUBP1 does not only 
interact with the single stranded FUSE DNA, but also with the p89 subunit of 
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TFIIH, and with FIR, the FUBP1 interaction repressor [4]. These interactions 
were not possible in the biochemical in vitro binding studies, where only FUBP1 
and a 53 bp ssDNA oligonucleotide were present. These additional intracellular 
interactions are likely to lead to conformational changes of FUBP1, which could 
result in a “loss” of the inhibitor binding motifs, explaining the negative results of 
the cellular assays. However, if pregnenolone and tosufloxacin indeed interact 
with FUBP1 intra-cellularly, the relevance of FUBP1 as a therapeutically target in 
HCC therapy needs to be reconsidered. To address this question, ChIP 
experiments with treated HCC cell lines could be performed to compare the 
prevalence of FUBP1 on different transcriptionally active sites within the genome, 
as for example on the p21 FUSE locus, before and after treatment of the cells. 
Furthermore, luciferase reporter assays with the FUSEp21 sequence could be 
performed to investigate the effects of the substances on the transcriptional 
activity of FUBP1. 
4.5.2 Camptothecin Treatment decreases Cell Proliferation and Increases 
Cell Death in Hepatocellular Carcinoma Cell Lines 
In contrast, however, camptothecin treatment influenced the cell behavior 
significantly. Hep3B cell expansion was diminished to the same extent as in cells 
treated with the HCC gold standard therapy Sorafenib (see page 82, paragraph 
3.5.1). WST assays, displaying the mitochondrial activity and revealed that 
treatment with camptothecin led to a sigmoidal, dose-dependent cell activity 
decrease. 100 nM camptothecin were sufficient to decrease the Hep3B cell 
activity to ≤ 50% (see page 83, paragraph 3.5.2.1). In a second approach, 
combinations of the camptothecin derivate 7-ethyl-10-hydroxycamptothecin with 
either mitomycin C or sorafenib were applied. Both combinations showed 
synergistic effects. When combining 0.3 µM 7-ethyl-10-hydroxycamptothecin with 
either 0.3 µM mitomycin C or 0.3 µM Sorafenib, a reduction of mitochondrial 
activity down to 13.5% and 12% of the original (untreated) value was seen (see 
page 83, paragraph 3.5.2.2). As cell expansion and WST assays do not allow to 
discriminate between cell death and reduced cell proliferation (and vice versa), 
additional tests were performed. To further elucidate the role of camptothecin in 
cell death induction in HCC tumor cells, Nicoletti assays were performed in 
Hep3B cells. In both setups, single and double treatment, camptothecin positively 
influenced the amount of dead cells. Camptothecin single-treated cells showed 
enhanced killing after 72 hours, and additionally, an alteration in the cell cycle 
distribution of the remaining cells, e.g. G2/M arrest and sustained S-phase. 
Furthermore, the mitomycin C / camptothecin double treatment revealed a 
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significant, synergistic cell killing effect after 24 hours. To validate these results, 
double treatment experiments were also performed in HuH7 and HepG2 cell 
lines, also resulting in increased cell death rates (see paragraph 3.5.3.1 - 
3.5.3.3.2).  
4.5.3 The Influence of Camptothecin on Cell Death 
Camptothecin induces DNA damage, which activates the checkpoint kinases 1 
(CHK1) and 2 (CHK2). CHK1 is phosphorylated by ATR (ataxia telangiectasia 
and Rad3-related protein) on serine 345 and phosphorylates in turn Cdc25A, 
leading to the proteasomal degradation of Cdc25A and resulting in a subsequent 
S-phase and G2/M-phase arrest [91, 92]. CHK 2 is primarily phosphorylated by 
ATM (Ataxia telangiectasia mutated) on threonine 68, which leads to its 
dimerization and subsequent auto-phosphorylation which are required for its 
complete activation [93]. Although both kinases seem to be activated after 
exposure to camptothecin, as indicated by the activation of the ATM and ATR 
pathway, the ATM pathway does not seem to be predominantly activated one 
after camptothecin application [92, 94] (see Figure 48). 
Figure 48: Camptothecin-induced cell death in p53-/- and p53+/+ cells. (Tomicic et al. 2013). In 
p53+/+ cells, camptothecin treatment leads to p21 activation followed by sustained G2/M arrest, and 
temporary senescence. After drug inactivation the cells are released into mitosis. In p53-/- cells, p21 
is not activated, leading to a transient G2/M block followed by a premature mitosis and subsequent 
excessive apoptosis 
4.5.4 Camptothecin Induces Excessive Apoptosis in p53-Negative Cells 
As checkpoint pathways are often connected to apoptosis, Tomicic et al. 
proposed a model in 2013, describing the ATR-CHK1-triggered signaling to cell 
cycle arrest and apoptosis [64] (see Figure 48). They claim that camptothecin 
M.T. Tomicic, B. Kaina / Biochimica et Biophysica Acta 1835 (2013) 11-27 
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triggers the ATR pathway, which leads to G2/M arrest and S-phase delay 
phenotype, which we also observed in our 72 hours Nicoletti assay. However, 
they propose that in p53-wildtype cells the G2/M arrest should be sustained 
through inactivation and subsequent degradation of Cdc2, which is a result of 
sustained p21 expression in those cells [95, 96]. In contrast, p53-deficient cells 
should lack p21 expression, which leads to a long-lasting activation of Cdc2, a 
transient G2/M arrest and finally to excessive apoptosis (see Figure 48). 
Interestingly, our cell death data with treated p53+/+ and p53-/- cells showed the 
opposite result. HepG2 cells (p53+/+), treated for 24 hours with either 
camptothecin or camptothecin combined with mitomycin C, doxorubicin, cisplatin 
or sorafenib, showed higher cell death rates as similarly treated Hep3B cell     
(p53-/-). 
In our laboratory, we could show that p21 is not only a target of p53 but also of 
FUBP1 [80]. Therefore inhibition of FUBP1 through camptothecin in p53-deficient 
cells should also lead to elevated p21 mRNA and protein levels, strengthening 
the hypothesis that camptothecin also targets FUBP1. 
4.5.5 Camptothecin Treatment of Hepatocellular Carcinoma Cell Lines 
Increases p21 mRNA Expression Levels 
We performed p21 mRNA expression studies with Hep3B cells (p53-/-) after 
6 hours of treatment with 1 µM, 5 µM and 10 µM camptothecin. We could show 
that indeed a dose-dependent increase in p21 mRNA expression can be 
observed after camptothecin treatment. To validate that this effect is not due to 
FUBP1 degradation, we performed Western blot analysis, showing stable FUBP1 
protein levels after treatment (see page 94, paragraph 3.5.4.1). Additionally, we 
performed the same experiment with the topoisomerase I inhibitors NSC 725776, 
NSC 724998 and 7-ethyl-10-hydroxy-camptothecin. All treatments resulted in 
increased p21 expression levels in p53-/- cells, whereas FUBP1 protein 
expression remained stable, strengthening the hypothesis of a possible influence 
of FUBP1 in camptothecin-induced apoptosis.  
FUBP1 inhibition does not alter the expression of c-myc in HCC cell lines [80]. 
Therefore, as an additional control, mRNA expression levels of c-myc were 
monitored, and they remained stable in p53-/- cells during treatment. Repetition of 
these experiments in p53mutant (HuH7) and p53+/+ (HepG2) cells again resulted in 
increased p21 mRNA expression levels (see page 96, paragraph 3.5.4.2). 
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4.5.6 Bi-Functional Activity of FUBP1 in Glioblastoma Cell Lines 
Correlates with Therapeutic Function of Topotecan in Those Cells 
Another hint that FUBP1 inhibition might be involved in cellular effects upon 
camptothecin treatment is seen when comparing apoptosis induction in different 
glioblastoma cell lines.  
U87 and LN-229 are both expressing p53+/+; nevertheless, U87 cells are resistant 
to topotecan and SN-38 treatment (both camptothecin derivates) [97, 98], 
whereas LN-229 cells are moderately sensitive [99]. As both cell lines express 
p53+/+, its p53 downstream signaling should not be responsible for the different 
apoptosis sensitivity upon topotecan treatment. Interestingly, FUBP1 does have 
different roles in these cells. While the knockdown of FUBP1 does lead to more 
apoptosis and less proliferation in LN-229, it does works in the opposite direction 
in U87 cells (Venkatesh Kolluru, GSH, unpublished data). If camptothecin inhibits 
the anti-apoptotic and pro-proliferative function of FUBP1, this could explain why 
its derivate works in LN-229 but not in U87 cells. 
4.5.7 The Camptothecin Derivate Irinotecan is Therapeutically Effective in 
Colorectal Cancer, a Tumor Known for its Frequently Mutated FIR 
Molecule 
FIR, the FUBP1 interacting repressor, was found to be frequently mutated in 
primary colorectal cancers, but not in the adjacent normal tissue. The mutation 
produces an alternative splicing variant, in which the N-terminal repression 
domain is deleted. Co-expression of this splicing variant with the repressor-
competent FIR in HeLa and SW480 cells abrogated the suppression of c-myc 
gene expression and inhibited apoptosis in these cells, indicating a dominant 
negative, oncogenic effect of the mutated splicing variant, which leads to an 
enhanced FUBP1 activity [21, 22]. Irinotecan, another camptothecin derivate, is 
frequently and successfully used in metastatic colorectal-cancer first-line therapy 
in combination with 5-Fluorouracil and Folin acid [100]. Furthermore, the 
treatment of colorectal cancer liver metastasis with a combination of irinotecan 
and mitomycin C administered via DEB-TACE led to a partial response in 4/4 
patients [101]. The molecular findings suggest, that irinotecan efficacy in 
colorectal cancer is not only due to topoisomerase I inhibition but also to FUBP1 
inhibition. 
4.5.8 Discrimination between FUBP1 and TOP1 Inhibition by 
Camptothecin 
As camptothecin is a known inhibitor of topoisomerase I, it is important to 
discriminate between the effects caused by the topoisomerase I inhibition and the 
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consequences of FUBP1 inhibition. As both molecules are expressed in the 
nucleus of the same cell, the separation of both effects is rather difficult to do. 
Although many findings hint into the direction, that camptothecin inhibits FUBP1 
function intracellularly, a direct proof is still missing. The fact that the FUBP1 
direct target gene p21 is regulated by camptothecin in p53-/- cells proofs that the 
assumed camptothecin-induced apoptosis mechanism, summarized by Tomicic 
et al. 2013, is at least incomplete.  However, it is also not a direct proof for the 
involvement of FUBP1 in these processes.  
If the attempt to solve the structure of FUBP1/FUSE is successful, this 
information could be used for an in-silico screening with camptothecin. 
Furthermore, if a crystallography protocol is established, one could also try to 
crystallize a complex of FUBP1/FUSE/camptothecin. 
Additionally to the effort of ChIP analysis and luciferase assays with 
camptothecin-treated cells (see paragraph 4.5.1), MS-analysis of the proteasome 
of camptothecin-treated HCC cells will be performed and compared with an 
analysis of FUBP1 knockdown and untreated HCC cells. If camptothecin inhibits 
not only TOP1 but also FUBP1, a similarity in the protein expression pattern of 
the FUBP1 knockdown and camptothecin-treated cells should be apparent. 
4.6 Irinotecan Treatment Led to Total Tumor Remission in Hep3B 
Xenograft Transplantation Experiments 
As camptothecin displays significant effects on HCC cell survival in cell culture in 
single and combinational treatments with mitomycin C, xenograft experiments 
were performed to monitor its effect on an already established tumor in vivo.  
The mouse xenograft tumor model with human tumor cells is frequently used in 
pre-clinical studies and its development was a major step towards clinically useful 
tumor models [102, 103]. Furthermore, in 2001 a retrospective study of the 
US NCI could show that in at least one third of all substances tested in human 
xenografts it was likely that the substances would achieve activity in a phase II 
clinical trial [104].  
Two studies were performed to monitor the effect of irinotecan and mitomycin C 
single and double treatment on established tumors in mice, compared to the 
effect of sorafenib in the same setting. Hep3B cells were injected into the flank of 
immune-compromised NOD/SCID mice, and afterwards, the tumor was allowed 
to reach a volume of approximately 100 mm3, before the appropriate treatment 
was started. 
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In the first experiment, a total tumor remission could be observed in 100% of the 
irinotecan-treated mice, representing a significant survival benefit compared to 
the mice of all other treatment groups (see page 97, Figure 44). The treatment 
schedule and substance concentrations, as well as application procedures were 
adopted as published by Cohen et al. 2010, who performed a peritoneally 
disseminated colorectal cancer xenograft experiment [105]. In the single 
treatment experiment, Cohen et al. found mitomycin C and irinotecan as the most 
potent substances, which was also the case in our experiment. Irinotecan-treated 
mice showed tumor-free survival for at least 53 days, resulting in an overall 
survival time of 136 days, which resembles the data from Cohen et al. with a time 
frame of 135 days survival after irinotecan treatment. They also tried different 
combinational treatments, among them a combination of irinotecan and 
mitomycin C. As this combination showed the best synergistic effect in our cell 
culture experiments, I decided to apply this double treatment. Unfortunately, an 
unexpected rapid weight loss of more than 20% in all mice of the 
irinotecan / mitomycin C double treatment group could be observed, and as a 
consequence, these mice were sacrificed after 7 days of treatment.  
In the following experiment, only half of the irinotecan dose (10 mg/kg) and a 
quarter of the mitomycin C concentration (0.8125 mg/kg) were used in the 
double- and the single-treated groups. The mitomycin C single-treated group 
showed no enhanced survival compared to the control group receiving solvent. 
100% of the irinotecan single- and irinotecan / mitomycin C double-treated mice 
showed a total tumor remission. Interestingly, tumor-free survival was 20 days 
shorter in irinotecan single-treated than in the double-treated mice. Furthermore, 
100% (6/6) of the single-treated mice experienced a tumor relapse, compared to 
only 50% (3/6) of the double-treated mice, with one double-treated mouse 
showing no progression at all until at least day 120. This statistic demonstrates a 
clear advantage of the irinotecan / mitomycin C double treatment compared to 
the single treatment.  
All mice were again treated with the double combination, when tumors relapsed 
and reached a volume of approximately 100 mm3, regardless of the first 
treatment. Again, all tumors responded to the double treatment, leading to a total 
tumor remission in all cases. These results show that a tumor HCC grown from 
human cells can be successfully treated in a xenograft transplantation model 
using a combination of irinotecan and mitomycin C. 
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In 2002, the group of Prewitt et al. also tested a combinational treatment in a 
xenograft transplantation model, investigating the effect of irinotecan combined 
with cetuximab in irinotecan-refractory-colorectal tumors [106]. The double-
treated tumors grew significantly slower than those receiving single treatment. 
This study represents an interesting example for a successful translation of a 
preclinical drug screening in xenografts into a clinical trial. In 2004, a phase II 
study with 329 patients with metastatic colorectal cancer, whose disease had 
progressed during or after irinotecan treatment was started, resembling the 
results of the xenograft model. Furthermore, the results of this study formed the 
basis of the approval by several regulatory agencies worldwide, to use a 
combination of cetuximab and irinotecan in irinotecan-refractory metastatic colon 
cancer patients [107].  
As our xenograft transplantation experiments resulted in a 100% response rate in 
already established HCC tumors towards an irinotecan / mitomycin C double 
treatment, a potential clinical use of this combination is of great interest. In 
cooperation with Prof. Zeuzem and Prof. Tojan, “Zentrum der inneren Medizin” at 
the University Hospital Frankfurt, two HCC patients are currently treated in 
Frankfurt in an investigator-initiated trial with camptothecin and mitomycin C. 
4.7 Conclusions about FUBP1 as a Potential New Target of Camptothecin 
and the Resulting New Treatment Options in HCC Therapy 
The results of this study strengthen the role of FUBP1 as a therapeutic target in 
hepatocellular carcinoma therapy.  
For the first time I, could show that camptothecin might display an additional 
mechanism of action for its cytotoxic activity, namely the inhibition of FUBP1. 
Unfortunately, through the lack of structural informations about FUBP1, a direct 
proof of the interaction between FUBP1 and camptothecin, such as co-
crystallization, is still missing.  
Nevertheless, the data collected during this study form the basis for the concept 
of a FUBP1-inhibitory effect of camptothecin.  
Two independent binding experiments showed that camptothecin was able to 
interfere with the binding between FUBP1 and FUSEp21. Furthermore, 
additionally tested interfacial TOP1 inhibitors, i.e. 7-ethyl-10-
hydroxycamptothecin, the active part of the camptothecin-derivate irinotecan, or 
indenoisoquinoles like NSC 725776 and NSC 724998, were also able to interfere 
with FUBP1/FUSEp21 binding in a dose-dependent manner. 
  Discussion 
 
 115 
In cellular assays performed in HCC cells, the effect of all TOP1 inhibitors on 
p21, the direct target gene of FUBP1, was elucidated via qRT-PCR experiments. 
Cells treated with the TOP1 inhibitors displayed significantly increased p21 
mRNA levels when compared to control-treated cells, while protein levels of 
FUBP1 were not altered, hence suggesting an inhibitory effect on FUBP1 protein 
function in HCC cells. 
A final proof for the direct interaction is still missing, but with the results obtained 
during this study, there is growing evidence for the inhibitory effect of 
camptothecin on FUBP1 activity. The results could be supported by further 
experiments such as CHIP analysis, luciferase-assays and MS-analysis, as 
discussed in paragraph 4. 
Although the molecular mechanism is not yet fully understood, the treatment with 
camptothecin with and without the addition of other chemotherapeutics like 
mitomycin C showed significant effects on HCC cell expansion (see paragraph 
3.5.1, page 82), cell activity (see paragraph 3.5.2, page 83) and apoptosis (see 
paragraph 3.5.3, page 84-93). These results finally led to the establishment of a 
mouse xenograft experiment, during which tumors derived from human HCC 
cells were treated with irinotecan. The treatments with irinotecan and irinotecan 
plus mitomycin C led to a total tumor remission and a significantly increased 
overall survival of the mice compared to the control-treated groups. These 
findings show that HCC tumors derived from human cells are treatable by 
camptothecin in a mouse xenograft experiment.  
Although additional HCC mouse xenograft experiments with different HCC cells 
need to be performed to confirm the results from the first two HCC xenograft 
experiments, the results of this study appear promising for HCC patients and 
have led to the initiation of a pilot study with two patients suffering from 
intermediate stage HCC, using transarterial chemoembolisation with a 
combination of CPT and mitomycin C. In case of a successful conclusion of the 
preclinical studies, the preparation of a clinical HCC-study with the combinational 
treatment of camptothecin and mitomycin C is planned in collaborations with the 
physicians of the university hospital Frankfurt  
Taken together, the results of this study propose a new role for camptothecin as 
an inhibitor of FUBP1 and led to the preparation of a new, promising therapeutic 
treatment option for HCC patients. 
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6 Abbreviations 
  
  
  ALPHA amplified luminescent proximity homogenous assay  
APS ammonium persulfate 
ASMS affinity selection/mass spectrometry 
BCLC Barcelona Clinic Liver Cancer 
C-terminal carboxy-terminal 
ccRCC clear cell renal cell carcinoma  
ChIP chromatin immunoprecipitation 
CIP alkaline phosphatase 
co codon-optimized 
CPT camptothecin 
dATP desoxyadenosine triphosphate 
DCS double colony selection 
dCTP desoxycytosine triphosphate 
dGTP desoxyguanosine triphosphate 
DNA desoxyribonucleic acid 
dNTP desoxynucleoside triphosphate 
ds double strand 
DTT dithiothreitol 
dTTP desoxytyrosine triphosphate 
E.coli Escherichia coli 
EALS European Association for the Study of Liver Disease 
ECL enhanced chemiluminescence 
EDTA ethylenethylenediaminetetraacetic acid 
EORTC European Organization for Research and Treatment of Cancer 
EpCAM epithelial cell adhesion molecule 
EtBr ethidium bromide 
EtOH ethanol 
FDA food and drug approved 
FGFR fibroblast growth factor receptor 
FIR FUBP1 interacting repressor 
fl full length 
FUBP1 FUSE element binding protein 1 
FUSE far upstream element 
GFP green fluorescent protein 
HAI hepatic aterial infusion  
HC 7-ethyl-10-hydroxycamptothecin 
HCC hepatocellular carcinoma 
HIF1α hypoxia inducible factor 1α  
His-tag hexahistidine-tag 
HRP horseradish-peroxidase 
HTS-NMR high-throughput screening - nuclear magnetic resonance 
HVB hepatitis virus B 
HVC hepatitis virus C 
i.p. intra-peritoneal 
IMAC immobilized metal ion affinity chromatography 
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KCl potassium chloride 
KD dissociation constant 
kDa kilo Dalton 
KH2PO4 potassium-dihydrogenphosphate 
KHSRP KH-type splicing regulatory protein 
l liter 
LB-medium Luria-Bertani medium 
M molar 
MCS multiple cloning site 
MeOH methanol 
MgCl2 magnesium chloride 
MgSO4 magnesium sulfate 
min minute(s) 
ml milliliter 
mM millimolar 
MST microscale thermophoresis 
MVI major vascular invasion 
N-terminal amino-terminal 
NA not available 
NCI National Cancer Institute 
Ni-NTA nickel-nitrilotriacetic acid 
NIH National Institutes of Health 
nM nanomolar 
NOD/SCID non-obese diabetic / severe combined Immunodeficiency 
NT N-terminal 
O/N over night 
OD optical density  
OS overall survival 
p-value probability-value 
PAGE polyacrylamide gel electrophoresis 
PAGE polyacrylamide gel electrophoresis 
PCR polymerase chain reaction 
PEI percutaneous ethanol injection 
pH pondus Hydrogenii 
PI propidium iodide  
PMSF phenylmethylsulfonylfluorid 
poly dIdC poly (2′-deoxyinosinic-2′-deoxycytidylic acid) sodium salt  
PST performance status 
qRT-PCR quantitative real-time pcr 
RF radiofrequency ablation 
RGG arginine-glycine-glycine 
RNAse ribonuclease 
rpm rounds per minute 
RU response unit 
s second(s) 
SD standard deviation 
SDS sodium dodecyl sulfate 
SEC size exclusion chromatography  
SELEX systematic evolution of ligands by exponential enrichment 
SHARP sorafenib HCC assessment randomized protocol 
  Abbreviations 
 
 X 
SOM self-organizing map  
SPR surface plasmone resonance 
ss single strand 
ssDNA single stranded DNA 
TACE transcatheter aterial chemoembolization 
TACE transcatheter aterial chemoembolization  
TBE tris-borate-EDTA buffer 
TEMED tetramethylethylenediamine 
TFIIH transcriptional factor II H 
TOP1 topoisomerase I 
TOP1cc topoisomerase I cleavage complex  
Tris 2-Amino-2-hydroxymethyl-propane-1,3-diol 
U2AF U2 auxiliary factor 
UHM U2AF homology motif 
VEGF vascular endothelial growth factor 
VLB virtual ligand binding  
WAF1/CIP1 cyclin-dependent inhibitor p21  
WST water soluble tetrazolium 
µg microgram 
µl microliter 
µM micromolar 
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